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SUMMARY 
 
This study reports the detailed analysis of the data from ten different clinical trials of 
first generation prophylactic vaccines (FGV) against leishmaniasis.  With the 
exception of one trial, clinical trials of leishmaniasis FGV's have failed to show 
efficacy.  However, some trials have indicated reduced infection rates in the subset of 
participants whose leishmanin skin test (LST) had converted after vaccination.  
Additionally boys were observed to be protected more than girls by the vaccine in one 
trial.  
 
Objectives 
 
One objective of this study  was to re-assess the effectiveness of FGV's in providing 
protection.  This was done both, overall, with all vaccines and trials included and 
separately, in more homogeneous subsets of clinical trials. The justification for this 
re-assessment was the potential ability of the combined analysis to bypass the trial-
specific limitations of individual studies and bring about the advantages of a larger 
sample size.  Efficacy was also evaluated in different demographic groups identified 
by age, gender and endemic/non-endemic origin of participants.   In addition to 
efficacy, immunological response (indicated by LST) to leishmanial antigen 
introduced by vaccination or naturally was evaluated in different demographic groups.  
LST reaction is an indication of delayed-type hypersensitivity (DTH) and has been 
used by investigators to assess exposure.  Another objective of this study was to 
assess the merit of LST as a marker of infection and/or immunity in endemic and non-
endemic populations.   
 
Findings 
 
Vaccine efficacy: 
 
Vaccine efficacy was re-evaluated by meta-analysis.  Results were consistent with the 
conclusion in most clinical trials that FGV's were not efficacious - L. amazonensis 
vaccines in South America were possibly the only exception. Restricting the analysis 
to more homogeneous subsets of trials (similar vaccine, same causative parasite, etc) 
did not change this overall conclusion.  Furthermore, overall no evidence of 
protection associated with LST conversion after vaccination in the vaccine arm was 
observed.  Additionally, different demographic groups were not different in their 
infection rates after vaccination.   
 
Other factors associated with lower incidence: 
 
In ALM+BCG (Autoclaved L. major + Bacille Calmette-Guerin) vaccine trials in Iran, 
it was observed that immunological reactivity (LST>0) 80 days after vaccination was 
associated with reduced incidence if LST measurement one year after study injection 
were LST≥5.  This observation, was independent of the study treatment (i.e., no 
difference observed between the ALM+BCG and BCG alone arms).  This could 
indicate a level of BCG related protection.    
 
Reduced infection rate associated with study participation (again, regardless of 
treatment) was observed in ALM+BCG trials in all participants of endemic origin 
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with previous natural exposure (screening LST≥5).  This confirms the protective 
effect of endemic exposure associated with LST conversion.  
 
Under endemic conditions, trials conducted with non-endemic participants showed 
higher rates of infection than those with endemic participants; another observation 
suggesting the effect of endemic immunity. 
 
Exposure and LST response:  
 
By design, two of the trials used in this analysis enrolled volunteers with LST>0 at 
screening.   This allowed studying natural exposure in demographic groups.  
Inhabitants of an endemic focus were observed to have a different LST profile (more 
frequent with smaller induration) from residents of a newly endemic focus.  
 
 LST as a marker of immunity: 
 
LST measurement changes as a result of exposure to leishmanial antigen.  However, 
LST does not provide a reliable marker of immunity independently of the information 
about factors that gave rise to it. For example, LST converts in a far greater percent of 
vaccine arm participants compared to BCG participants. However, this difference is 
not associated with better protection.  Additionally, LST is subject to significant 
variability from measurement to measurement.  For example, in Borkhar, 38% of 
participants with LST>0 at screening, had LST=0 eighty days after vaccination.  This 
could constitute a source of misclassification of previous exposure.  Also, LST 
reflects immune system stimulation due to different factors: natural exposure, 
vaccination and even BCG could affect the LST response.  Therefore, unless the 
reasons for a reactive LST are known, LST cannot be used as a marker of immunity.    
 
Thesis organization 
 
This thesis is organized into 8 Chapters: 
 
CHAPTER 1 - Background  
CHAPTER 2 - Research objectives and methods  
CHAPTER 3 - Efficacy of killed whole-parasite vaccines in prevention of 
leishmaniasis - a meta-analysis 
CHAPTER 4 - Prophylactic efficacy of whole-parasite killed vaccines in 
demographic subgroups 
CHAPTER 5 - Immunological response (measured by LST) in demographic 
subgroups to the leishmanial antigen introduced by vaccine or 
natural exposure  
CHAPTER 6 - LST response as a correlate of immunity 
CHAPTER 7 - Discussion 
CHAPTER 8 - Conclusions and recommendations for further research 
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ZUSAMMENFASSUNG 
 
Diese Studie berichtet über die detaillierte Datenanalyse von 10 verschiedenen 
klinischen Studien der prophylaktischen Impfstoffe der ersten Generation (Englisch: 
„first generation prophylactic vaccines“ FGV) gegen Leishmaniose. Mit Ausnahme 
von einem Versuch haben klinische Studien von Leishmaniose FGVs bisher keine 
Wirksamkeit gezeigt. Jedoch haben einige Versuche verringerte Infektionsraten in 
einer Untergruppe der Versuchsteilnehmer gezeigt, deren Leishmaniose Hauttest 
(Englisch: „leishmanin skin test“ LST) sich nach der Schutzimpfung umgewandelt 
hatte. Des Weiteren wurde in einer Studie beobachtet, dass Jungen besser von dem 
Impfstoff geschützt werden, als Mädchen.  
 
Zielsetzung  
 
Eine Zielsetzung dieser Studie war es, neu einzuschätzen, inwieweit FGV einen 
wirksamen Impfschutz herstellen können. Dieses wurde in zwei Gruppen untersucht: 
insgesamt mit allen Impfstoffen und allen Versuchen zusammen, und separat mit 
homogeneren Untergruppen klinischer Studien. Die Rechtfertigung für diese Studie 
war die Möglichkeit der kombinierten Analyse, die Versuchs-spezifischen 
Beschränkungen der einzelnen Studien überbrückt sowie die Vorteile einer größeren 
Stichprobe. Die Wirksamkeit wurde in den verschiedenen demographischen Gruppen 
ausgewertet, die durch Alter, Geschlecht und endemischen/nicht-endemischen 
Ursprung der Teilnehmer bestimmt wurden. Zusätzlich zur Wirksamkeit wurde die 
immunologische Reaktion zum Leishmaniosis Antigen (angezeigt durch LST), das 
durch Schutzimpfung oder natürlich eingeführt wurde, in den verschiedene 
demographischen Gruppen ausgewertet. Die LST-Reaktion ist ein Indiz für eine 
verzögerte Überempfindlichkeit (Englisch: „delayed-type hypersensitivity” DTH) und 
wird in Studien verwendet, um eine Exposition festzustellen.  
 
Eine weitere Zielsetzung dieser Studie war, den Benefit von LST als Markierung der 
Infektion und/oder der Immunität in den endemischen und nicht-endemischen 
Gruppen zu evaluieren.  
 
Ergebnisse 
 
Wirksamkeit des Impfstoffes:  
 
Die Wirksamkeit des Impfstoffes wurde durch eine Meta-Analyse neu bewertet. Das 
Ergebnis der Meta-Analyse deckt sich mit den Schlussfolgerungen der meisten 
klinischen Studien, die FGVs als nicht wirkungsvoll bewerten. Die wahrscheinlich 
einzige Ausnahme bilden die L. Amazonensis-Impfstoffe in Südamerika. Die 
Beschränkung der Analyse auf homogenere Untergruppen der Studien (ähnlicher 
Impfstoff, der gleiche kausale Parasit, usw.) erbrachte keine Änderung der 
Schlussfolgerung. Darüber hinaus wurde in der Impfgruppe beobachtet, dass die 
Umwandlung des LST-Tests nach Impfung nicht mit einem Impfschutz assoziiert ist. 
Zusätzlich unterschieden sich die verschiedenen demographischen Gruppen nicht in 
ihren Infektionsraten nach der Schutzimpfung.  
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Andere Faktoren, die mit geringer Inzidenz assoziiert sind:  
 
Bei Versuchen mit dem ALM+BCG (Autoklavierten L. major + Bacille Calmette-
Guerin)-Impfstoff im Iran wurde beobachtet, dass die immunologische Reaktion 
(LST> 0) 80 Tage nach der Impfung mit einer verringerten Inzidenz verbunden war, 
wenn der LST ein Jahr nach der Impfung LST≥5 war. Dieses Ergebnis war 
unabhängig von der Art der Impfung (d.h., kein Unterschied zwischen den 
ALM+BCG und nur-BCG Gruppen). Dieses könnte ein gewisses Mass eines BCG- 
bezogenen Schutzes anzeigen.  
 
Die verringerte Infektionsrate, die mit Studienteilnahme verbunden ist (wiederum 
unabhängig von der Behandlung) wurde in den ALM+BCG- Versuchen in allen 
Teilnehmern der endemischen Gruppe mit vorangegangener natürlicher Exposition 
beobachtet (LST≥5). Dieses bestätigt den schützenden Effekt der endemischen 
Exposition verbunden mit LST-Umwandlung.  
 
Unter endemischen Bedingungen zeigten die Versuche, die mit nicht-endemischen 
Teilnehmern durchgeführt wurden eine höhere Infektionsrate, als die mit endemischen 
Teilnehmern; eine weitere Beobachtung, die auf den Effekt der endemischen 
Immunität hinweist.  
 
Exposition und LST-Antwort:  
 
Zwei der Studien, die in dieser Analyse untersucht wurden, hatten Freiwillige mit 
einem LST>0 eingeschlossen. Dieses ermöglichte die Untersuchung natürlicher 
Exposition in den demographischen Gruppen. Es wurde beobachtet, dass Bewohner 
einer endemischen Region ein anderes LST-Profil aufwiesen (häufiger mit geringerer 
Verhärtung), als Bewohner eines neu entstandenen endemischen Gebietes.  
 
LST als Immunitäts-Marker:  
 
Die Messung von LST ändert sich als Resultat von einer Belastung durch das 
Leishmaniose-Antigen. Jedoch liefert LST keine zuverlässige Markierung der 
Immunität unabhängig der Informationen über Faktoren, die sie verursachten. Zum 
Beispiel wandelt LST sich zu einem weit größeren Prozentsatz in den Impf-Gruppen 
um, als BCG-Gruppen. Jedoch ist dieser Unterschied nicht mit besserem Schutz 
verbunden. Darüber hinaus ist der LST-Test sehr variabel: Zum Beispiel hatten in 
Borkhar 38% der Teilnehmern mit einem LST>0 bei den Vortests, einen LST von 0 
achtzig Tage nach der Impfung. Dieses könnte eine Quelle für Fehlklassifizierung der 
vorhergehenden Expositiondarstellen. Ebenso spiegelt der LST die 
Immunsystemanregung aufgrund verschiedener Faktoren wider: natürliche Exposition, 
Impfung, und sogar BCG konnten die LST-Antwort beeinflussen. Folglich eignet sich 
der LST nicht als Immunitäts-Marker; es sei denn, die Gründe für einen reagierenden 
LST sind hinreichend bekannt.  
 
Gliederung 
 
Diese Arbeit ist in acht Kapitel gegliedert:  
 
KAPITEL 1 - Hintergrund  
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KAPITEL 2 - Forschungszielsetzungen und -methoden  
KAPITEL 3 – Die Wirksamkeit von abgetöteten Voll-Parasit-Impfstoffen in der 
Prävention der Leishmaniose - eine Meta-Analyse  
KAPITEL 4 – Die prophylaktische Wirksamkeit des Voll-Parasit-Impfstoffes in 
den demographischen Untergruppen  
KAPITEL 5 – Immun-Reaktion (gemessen durch LST) in den demographischen 
Untergruppen zum Leishmaniose-Antigen durch Impfstoffe oder 
natürliche Exposition 
KAPITEL 6 - LST-Antwort als Korrelat der Immunität  
KAPITEL 7 - Diskussion  
KAPITEL 8 - Zusammenfassungen und Empfehlungen für weitere Forschung
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ABBREVIATIONS 
 
 
ACL 1. Anthroponotic cutaneous leishmaniasis 
2. American cutaneous leishmaniasis (by various species) 
ALM Autoclaved Leishmania major  
Alum-ALM 
 
ALM precipitated in aluminium hydroxide (a more immunogenic, 
formulation of ALM) 
AVL Anthroponotic visceral leishmaniasis 
BCG Bacille Calmette-Guerin, at 1/10 of the normal dose used as an 
adjuvant in ALM+BCG Leishmania vaccine 
CL Cutaneous leishmaniasis 
DCL Diffuse cutaneous leishmaniasis 
DTH Delayed type hypersensitivity 
Efficacy The percentage reduction in the incidence of leishmaniasis in 
vaccinated individuals compared to the control group 
End point The outcome of interest, could be determined by change in status 
(appearance of a lesion), time to the change of status (time to 
appearance of the lesion), or the severity of symptoms (e.g., size 
or number of lesions). 
FGV First generation vaccines including ALM+BCG, alum-
ALM+BCG and other vaccine candidates 
GCP Good clinical practice (international guidelines for clinical trials) 
GLP Good laboratory practice (international guidelines for laboratory 
production) 
GMP Good manufacturing practice (international guidelines for 
manufacturing pharmaceuticals) 
IFN-γ Interferon γ 
IL-2, IL-4, etc Interleukin 2, interleukin 4, etc. cytokines secreted by cells of the 
immune system 
LR Leishmaniasis recidivans 
LST Leishmanin Skin Test used to evaluate immune response to 
leishmanial antigens. This procedure includes intradermal 
inoculation of 0.1 mL of leishmanin (containing 5-20 µg of 
Leishmania protein from killed whole promastigotes), the result 
will be evaluated by measuring induration induced at the site of 
inoculation in 48-72 hours. Normally (but arbitrarily) an 
induration of 5 mm or larger is considered as a positive response. 
LST conversion Changes from negative LST to positive  
LZ Leishmanization.  Using live Leishmania major to cause artificial 
cutaneous leishmaniasis.  This method is proposed to be used as 
live challenge in efficacy trials of candidate vaccines for 
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leishmaniasis. 
MCL Mucosal or mucocutaneous leishmaniasis 
MST Montenegro skin test (alternate designation for LST, frequently 
used by Latin American investigators) 
PKDL Post kala azar dermal leishmaniasis 
TFN-α Tumour necrosis factor-α 
VL Visceral leishmaniasis (kala azar) 
ZCL Zoonotic cutaneous leishmaniasis 
ZVL Zoonotic visceral leishmaniasis 
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CHAPTER 1 
 
BACKGROUND1 
 
 
1.1  Etiology of leishmaniasis 
 
Leishmaniasis is a vector-borne disease caused by several species of protozoan 
parasites of the genus Leishmania (table 1.1).  Genus Leishmania includes the two 
subgenus Leishmania (in the Old World) and Viannia (in the New World).  
Leishmanial infection has diverse clinical manifestations, including cutaneous (CL), 
mucocutaneous (MCL), diffuse cutaneous (DCL), visceral (VL or kala-azar), post 
kala-azar dermal leishmaniasis (PKDL) and recidivans (LR) (WHO Expert 
Committee on the Control of the Leishmaniases, 1990). 
 
 
Table 1.1 - Main species of leishmania with pathogenicity in human  
(SOURCE: http://www.bio.tuebingen.mpg.de/membio/staff/thilg.html  Citation: April 2006)  
Kingdom Protista 
Subkingdom Protozoa 
Phylum Sarcomastigophora 
Subphylum Mastigophora 
Class Zoomastigophora 
Order Kinetoplastida 
Suborder Trypanosomatina 
Family Trypanosomatidae 
Genus Leishmania 
Section Peripylaria Suprapylaria 
L. 
braziliensis 
complex: 
L. 
donovani 
complex:
L. mexicana 
complex: 
L. 
braziliensis 
L. 
donovani
L. mexicana 
L. 
panamensis 
L. 
infantum 
L. 
amazonensis 
L. 
guyanensis 
L. 
chagasi 
L. pifanoi 
  L. garnhami 
  
 
    L. 
peruviana
 
   L.     
major 
  L.     
tropica
L. 
aethiopica 
L. 
venezuelensis
Host mammals, including humans 
Disease 
pattern in 
humans 
CL (Pian 
Bois), MCL 
(Espundia) 
CL (Uta) VL (Kala 
Azar), 
CL, 
PKDL 
CL 
(oriental 
sore) 
CL 
(orien-
tal 
sore), 
VL 
CL, DCL CL (Chiclero’s 
ulcer), DCL 
 
                                                   
1 This chapter has been in part published in the Vaccine (see Annex) 
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1.2 Transmission:   
 
Leishmaniasis is transmitted via the bite of the female phlebotomine sandfly.  There 
are 30 proven species of sandflies of the genus Papatasi or Lutzumyia acting as the 
vector in the transmission of the disease. Table 1.2 depicts some of the main 
pathogenic species.  Leishmaniasis has both, zoonotic (reservoir in animals) and 
anthroponotic (reservoir in humans) forms.  Many mammalian species constitute the 
reservoir and/or the host for the disease including dogs, rodents and humans.   
 
Table 1.2 - Proven and suspected sandfly vectors in the Old World 
Parasite Clinical 
association 
Geographical 
distributions 
Proven or 
suspected vectors 
China P. alexandri 
Indian subcontinent P. argentipes 
East Africa P. martini 
L. donovani AVL; PKDL 
East Africa P. orientalis 
Southern Europe P. ariasi 
Southern Europe; 
Eastern Mediterranean 
 
P. perniciosus 
Eastern Mediterranean P. langeroni 
China P. chinensis 
L. infantum ZVL; ZCL 
China; Eastern Medit P. major 
Africa, Middle East, 
South-west Asia 
P. papatasi L. major ZCL 
Africa P. dubosqi 
Africa, Middle East, 
South-west Asia 
P. sergenti L. tropica ACL; LR 
Kenya P. saevus 
East Africa P. longipes L. aethiopica CL; MCL; DCL 
East Africa P. pedifer 
a. AVL, anthroponotic visceral leishmaniasis; PKDL, post kala-azar dermal leishmaniasis; 
ZVL, zoonotic visceral leishmaniasis; ZCL, zoonotic cutaneous leishmaniasis; ACL, 
anthroponotic cutaneous leishmaniasis; LR, leishmaniasis recidivans; MCL, 
mucocutaneous leishmaniasis; DCL, diffuse cutaneous leishmaniasis. 
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1.3  Geographical distribution and global burden: 
 
Figure 1.1 - Global distribution of leishmaniasis 
 
Source: (Handman, 2001) 
 
 
Leishmaniasis is a public health problem in 88 countries (figure 1.1), including 72 
developing countries, with 80% of their population earning incomes less than $2 
daily)(Davies et al., 2003;WHO, 2006).  Most cases of leishmaniasis occur in Asia, 
Africa and Latin America. The following statistics are provided by the World Health 
Organization (WHO, 2006): 
 
 90% of all visceral leishmaniasis cases occur in Bangladesh, Brazil, India, Nepal 
and Sudan;  
 90% of mucocutaneous leishmaniasis occurs in Bolivia, Brazil and Peru;  
 90% of cutaneous leishmaniasis cases occur in Afghanistan, Brazil, Iran, Peru, 
Saudi Arabia and Syria 
 
Its burden is higher among the poor, with anaemia and malnutrition being among the 
major risk factors for death (Collin et al., 2004).  The estimated global prevalence of 
all forms of the disease is 12 million, with 1.5 to 2 million added cases annually of CL 
(with average duration of few months to one year) and 500,000 of VL (with average 
duration of several months to more than one year) (WHO, 2002;WHO, 2006).  Due to 
increases in urbanization and other risk factors, different forms of leishmaniasis have 
wider presence and more severe prevalence world wide than ever before (WHO, 
2002).  Recent epidemics have caused hundreds of thousands of deaths and 
immeasurable morbidity and economic consequences. In 1977 in Bihar, India there 
were 100,000 cases of kala-azar with the death rate in Vaishali district of 28.7% of 
affected cases (Thakur, 1984). In Sudan (Western Upper Nile) in 1993, 100,000 
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people died over a period of 5 years from an area with less than one million 
population (Desjeux, 1996).  It took five years to control the epidemic. 
 
The transmission cycle for natural leishmanial infection requires the presence of the 
mammalian reservoir and the sandfly vector.  All factors contributing to the spread of 
the reservoir and vector also contributes to the spread of leishmaniasis.  The 
epidemiology of leishmaniasis infection is affected by naive human populations 
migration to endemic areas.  Examples include outbreaks of cutaneous disease caused 
by Leishmania tropica in Afghan refugees, visceral disease in Sudanese refugees, and 
cutaneous disease caused by L. major in American forces in Iraq (Berman, 
2005;Weina et al., 2004).  Additionally, human interventions in previously non-
endemic areas (e.g., construction of dams) could trigger the outbreak of leishmaniasis 
in the non-immune local population (Neouimine, 1996).  New foci could also be 
created by introduction of the parasite into a susceptible and previously non-endemic 
area and could lead to outbreak in the non-immune residents (Neouimine, 1996). 
 
There are important interactions between Leishmania and HIV infections.  HIV 
infection in leishmaniasis endemic areas has lead to a higher incidence of 
leishmaniasis (Puig and Pradinaud, 2003). Compared to immune competent persons, 
AIDS patients in endemic VL foci have 100-1000 times the risk of developing clinical 
VL.  Also, VL infection accelerates the development of HIV into AIDS (Desjeux and 
Alvar, 2003).  Another factor contributing to the higher incidence of leishmaniasis in 
HIV endemic areas is the higher rate of sandfly infection after feeding on the blood of 
immunodeficient persons. Infectivity seems to be proportional to the severity of 
infected immunodeficiency (Molina et al., 2003).  In addition, in HIV positive 
individuals, normally non-pathogenic strains of leishmania and even lower 
trypanosomatids could cause infection (Chicharro and Alvar, 2003;Molina et al., 
2003) .  
 
 
1.4  Clinical forms 
 
Despite their similarities, pathogenic species of Leishmania cause different forms of 
the disease (CL, MCL, DFL, VL, PKDL - table 1.3). Furthermore, possibly due to the 
interactions between the vector, the parasite, the host and the environment, basic 
clinical manifestations within the different forms of the disease vary by endemic 
region (Berman, 2005;WHO Expert Committee on the Control of the Leishmaniases, 
1990).   
 
 
1.4.1  Cutaneous Leishmaniasis (CL) 
 
Infection with any of several species can produce cutaneous leishmaniasis.  According 
to the causative parasite species, CL can be classified into Old World and New World 
CL.  The former is primarily due to L. major (known as rural or zoonotic CL -ZCL), L. 
tropica (urban or anthroponotic - ACL), and L. (L) aethiopica but also due to  L. 
infantum and L. donovani.  New world CL is caused by L. mexicana, L. (L) 
amazonenesis, L. braziliensis, L. (V) panamensis, L. (V) peruviana, and L. (V) 
guyanensis and also L. chagasi (Murray et al., 2005;WHO Expert Committee on the 
Control of the Leishmaniases, 1990). 
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CL due to L. major tends to heal spontaneously and without systemic complication or 
dissemination to other sites.  Individuals with history of CL are usually protected 
against future infection (Khamesipour et al., 2005;WHO, 2002;WHO/TDR, 2002). 
CL due to other species may lead to other complications (such as mucosal 
involvement in L. tropica or L. aethiopica infection) (WHO Expert Committee on the 
Control of the Leishmaniases, 1990;Yaghoobi and Hoghooghi-Rad, 2001).  In 
infection with L. major and L. tropica, an erythematous papule at the site of the 
sandfly bite  is normally the initial stage of the lesion later developing into a painless 
nodule which typically ulcerates in 1-3 months(Dowlati, 1996;Murray et al., 2005). 
The lesion duration in ZCL cases is usually less than a year and in ACL (L. tropica) 
up to 2 years.  Cases with lesion duration longer than one year in ZCL or 2 years in 
ACL are considered chronic (Dowlati, 1996;Murray et al., 2005).  Compared to CL 
due to L. major, infections due to L. tropica and L. aethiopica takes longer to 
heal(Dowlati, 1996;WHO Expert Committee on the Control of the Leishmaniases, 
1990).  Leishmaniasis recidivans (LR) is the rare, lupoid chronic form caused by the 
recurrence of L. Tropica up to 40 years after the initial infection (Marovich et al., 
2001).  Although the localized form is far more common, American CL caused by the 
New World species could range from a single, self healing lesion to multiple, slowly 
progressive nodules characteristic of diffuse CL(Barral et al., 1995;Machado et al., 
2002).   
HIV-associated cutaneous leishmaniasis has been relatively infrequent but this will 
probably change in the future (Murray et al., 2005).  HIV+ cases infected with CL 
seem to experience more frequent recurrences and longer treatment periods (Couppie 
et al., 2004). The success of  antiretroviral drug distribution in countries such as 
Brazil has had a positive impact on the incidence of leishmaniasis among HIV 
patients (Rabello et al., 2003).  American CL is also associated with the destructive 
MCL form. 
  
 
1.4.2  Mucocutaneous (Mucosal) Leishmaniasis (MCL):  
 
MCL is a potentially life threatening, degenerative inflammatory form of 
leishmaniasis of the nasal and oral mucous membranes, extending to the pharynx. The 
appearance of the disease resembles leprosy and it is associated with the same stigma. 
Diagnosis and treatment is difficult (Evans, 1993).   In the Old World MCL is rarely 
seen and is usually due to L. tropica and L. aethiopica (Kharfi et al., 2003;WHO 
Expert Committee on the Control of the Leishmaniases, 1990).  However, cases 
associated with other species have also been reported (el-Hassan and Zijlstra, 
2001;Guddo et al., 2005;Yaghoobi and Hoghooghi-Rad, 2001). In Sudan, MCL is 
rarely observed as an aftermath of VL (unlike PKDL)(el-Hassan and Zijlstra, 2001). 
 
MCL in the New World is primarily due to L. braziliensis, L. panamensis and L. 
guyanensis (Weigle and Saravia, 1996;WHO Expert Committee on the Control of the 
Leishmaniases, 1990).  About 1-10% of CL patients in the New World develop 
mucosal manifestation within 1-5 years of healing (Murray et al., 2005). CL in the 
New World is associated with the risk of developing mucosal infection if the 
treatment is delayed due to the causing parasite genus not being rapidly identified 
(Peyron-Raison et al., 1996). 
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Mucosal leishmaniasis begins with erythema and ulcerations at the nares, proceeding 
to nasal septum perforation and destructive inflammatory lesions. The latter can 
obstruct the pharynx or larynx and produce remarkable disfigurement (Murray et al., 
2005).  
 
1.4.3  Diffuse Cutaneous Leishmaniasis (DCL)   
 
DCL is a rare form of the disease caused by various species. In the Old World  the 
primary causative agent is L. aethiopica.and in the New World  the L. mexicana 
complex and specifically L. amazonensis (Silveira et al., 2005;WHO Expert 
Committee on the Control of the Leishmaniases, 1990). In DCL patients, the absence 
of delayed type hypersensitivity (DTH) is associated with widespread plaques, 
papules or multiple nodules especially on the face or the limbs and could resemble 
leprosy. DTH normally is observed after cure.  The disease does not heal 
spontaneously and tends to recur (Silveira et al., 2005;WHO Expert Committee on the 
Control of the Leishmaniases, 1990). 
 
 
1.4.4  Visceral Leishmaniasis (VL)/Kala Azar:  
 
VL is primarily caused by members of the L. donovani complex (L. donovani in 
Sudan and India, L. infantum in other parts of the Old World and L. chagasi in the 
New World). Some cases of VL in humans and dogs are due to L. tropica (Alborzi et 
al., 2006;Lemrani et al., 2002;Mohebali et al., 2005;Sacks et al., 1995).  Because of 
its associated complications and severity, VL has more significant public health 
consequences than other forms of leishmaniasis.  Children are especially susceptible 
(Murray et al., 2005;WHO Expert Committee on the Control of the Leishmaniases, 
1990).  The spleen, the liver, the mucosa of the small intestine, the bone marrow, 
lymph nodes and other lymphoid tissues are heavily parasitized (WHO Expert 
Committee on the Control of the Leishmaniases, 1990).  Symptoms include fever, 
weight loss, splenomegaly, hepatomegaly, lymphadenopathy, cachexia, nausea  and it 
is typically fatal if not appropriately treated (Seaman et al., 1996;Zijlstra and el-
Hassan, 2001b). 
 
1.4.5  Post Kala Azar Dermal Leishmaniasis (PKDL):  
 
PKDL is the dermal complication developed in VL patients after clinical cure and is 
characterized by a macular, maculopapular, and nodular rash which normally starts 
around the mouth.  The rash is typically the only complication in PKDL.  Chronic 
PKDL is the source of considerable morbidity.  PKDL is mainly seen in Sudan and 
India (about 50% of the Sudanese and 5-10% of Indian VL patients) and is restricted 
to infection with L. donovani (Musa et al., 2002;Zijlstra et al., 2003;Zijlstra and el-
Hassan, 2001a).  PKDL follows within 6 months of VL cure in Sudan and 2 years or 
longer in India.  While the Indian PKDL needs treatment, the Sudanese form tends to 
self heal within 1 year post onset. Chronic cases, however, need treatment and are 
hard to cure (Musa et al., 2002;Zijlstra and el-Hassan, 2001a). 
 
PKDL is believed to play a role in the transmission of  kala azar by providing the 
human reservoir in the skin of the PKDL patient despite recovery from the symptoms 
of the visceral disease (Zijlstra et al., 2003).  
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Table 1.3 - Clinical manifestations of leishmanial infection 
  
Disease Form 
  Mucocutaneous Cutaneous Diffuse Visceral 
Characteristic:         
Lesions  
Ulcerative 
destruction of the 
nasal septum 
Single, 
occasionally 
a small 
number, 
ulcerated 
lesions with 
elevated 
borders and 
necrotic 
centre 
Non-ulcerated 
nodules 
spread 
through 
different areas 
of the body 
Internal Organs 
Histopathology 
and parasite 
numbers 
Granulomatous 
reactions with very 
few parasites 
Chronic 
inflammatory 
responses 
with 
moderate 
number of 
parasites 
Monotonous 
macrophagic 
infiltration with 
abundant 
parasites 
Marked 
macrophagic 
proliferation 
with heavy 
parasitism in 
the 
haematopoietic 
organs 
Anti-Leishmania 
antibody levels     Low Low 
Moderate to 
high high 
Anti-Leishmania 
CMI (in vitro and 
in vivo tests) 
Strongly positive Positive Negative Negative 
 
 
 
1.5  Current control methods 
 
Given the significance and the public health burden, effective control of leishmaniasis 
is an important item on the public health agenda of many endemic countries.   Due to 
the complexity and diversity of the epidemiology, transmission and pathology of 
leishmaniasis, no single diagnosis, treatment or control approach could offer the 
complete solution.  HIV co-infection is making the situation more complex by 
changing the epidemiology of the disease and presenting new problems in diagnosis 
and case management (Sinha et al., 2005). Moreover, control methods, even when 
potentially viable, are seldom used  (Guerin et al., 2002).  Overall, current methods of 
control and case treatment have been unable to provide a solution in areas of high 
burden (Ahluwalia et al., 2003;Dantas-Torres and Brandao-Filho, 2006;WHO/TDR, 
2004).  
 
Currently, three general categories of control methods can be identified: vector 
control, reservoir control and case identification/therapy.  Of these methods, vector 
control through insecticides is considered as the most effective (de Oliveira and de 
Araujo, 2003;Dye, 1996;Thakur and Kumar, 1992).  However, sustainable vector and 
reservoir control methods require infrastructure resources beyond the means of most 
endemic countries.  Dispersed communities, hard to reach areas, vast desert areas, 
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difficulties of identifying and treating/eliminating infected dogs or wild animals in 
forests or deserts and existence of human reservoirs in anthroponotic infection are 
among many challenges in the way of such control methods.  Sustainability of vector 
and reservoir control efforts is an essential requirement for their success. In 
developing country settings, the enormity of the problem and the cost and labour 
associated with such measures makes them difficult to implement (Dantas-Torres and 
Brandao-Filho, 2006).  As an example, the eradication efforts and disinfection in 
Bukhara region next to Kisil-Kum desert (Uzbekistan) over a 15 year period did not 
lead to a significant reduction in rates of infection.  The vast desert with high 
prevalence of infection among rodents does not allow such measures to be effective 
(Gafurov, 1999). Once such efforts are discontinued due to financial, logistic or health 
concerns, re-emergence of vector colonies would be the likely outcome. To cite an 
example, it is possible that after the DDT spraying in India was stopped (1958-1970), 
newly emerging sandfly colonies used PKDL cases as the reservoir to start the 
epidemic in Bihar in early 1970's (Thakur and Kumar, 1992).   
 
Among other factors contributing to the problem is that vector and reservoir control 
measures are developed under laboratory conditions that are different from natural 
settings in a variety of ways.  For example sandfly reaction to fabrics treated with 
repellents and insecticides under laboratory conditions could be different from that in 
the wild. One reason for such a difference could be that infected sand flies have a 
more aggressive biting behaviour and probe more frequently than uninfected sand 
flies.  Such factors could compromise the efficacy of impregnated uniforms (Asilian 
et al., 2003;Croft et al., 2006a).  Additionally, the use of chemically treated fabrics 
could cause skin irritation and absorption into the systemic circulation (Asilian et al., 
2003;Schreck et al., 1984;Schreck et al., 1986).  
 
For the past 60 years, the first line treatment for leishmaniasis has consisted of long 
courses of pentavalent antimonials.  Despite their toxicity, these drugs constitute the 
most practical and economically feasible chemotherapy currently available.  
Unfortunately, resistance to antimonials is becoming a major and growing problem.  It 
is estimated that 60% of VL patients in Bihar, India do not respond to antimonials due 
to drug resistance (Bryceson, 2001;Croft et al., 2006b;Dube et al., 2005).  Resistance 
to antimonial drugs has also been observed in VL caused by L. donovani in the Sudan 
(Khalil et al., 1998) and in ACL caused by L. tropica in Iran (Hadighi et al., 2006), 
which may be pointing at the possibility of a similar problem in Afghanistan which is 
the world's largest focus of CL (Reithinger and Coleman, 2007).  Other, recently 
discovered drugs such as amphotericin B, miltefosine, paromomycin, are expensive 
and unavailable to most patients in developing countries (Croft and Coombs, 2003).   
 
Diagnostic tests constitute another aspect of case management.  Unfortunately, there 
are shortcomings in the sensitivity and specificity of currently available tests.  In 
addition, they are not available to all patients in rural areas (WHO/TDR, 2004). 
 
For many infectious diseases, reducing susceptibility through vaccination is  a highly 
effective method of control (Dye, 1996;Guerin et al., 2002).  However, vaccination is 
not currently an option for leishmaniasis control since a prophylactic vaccine against 
leishmaniasis is yet to be developed (Khamesipour et al., 2006;Modabber and Reed, 
2004).   
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Overall, current control methods present significant challenges including toxicity, cost, 
practicality, and sustainability.  Any one of these obstacles in developing country 
settings could render these measures impractical.  These serious challenges and the 
growing prevalence of drug resistant organisms underscore the need for an effective 
prophylactic vaccine reagent as a viable alternative strategy for control (Handman, 
2001;Khamesipour et al., 2006;Webb et al., 1998). 
 
 
1.6  Immunology 
 
Studying host response to the parasite has been facilitated by using animal models, 
particularly inbred strains of mice.  After  inoculation with L. major, leishmaniasis-
prone BALB/c mice develop uncontrolled, extensive lesions which eventually cause 
death. Other strains, such as C57BL/6, CBA/J, C3H and B10D2, on the other hand, 
develop a small self healing lesion and an effective immune response shortly after 
infection (Campos-Neto, 2005;Handman et al., 1979;Webb et al., 1998). Other strains 
of mice have different levels of susceptibility to various species of Leishmania.  These 
differences are attributable to the differences in immunological response to the 
infection by each strain.  Since Leishmania is an intracellular protozoa, the relevant 
immune response is T cell-mediated.  The susceptibility in BALB/c mice is linked to 
the predominant development of Th2 subset of CD4+ cells which leads to an antibody 
oriented response.  In the resistant mice, on the other hand, response is the 
development of Th1 subset of CD4+ cells(Campos-Neto, 2005;Handman et al., 
1979;Webb et al., 1998).  Stripping otherwise resistant mice of their T cells makes 
them susceptible to infection, while injection of these mice with T cells from  
recovered mice restores resistance (Mitchell et al., 1980).  
 
In humans, most of the evidence suggesting the association of Th1 with cure and 
immunity is applicable to CL. In contrast, in chronic CL or ML cases, a combination 
of Th1 and Th2 response is observed. In VL, a different pattern of cytokine profile 
occurs (Modabber and Reed, 2004). 
 
Cell-mediated immunity is facilitated by different proteins, known as cytokines, that 
are secreted by T lymphocytes, especially CD4+ T cells, after activation by antigens 
displayed on the MHC (major histocompatibility complex) of APC's (antigen 
presenting cells). In innate immune response cytokine production is mainly done by 
macrophages, while in adaptive immunity, they are mainly secreted by T cells.   
 
Activated CD4+ T cells, start the production of cytokines and at the same time 
become able to respond and bind to cytokines.  Interleukin-2 (IL-2) is among the first 
cytokines to be produced by CD4+ T cells within 1-2 hours after activation.  IL-2 
plays an important role in clonal expansion of both CD4+ and CD8+ T cells, within 
one or two days after activation.  Both CD4+ and CD8+ cells differentiate into 
effector cells and memory cells.   CD4+ T cells can differentiate into subsets of 
effector cells known as Th1 and Th2 cells (type 1 and type 2 helper T cells).  Th1 
cells stimulate phagocyte-dependant immunity, which is the beneficial response in the 
context of intracellular infection.  Th2 cells, on the other and, stimulate phagocyte-
independent, eosinophil- and IgE-dependent immunity which can exacerbate the 
disease.  Differentiation of naive helper T cells into Th1 rather than Th2 is believed to 
be facilitated by IL-12 produced by parasite-activated macrophages and dendritic cells.  
 28
In the absence of IL-12, the T cells themselves (and perhaps other cells) produce IL-4 
which stimulates differentiation into the Th2 subset and IgE production. Therefore, 
IL-12 is an essential pretext of Th1 response(Abbas and Lichtman, 2004).  
 
Th1 and Th2 subsets of CD4+ T cells secrete different cytokines which lead to their 
distinct actions (table 1.4).   
 
Table 1.4 - Cytokines in relation to Th1 and Th2 subsets of CD4+ cells 
 
Cytokine Th1 Th2 
IL-2 ++ - 
IFN-γ ++ - 
TNF-β ++ - 
G-CSF ++ + 
TNF-α ++ ++ 
IL-3 ++ ++ 
IL-4 - ++ 
IL-5 - ++ 
IL-6 - ++ 
IL-10 - ++ 
IFN-γ: Interferon-γ, IL: Interleukin, GM-CSF: granulocyte macrophage-colony 
stimulating factor, TNF: tumor necrosis factor α or β. 
Source: (Cabrera, 1994) 
 
These cytokines are mutually inhibitory. For example, IL-10 and IL-4 down regulate 
Th1 differentiation, while IFN-γ down regulates Th2 expansion. IL-10 inhibits IFN-γ 
and promotes the persistence of the parasites in skin lesion.  IL-4 also inhibits INF-γ 
production and its disruption enables BALB/c mice to resist infection (Belkaid et al., 
2001;Cabrera, 1994;Campos-Neto, 2005;Kopf et al., 1996;Mosmann and Moore, 
1991) 
 
The most important cytokine produced by Th1 cells is IFN-γ (interferon-γ), a potent 
activator of macrophages.  Macrophage activation for effective killing of ingested 
parasites is the differentiating aspect of cell mediated response to intracellular 
infection and is conducted in a nitric oxide-dependent manner (Abbas and Lichtman, 
2004;Vanloubbeeck and Jones, 2004b).  It should be noted that early supply of IFN-γ 
is mainly by NK (natural killer) cells (Cabrera, 1994).  It is important to emphasize 
that immunity is not associated with an exclusive Th1 differentiation, but rather the 
predominance of a Th1 response (Erb et al., 1996;Vanloubbeeck and Jones, 
2004a;Vanloubbeeck and Jones, 2004b).  Factors that drive CD4+ differentiation into 
the Th1 subset relate host genetics, parasite factors and the role of the vector and 
include(Cabrera, 1994;Vanloubbeeck and Jones, 2004a;Vanloubbeeck and Jones, 
2004b): 
1. Type of Antigen presenting cell (APC) 
2. Endogenous cytokine levels  
3. Nature of the antigen recognized 
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In addition to CD4+ and their differentiation into Th1, activation of CD8+ cells has 
been shown to play an important role in protection, both after primary infection and 
during a memory response (Vanloubbeeck and Jones 2004). 
 
Both CD4+ and CD8+ stimulate macrophage killing.  CD8+ cells play another, more 
direct role in parasite eradication.  Naive CD8+ cells differentiate into CTL's (cytolitic 
T lymphocytes) that kill infected host phagocytes, thus eliminating the parasite.  Both 
CD4+ and CD8+ recognize, and are stimulated by, the MHCs (major 
histocomatibility complexes) displayed by antigen presenting cells (APCs) such as 
macrophages and dendritic cells.  Peptides associated with class I MHC molecules 
(from parasites that escape into the cytoplasm from the vesicle formed inside the 
macrophage) are recognized by CD8+ T cells while peptides associated with class II 
MHC molecules (obtained within the vesicles) are recognized by CD4+ T cells.  
Expansion of CD8+ cells is also dependent on help from CD4+ cells through IL-2 
action (Abbas and Lichtman, 2004;Vanloubbeeck and Jones, 2004a;Vanloubbeeck 
and Jones, 2004b).  Immunology of Leishmaniasis is summarized in figure 1.2. 
 
 
Figure 1.2 -  Immunology of leishmaniasis 
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As mentioned earlier, in humans, the direct and clear association between immunity 
or cure and Th1 response applies to CL where predominant Th1 response and 
elevated levels of IFN-γ producing cells has been observed in healing lesions. In 
contrast, in chronic CL or ML cases, a combination of Th1 and Th2 response coupled 
with abundant IL-4 is observed. In VL, on the other hand, both IFN-γ and IL-4 are 
 30
raised during the disease, but they decline after the disease (Modabber and Reed, 
2004).  Table 1.5 demonstrates the immunology in different forms of leishmaniasis. 
 
Table 1.5 - Main Immunological features of leishmanial infection in man 
   Primary Immune response 
Species disease DTH Antibody 
Parasite  
in Lesion 
  
Self cure 
            
L. tropica CL present variable present yes 
  LR strong variable scanty no 
L. major CL present present present rapid 
L. aethiopica CL weak variable present slow 
  DCL absent variable abundant no 
L. donovani VL absent abundant abundant rare 
  PKDL variable variable variable variable 
  CL present variable present yes 
L. braziliensis CL present present present yes 
  MCL  present present scanty no 
L. mexicana CL present variable present yes 
  DCL absent variable abundant no 
Source: (WHO Expert Committee on the Control of the Leishmaniases, 1990) 
 
 
1.6.1  Delayed-type hypersensitivity and skin test for leishmaniasis 
 
Cell mediated immune response includes recruitment of T cells that recognize the 
specific antigen into the infection site and activation of macrophages that have 
phagocytosed and display that specific antigen.  This type of response involves 
production of substances that are toxic to microbes and, if released into the 
extracellular space, to normal tissues. The resulting tissue injury is known as 
hypersensitivity.  The antigen-specific nature of this process leads to a similar 
response every time the immune system encounters the same antigen (Abbas and 
Lichtman, 2004). 
 
The same reaction could be induced by injecting the specific antigen into the skin of a 
previously exposed (infected or immunized) individual. This reaction is called 
delayed-type hypersensitivity (DTH). The term "delayed" signifies the length of time 
(24 to 48 hours after challenge with the antigen) for circulating effector T cells to 
accumulate at the site (Abbas and Lichtman, 2004).  DTH is used as a diagnostic test 
in different diseases, e.g., Tuberculosis (Purified Protein Derivative - PPD) and 
leishmaniasis (Leishmanin Skin Test - LST). LST is widely used as a diagnostic tool 
for leishmaniasis (Handman, 2001;Khalil et al., 2000a;Khamesipour et al., 2006;Reed, 
1996)). 
  
 
1.6.2  Leishmanin skin test (LST) and its application in vaccine clinical trials 
 
The widely used diagnostic test for present or past infection with Leishmania species 
is the Leishmanin Skin Test (LST),  know as Montenegro Skin Test (MST) in the 
New World.  LST is essentially an indicator of DTH due to exposure to leishmanial 
antigens and is used in detecting CL, MCL and asymptomatic VL.  However, it is 
negative in acute VL patients(Reed, 1996;Saran et al., 1991).  LST has been 
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classically used in epidemiological studies for detection of exposure to Leishmanial 
antigen (Reed, 1996) and is frequently used in vaccine clinical trials to assess immune 
response to the vaccine.   
 
LST consists of intradermal injection of 0.1 ml of leishmanin.  Leishmanin is 
produced slightly differently by different laboratories (e.g., 6 x 106 promastigotes/ml 
of Phosphate Buffered Saline (PBS) containing 0.01% of thimerosal, as produced by 
Pasteur Institute, Iran: 
http://www.pasteur.ac.ir/researchDepartment/Immunology/new_page_1.htm ).  
Results are measured in 48 to 72 hours.  The emergence of a skin reaction to the agent 
is indicative of delayed-type hypersensitivity (DTH) due to previous exposure to the 
antigen.  By convention, an induration ≥ 5 millimetres (measured by the ballpoint pen 
method (Sokal, 1975) is considered to be a positive result, while a smaller induration 
is considered as negative.  Skin test conversion signifies an increase to ≥ 5 (or another 
pre-determined value) due to infection or vaccination.  
 
A 98% sensitivity has been reported for LST in CL patients after 6 weeks from the 
onset of lesion (Manzur and ul Bari, 2006).  However, it is important to note that 
different preparations of leishmanin, and even leishmanin produced by different 
laboratories, have different sensitivity (Akuffo et al., 1995;Solano-Gallego et al., 
2001).   
 
LST with leishmanin prepared from L. major promastigotes seems to be sensitive in 
detecting exposure even when the cause of the infection is a species other than L. 
major (Ben Alaya Bouafif et al., 2001;Ben Salah et al., 2005).  As such, LST 
conversion is routinely observed in a percentage of the control arm participants in 
clinical trials (for example in (Bahar et al., 1996;Momeni et al., 1999;Sharifi et al., 
1998).  
 
In Leishmaniasis vaccine trials, LST plays an important role as the method of 
detection of previous exposure.  Studies of vaccines for prophylaxis normally require 
participants to be LST negative.  This allows identifying:  1) previous exposure and 
asymptomatic infection and 2) the effect of the vaccine in inducing an immune 
response (by converting LST).  In several efficacy trials there has been an important 
finding regarding LST results in the vaccinated arm: even if efficacy is not observed 
for the entire vaccinated arm, significantly lower incidence is usually observed in the 
subset of vaccinated participants with LST conversion post-vaccination; i.e., those 
whose immune system responds to the treatment (Antunes et al., 1986;Khalil et al., 
2000a;Momeni et al., 1999).  It has been suggested that this apparent protection is due 
to the vaccine.  However, in the trial in Esfahan by Momeni et al, the significantly 
lower incidence was observed in LST converted participants, regardless of their 
treatment assignment.  
 
 
1.7  Vaccine development 
 
1.7.1  Introduction 
 
Given the enormity of the public health burden in several developing countries and 
the problems with control and treatment as discussed earlier, any method of 
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prevention would be of great value.  A prophylactic vaccine could constitute a 
reasonable and practical approach to prevention and control, if the price could be kept 
at levels affordable to the at-risk population in developing countries.  Unfortunately, 
the time and the cost required for the development of a vaccine and the low potential 
for a sizeable return on investment makes leishmaniasis vaccine development an 
unattractive investment for drug manufacturing companies (Khamesipour et al., 
2005;Modabber and Reed, 2004).  A feasible approach to leishmaniasis vaccine 
production would be to create facilities with GMP capabilities in developing countries 
and to seek local governments' support for purchasing and distribution.  Philanthropic 
support for the transfer of technology and production under GMP conditions is needed 
as most donor agencies for medical research are not interested in development 
(Modabber and Reed, 2004).  Fortunately, there is awareness and commitment on the 
part of foundations such as the Bill and Melinda Gates and international and non-
governmental organizations to address this significant health problem.   
 
Development of a vaccine against leishmaniasis has been the focus of many 
investigators around the world. During the past several decades, many vaccine 
candidates have been developed and some have entered the clinical development 
stage.  However, to-date, no prophylactic vaccine for widespread use against 
leishmaniasis is available.  Despite the discovery of many antigens  which showed 
immunogenicity in animals, some of which have been shown to be safe and 
immunogenic in humans (Handman, 2001;Khalil et al., 2000a;Khamesipour et al., 
2006), prophylactic efficacy for killed or sub-unit vaccines remains to be shown in a 
reproducible manner. The only efficacious prophylaxis against leishmaniasis to-date 
is infection with live, virulent Leishmania parasites, known as leishmanization (LZ).    
 
Although an efficacious vaccine for leishmaniasis has not yet been identified, the 
existence of a natural model of protection (i.e., LZ) and the accumulating evidence of 
the effectiveness of immuno-chemotherapy in leishmaniasis patients (discussed later 
in this chapter) support the idea that developing an efficacious prophylactic vaccine is 
feasible.  
 
 
1.7.2  Development process 
 
Many challenges lie in the way of vaccine development.  Since vaccines are destined 
for use in healthy individuals and frequently young children, it is critical to ensure the 
safety of the product.  Efficacy is important not only from a medical standpoint but 
also from the standpoint of ethics.  Requirements of Good laboratory practices (GLP), 
Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) guarantee 
the reliability and reproducibility of the development and manufacturing process, 
clinical evaluation of the product and the evaluation of the vaccine's safety and 
efficacy. Quality control (QC) and quality assurance (QA) safeguards and 
requirements must all be met (Khamesipour et al., 2006).  
 
After showing promising results in the discovery stage, a candidate antigen would 
have to prove safe and immunogenic in preclinical studies and only then enter the 
clinical trial stage, provided that technical and financial support are available. All 
phases of clinical trials have a focus on safety of the product.  For "first in human" 
studies (phase 1), the primary assessment is of safety.  Successful phase 1 studies are 
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followed by evaluation of safety and immunogenicity in larger numbers of subjects 
(phase 2).  Phase 3 trials are also heavily oriented towards the assessment of efficacy.  
Hence, Phase 3 trials involve many more participants (in the thousands) than phase 1 
(dozens) and phase 2 (hundreds) trials. The process of clinical trial from pre-clinical 
to phase 3 is demonstrated in figure 1.3.  Phase 4 or post marketing trials aim to detect 
any safety problems after the vaccine is released and also to evaluate effectiveness 
under normal conditions of use.  Normally Phase 3 trials for vaccines take several 
years to complete, depending on the incidence rate of the disease.  A more rpid 
method to assess efficacy is to challenge study participants with live parasite after a 
pre-specified length of time post-vaccination.  A challenge system, such as LZ, could 
bring about significant time and cost saving in the development process.  Steps in 
clinical development of vaccines are displayed in the following figure. 
 
Figure 1.3 - Clinical trials for vaccine development 
 
Source: University of Washington, http://depts.washington.edu/hptu/trials.html 
 
 
1.7.3  Live virulent parasite (Leishmanization) 
 
Leishmanial infection, particularly CL, is associated with subsequent protection 
against future infection (Khamesipour et al., 2006).  The strength of the immune 
response to infection seems to be directly correlated with the rate of protection in 
patients (Ben Salah et al., 2005).  Historically, it has been known that leishmanial 
infection induces long lasting protection against future infection (Khamesipour et al., 
2005).  This knowledge in the endemic foci of Leishmania in South West Asia led to 
the practice of inoculation of at-risk individuals, usually children, with the pus from 
live lesion of a patient. However, in modern days, this is done with cultured parasite 
and is known as leishmanization (LZ) (Modabber and Reed, 2004).  In Uzbekistan the 
first LZ campaign began in 1967 and lasted until 1970, modelled after a similar 
campaign in Turkmenistan. The standard preparation, registered in Uzbekistan for 
prophylaxis, consists of a mixture of live and killed promastigotes (Gafurov, 1999) 
and is the only prophylactic live vaccine in current use(Khamesipour et al., 2006).  
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LZ was used in Iran (1980's) and Israel (1970's) as a prophylaxis against leishmaniasis. 
It is not currently practiced in either country (Jaffe and Greenblatt, 1991;Khamesipour 
et al., 2006). In Israel, LZ program was discontinued because of loss of infectivity of 
the parasite due to repeated sub-culturing as well as immunosuppression that resulted 
in reduced responsiveness to diphtheria, pertussis and tetanus (DPT) vaccine in 
children following LZ  (Jaffe and Greenblatt, 1991;Khamesipour et al., 2006).  In Iran, 
in the preliminary experiment by Nadim et al, LZ achieved 80% efficacy (Nadim et 
al., 1983;Nadim et al., 1997).  After this initial trial, the practice was used to 
immunize nearly 2 million individuals in Iran who were at risk of leishmaniasis after 
moving into endemic areas as a result of the Iran-Iraq war.  Despite its effectiveness, 
the LZ campaign in Iran was stopped in 1986 and is currently not used as a method of 
vaccination in Iran and Israel due to a small percentage of cases with complications 
such as protracted and non-healing lesions (Nadim et al., 1997).   
 
Development and registration of live, attenuated or drug-sensitive parasites (through 
culture, chemical, radiation or genetic manipulation) could lead to a significant 
improvement in LZ and enable its standardization, either as a vaccine or a challenge 
in clinical trials.  However, questions such as parasite reversion to its original 
pathogenic state, consequences of its release into the environment should be 
addressed (Handman, 2001).  
   
In addition to its potential as a prophylactic vaccine (after standardization), LZ (even 
in its current unstandardized form) could be used, and is currently used in Iran, as a 
tool in vaccine development; i.e., as challenge in vaccine efficacy trials in hyper 
endemic foci (where trial participants are in very high risk of natural infection). LZ 
challenge could provide a number of advantages (Khamesipour et al., 2005): 
 
 Reduce the length of follow-up time 
 Reduce the number of volunteers needed in a trial 
 Therefore, reduce the trial cost 
 Provide a consistent/standardized challenge to make better comparison between 
the vaccine and the control arm, without unaccounted variation due to differences 
resulting from natural infection 
 Since efficacy vaccine trials take place in endemic foci, LZ would bring about a 
second advantage: conferring protection in study volunteers who are at great risk 
of natural infection  
 
LZ with virulent, non-attenuated parasites also has certain shortcomings such as its 
differences with natural infection and variability inherent in production of the 
parasites which makes LZ difficult to standardize. 
 
The safety and protective ability of LZ was observed in a clinical trial in Iran 
(Khamesipour et al., 2005).   
 
 
1.7.4  Whole parasite vaccines  
 
This general class of vaccines against leishmaniasis consists of vaccines made with 
whole killed parasites.  As a result, standardization is a problem in the way of 
registration of these vaccines.  In recent years  the three killed parasite vaccines 
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evaluated in most human studies have been:  L. amazonensis (BIOBRAS, Brazil), L. 
mexicana (Instituto Biomedicina, Venezuela) and L. major (Razi Vaccine and Serum 
Institute, Iran)(Modabber, 2000).  In addition, a trivalent preparation consisting of L. 
brazilensis, L. guyanensis and L. amazonensis antigens was evaluated in Ecuador 
(Armijos et al., 1998). The adjuvant used in the Venezuelan, Ecuadorian and Iranian 
preparations was BCG. 
 
 
 1.7.4.1  Killed whole parasite (first generation) prophylactic vaccines, New World 
 
First generation vaccines have been the subject of experiments in Latin America since 
early 20th century.  The two main vaccines evaluated in the New World have been the 
pentavalent preparation in Brazil by Mayrink et al, which was later simplified to a 
monovalent L. amazonensis vaccine with no adjuvant.  Originally, this vaccine was 
produced using merthiolate for parasite inactivation.  The autoclaved preparation was 
also evaluated with similar immunogenicity results to the merthiolate preparation 
(Modabber, 2000;Velez et al., 1997).  The other vaccine produced in Venezuela has 
been autoclaved L. mexicana with BCG adjuvant, used in immunotherapy of patients.  
Prophylactic studies of this vaccine apparently faced difficulties due to less-than-
expected incidence (Modabber, 2000).  Additionally, a trivalent preparation consisting 
of L. brazilensis, L. guyanensis and L. amazonensis antigens was evaluated in 
Ecuador (Armijos et al., 1998) 
 
Brazil: 
 
Brazilian investigators conducted trials of different preparations of killed parasites as 
early as 1939 by Sales-Gomes  followed by Pessoa and colleagues in 1940's who used 
a polyvalent vaccine of 18 strains of Leishmania (Genaro et al., 1996).   
 
These efforts were later followed in the 1970's by Mayrink and colleagues in Brazil 
who developed a pentavalent vaccine which, after 2 intramuscular injections (one 
week apart), was able to convert the MST (Montenegro skin test) results in 78.4% of 
vaccinated volunteers within three months, with no major side effects. Despite the 
fairly large sample size (614 vaccinated vs 974 control) the efficacy of the vaccine 
could not be assessed since no cases occurred in the study area after vaccination 
(Genaro et al., 1996;Mayrink et al., 1978;Mayrink et al., 1979).  
 
Suggestion of protection associated with vaccination was given by another trial of 2 
injections of the same vaccine by Mayrink et al (Mayrink et al., 1985) in a clinical 
trial with 216 volunteers in the vaccine arm and 266 in the control arm.  Two years 
after vaccination the numbers of followed-up volunteers had dropped to 203 and 179 
in the vaccine and control arms.  Despite the reduced sample size, statistically 
significant results (P < 0.01) were observed between the vaccine and control arms 
with respect to the number of cases (1.7% vs 8.9%, respectively).  However, the trial 
was not a double blind controlled trial(Genaro et al., 1996).    
  
In 1981 and 1983 two randomized, double blind, controlled trials of the pentavalent 
vaccine were conducted by Mayrink, Antunes, and colleagues with Brazilian army 
personnel. As in previous trials, 2 intramuscular injections, one week apart were 
administered.  The vaccine concentration was somewhat different (Antunes et al., 
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1986).  In the 1981 trial, 667 and 645 volunteers were included in the vaccine and 
placebo arms, respectively. LST conversion was 35%, considerably lower than in 
previous trials.  This was attributed to the immunosuppression effect of the routine 
army yellow fever vaccination about 60 days prior to the study injection.  Trial results 
did not show a significant difference between the vaccine and the placebo arms, 
despite some complications due to difference in incidence rate in the two army 
training groups in the study.  In the 1983 trial, 658 and 616 army recruits were 
randomly assigned to the vaccine and placebo arms, respectively.  LST conversion 
rate was 68% (more than that in the1981 trial, possibly because study started 120 days 
after routine yellow fever vaccination). Again, trial results were not significant. 
 
However, importantly, 1981 results in group 1 of trainees (who spent a longer time in 
the jungle and experienced greater incidence of the disease) did show significantly 
lower incidence in those whose LST results had converted (induration ≥ 5) after 
vaccination (compared to either both placebos or non-LST converted vaccines).  The 
reason for the overall lack of statistical significance seems to be the lower-than-
expected incidence in the Group 2 in 1981 and the entire 1983 participants.  Sample 
size calculations in both these studies were based on an expected incidence of 10%.  
Although more participants were registered in the study than the calculated sample 
size of 580. 
 
Despite promising results, because of the difficulties of producing and standardizing 
the 5-strain Leishvacin® presented difficulties in preparation and registration.  
Additionally, subsequent studies demonstrated the immunogenicity of a single-strain 
L. amazonensis antigen vaccine.  To address the development of a vaccine against CL, 
two Vaccine Advisory Groups  with the participation of representatives of national 
and international organizations interested in developing an anti-leishmaniasis vaccine 
were organized by World Health Organization  in Washington DC, USA and Belo 
Horizonte, MG, Brazil in February and September 1991, . It was suggested that 
studies with the vaccine should continue, using only one strain, the L. amazonensis 
(IFLA/BR/67/PH8). This strain was chosen because its antigens induced high 
stimulation indexes for lymphocytes from vaccinated volunteers it is easy to grow in 
non-cellular media, it is internationally known and it is taxonomically well defined" 
(Genaro et al., 1996;Mayrink et al., 2002). 
 
 It was later observed that L. amazonensis promastigotes have similar immunogenicity 
in mice as the 5-strain Leishvacin (Mayrink et al., 2002).  Another study confirmed 
the immunogenicity of 2 and 3 doses of various concentrations of the monovalent 
vaccine in human volunteers (De Luca et al., 2001).  
 
Colombia: 
 
Immunogenicty and safety of three doses of the monovalent L. amazonensis vaccine 
was confirmed in Colombia in a phase 2 and a phase 3 randomized, double blind 
clinical trials. The phase 2 trial in 296 army volunteers was conducted (intradermally) 
with BCG as adjuvant  and also intramuscularly without BCG.  The vaccine with 
BCG was only administered twice (despite the protocol requiring 3 doses), due to the 
BCG-induced lesions that were unacceptable to volunteers.  The intramuscular 
administration proved to be safe and immunogenic and as a result the phase 3 was 
conducted (Velez et al., 2000). 
 37
 
The phase 3 trial was conducted in LST negative (<3 mm LST induration) army 
volunteers.   Participants in the vaccine arm (n = 1295) and the placebo arm (n = 1302) 
were followed for 12 months. The vaccine was safe and immunogenic but did not 
provide protection against CL (Velez et al., 2005).  Participants in this study were not 
LST tested after vaccination.  Therefore, it is not possible to compare incidence in 
those whose LST results converted after vaccination with those who did not.  
 
Ecuador: 
 
The only leishmaniasis vaccine clinical trial in which prophylaxis efficacy was 
observed (regardless of LST conversion after vaccination) was conducted in Ecuador 
(Armijos et al., 1998).  In this study, safety, immunogenicity and efficacy of 2 
intradermal doses of a locally prepared vaccine were assessed against 2 doses of BCG 
alone (n = 438 vaccine arm vs n = 406 controls).  The vaccine consisted of L. 
braziliensis, L. guyanensis and L. amazonensis promastigotes originally collected 
from the lesions of patients living in the study area, mixed with BCG.  After 12 
months of follow up, the vaccine was shown to be safe and the protective efficacy of 
the vaccine was evaluated at 72.9%, with 2.1% incidence of CL in the vaccine arm vs 
7.6% in the control arm (Armijos et al., 1998).  In this study, similar to some of 
Mayrink's works, the incidence in the control arm was less than the expected 13-15% 
(Armijos et al., 1995a;Armijos et al., 1995b).  However, the sample size calculation 
had been based on 7.5% incidence, rather than 14%.  
 
The differentiating aspects of this trial are 1) the origin of the vaccine being from 
locally obtained parasites, and 2) the average age of subjects being around 5.5 years 
(5.4±3.9 vaccines and 5.7±3.9 controls). 
 
After the original 12 months of follow up, these subjects were followed up, in a 
separate study, for another 4 years.  Results indicated that although the protective 
efficacy was still significant between the 13th and the 18th months, it was not so after 
the 19th month of follow-up (Armijos et al., 2003).  The incidence in each 6-month 
period and the total incidence from the 19th to the 60th month were not significantly 
different between the vaccine and the control arm subjects who were followed-up.  
 
However, examining the table provided in the article by Armijos, et al, suggests that 
the loss of statistical significance in the difference between arms after the 19th month 
was not due to an increase in the number of cases in the vaccine arm, but rather a 
reduction in the number of new cases in the control group.  In addition, the gradual 
reduction in the number of subjects followed seems to be another factor contributing 
to differences that are not significant (number of subjects were calculated for each 6-
month follow-up period based on incidence values reported in the article).  It could, 
therefore, be argued that this study is inconclusive with respect to the erosion of the 
vaccine-derived protection after 18 months of vaccination.     
 
The other vaccine trial conducted by Armijos et al, compared 2 doses of vaccine (n = 
750) against placebo (n = 756).  The vaccine consisted of autoclaved L. amazonensis 
mixed with BCG.  Although the vaccine was safe and immunogenic (significantly 
more LST conversion in the vaccine arm), results indicated no protection associated 
with vaccination; not even in the LST-converted subgroup (Armijos et al., 2004).  In 
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this trial, the average age of participants was 11.2±10.5 in the vaccine arm and 
10.5±10.1 in the placebo arm; on average nearly twice as old as those in the earlier 
study.  Authors mention the possibility of the parasite killing method (heat), and the 
geographic origin of the parasite or the parasite species used in the vaccine as possible 
factors contributing to its ineffectiveness.  As in some of the other studies, the 
observed incidence in the placebo arm was less than expected.  This must have lead to 
a reduction in statistical power and contributed to inconclusive results.  
 
 
1.7.4.2  Killed whole parasite (first generation) prophylactic vaccines, Old World 
 
After the LZ program in Iran in the 1980's, a national vaccine development program 
was planned and the production of the killed Leishmania vaccine was started at the 
Razi Vaccine and Serum Institute, Hessarak, Iran, using the same organism as used in 
the LZ program(Khamesipour et al., 2006;Modabber, 2000).  Phase 1 and 2 clinical 
studies of safety and immunogenicity of different doses of inactivated L. major 
promastigotes with or without a low dose of BCG (as adjuvant) were conducted in 
non-endemic areas in Iran.  The potential advantage of BCG adjuvant was that it 
could facilitate introducing leishmaniasis vaccination into the national vaccination 
programs, which already included BCG vaccination. These early results demonstrated 
the ability of a low dose of BCG in enhancing the immune response to the antigen 
(Bahar et al., 1996;Dowlati et al., 1996).  It should be noted that in the study by Bahar 
et al, vaccines produced by two methods of parasite inactivation (thimerosal treatment 
vs autoclaving) were used with similar results.  Since autoclaving provided a less 
complicated and less expensive method of preparation, it was recommended by the 
authors as the preferred method of vaccine preparation for the future efficacy trials 
(Bahar et al., 1996).  The autoclaved L. major (ALM) preparation mixed with BCG 
adjuvant (10% the dose normally used in vaccination against TB) was used in several 
field trials in Iran and Sudan.  The results of some of these studies in the late 1990's 
(multiple injections in Bam, Iran, multiple injections in Zavareh, Iran and multiple 
injections in Borkhar, Iran) have not yet been published.  This preparation was later 
replaced by an improved formulation involving precipitation of the ALM in 
aluminium hydroxide (alum), known as alum-ALM.  Alum-ALM mixed with BCG 
showed significantly higher ability to convert the LST results in vaccinees. 
 
Iran: 
 
Esfahan single injection (Esf1): Momeni et al conducted a randomized, double-blind, 
controlled field efficacy trial of ALM+BCG against ZCL due to L. major.  One 
injection of the vaccine (n = 1188) was compared with one injection of BCG alone (n 
=1122).  Study volunteers were from healthy, LST-negative (LST=0), residents of an 
airbase in an endemic part of Isfahan, Iran. Volunteers' age ranged from 5 to 72 years.  
The distinguishing aspect of the sampled population was that they had moved into the 
airbase from throughout Iran, including non-endemic areas (Momeni et al., 1999).  
Study duration was originally planned to be 1 year, but after interim analysis, another 
year of follow up was recommended.  Post-vaccination LST was conducted on day 80 
and again in one year.  
 
The annual incidence rate in the area during the years prior to the study had been 
consistently around 4-6% in the native community.  Study results indicated higher 
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annual incidence rate (about 10% in the controls, for those with LST results obtained). 
Authors indicate higher LST conversion compared to other studies conducted in non-
endemic or low endemic areas in Iran. They attribute the higher LST conversion in 
the vaccine arm and the conversion observed in the control arm to natural exposure.  
It is possible that the higher response reflect the non-endemic origin of participants. 
 
Although the two years of follow-up did not produce significant results to support 
vaccine efficacy overall, infection rates in the LST converted individuals (in the 
vaccine and the control arm combined) were lower than in those whose LST had not 
converted (7.3% vs 11.3 in the vaccine arm and 3.4% vs 10% in the control arm).  
This is consistent with earlier discussed findings in Brazil  (Antunes, Mayrink et al. 
1986). The difference is that in Brazil the significant difference was between LST 
converted vaccine participants and all others, while in Esfahan the difference was 
between participants whose LST converted and those who did not, regardless of BCG 
or vaccine treatment.  This may reflect the fact that in Brazil the control treatment was 
not BCG.  Another outcome of this study was the lower disease severity in vaccinated 
children less than 14 years old.  A subsequent study of the immunogenicity data from 
this trial did not substantiate a significant correlation between proliferation response 
(IFNγ production) to ALM and the magnitude of LST response (Mahmoodi et al., 
2003).  Authors compared several different subgroups of the study but did not 
compare the vaccinated volunteers whose LST had converted with other groups.  
Authors raise the possibility that BCG may not be an ideal control arm treatment since 
it could induce a similar immune response to the ALM+BCG.  
 
Bam single injection (Bam1): Randomized, double-blind, BCG controlled clinical 
trial in Bam, Kerman, assessed the efficacy of ALM+BCG in protection against the 
anthroponotic CL (ACL) caused by L. tropica in LST-negative (LST = 0) school 
children 5 to16 years old (Sharifi et al., 1998).  One injection of the vaccine (n = 1839) 
was compared with one injection of BCG alone (n = 1798).  Post vaccination LST 
was conducted on day 80 and again after 1 year.  
 
Previous studies had indicated a 2% annual incidence rate.  Two years of follow-up 
uncovered infection rates that were not significantly different between the vaccine and 
the control arms (2.8% and 3.3%, respectively).  The LST conversion was 
significantly greater in the vaccine arm (16.5% vs 3.6% on day 80 after vaccination), 
but overall, less than that observed in Isfahan, possibly due to the lower incidence rate 
in Bam compared to Esfahan.  Protection in the LST converted subgroups was not 
reported.  Protection was observed in vaccinated boys, but not girls. Also, it was 
noticed that through the 6th month of follow up more cases were identified in the 
vaccine arm, while fewer were identified thereafter.  This observation may point at 
the longer time it takes for the L. tropica to lead to clinical infection 
 
Other studies were conducted in Iran with multiple doses of ALM+BCG.  These 
studies were carried out in Bam, province of Kerman and in Borkhar and Zavareh in 
the province of Esfahan.  Results have not been published, but will be used in the 
analysis in the present investigation.  Briefly, they include the following trials 
 
Bam 3-injections (Bam3): Sharifi, et al conducted a study in LST = 0 school age 
children with 3, one month apart injections of ALM+BCG.  BCG was used as the 
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control treatment.  Two post vaccination LST measurements (day 80 and 1 year) were 
taken.   
 
Borkhar 3-injection (Bor3): Khamesipour et al conducted a 3-injection trial in school 
age children in Borkhar, Esfahan province.  The two main distinguishing aspects of 
this trial was 1) Inclusion criteria allowed any initial LST values accepted into the 
trial and 2) although the first 2 injections of the vaccine were one month apart, the 
third injection was one year after the first. Several LST measurements were taken 
throughout the trial.  
 
Zavareh 3-injection (Zav3): Khamesipour et al also conducted a 3-injection trial in 
Zavareh, in the province of Esfahan.  Participants' age ranged from 5 to 59.  Vaccine 
injections were one month apart.  In this study only the pre-vaccination LST was 
conducted.  
 
Additionally, a clinical trial assessing the safety, immunogenicity and effectiveness of 
alum-ALM (alum-precipitated ALM an improved formulation of ALM) mixed with 
BCG followed by LZ challenge was conducted in a hyper-endemic area of Esfahan.   
This study (unpublished) did show the safety of alum-ALM+BCG but was 
inconclusive about the vaccine efficacy against challenge due to problems with the LZ 
reagent.  This trial with an improved study design is currently underway in Iran. 
 
Sudan: 
 
Safety and immunogenicity of ALM+BCG was assessed in endemic and non-endemic 
areas of Sudan (Khalil et al., 2000b;Satti et al., 2001).  Subsequently, a double-blind 
randomized field efficacy trial of two injections of ALM+BCG (n = 1155) vs BCG 
alone (n = 1151) was conducted in the late 1990's in Sudan in an area endemic for VL 
due to L. donovani (Khalil et al., 2000a).  LST-negative (LST = 0) volunteers between 
the ages of 1 and 65 years were admitted to the study.  Post vaccination LST 
conversion was significantly higher in the vaccine arm (30% vs 7% after 42 days of 
vaccination).  However, after 2 years of follow up, the rate of infection in the two 
study arms were not significantly different (11.5% in the vaccine arm and 12.3% in 
the control arm). Although the overall vaccine efficacy was not significant, 
individuals whose LST converted after vaccination had a significantly lower 
incidence of VL than non-responders (7.2% vs 12.7%), regardless of the BCG or 
vaccine treatment.  These results are consistent with findings in studies in Esfahan and 
Brazil, discussed earlier (with the difference that the control treatment in Brazil was 
not BCG). 
 
In addition to the studies of ALM+BCG, safety and immunogenicity of different 
doses (10, 100, 200 and 400 µg of leishmanial protein) of alum-ALM+BCG was 
assessed in Khartoum (Kamil et al., 2003).  LST conversion 42 days after vaccination 
was observed in all volunteers in the 10 µg, 100 µg and 400 µg doses but only in one 
of five volunteers in the 200 µg group.  All doses were safe with minimal, local side 
effect (Kamil et al., 2003).  Additionally, an extended phase 2 study (Khalil et al., 
2006) confirmed safety and immunogenicty of alum-ALM+BCG compared to vaccine 
diluent as the control treatment in 544 leishmanin non-reactive children younger than 
15 years old.  The four cases observed in this study were all in the control arm.  
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Although not an efficacy trial, this evidence may suggest lower incidence associated 
with vaccination.  
 
 
1.7.4.3  BCG as adjuvant in first generation vaccine trials: 
 
Bacille Calmette-Guérin (BCG) has been used in several of the formulations of first 
generation leishmania vaccines.  In the New World, the vaccines tested in Brazil did 
not contain adjuvant.  However, Armijos used BCG (about 1:2 dose of what is 
normally used for vaccination) in both his trials; with the locally produced trivalent 
vaccine and with the Brazilian Leishvacin.  In immunotherapy, variable doses of BCG 
were used depending on the PPD results of each volunteer, per Convit's protocol 
(Cabrera, 1994). In the Old World different doses of BCG were tested in phase one 
trials (Dowlati et al., 1996) and subsequently 1/10 of the normal dose (in TB 
vaccination) was used in all leishmaniasis vaccine trials (Alimohammadian et al., 
2002;Bahar et al., 1996).  
 
The use of BCG has both advantages and disadvantages.  Injection of BCG mixed 
with the antigen significantly increases the LST response to the vaccine; i.e., it 
enhances the desirable Th1 response.  Additionally, it has been observed that LST 
conversion due to vaccination is associated with reduced infection (Alimohammadian 
et al., 2002).  Therefore, BCG inclusion as an adjuvant could help the 
immunogenicity and protection due to the vaccination.  However, BCG, even without 
the antigen can induce short-term LST conversion.  Therefore, from the standpoint of 
assessing the efficacy of the vaccine, BCG is not a good candidate for use in the 
control arm efficacy trials. (Alimohammadian et al., 2002;Armijos et al., 1998).   
 
 
1.7.4.4  Killed whole parasite (first generation) therapeutic vaccines 
 
Although prophylactic efficacy has not been demonstrated for any of leishmaniasis 
candidate vaccines, several vaccine candidates have been shown to be efficacious in 
treatment of different forms of leishmaniasis when used in combination with 
chemotherapy.  In fact, some candidate vaccines have shown efficacy when used 
alone.  
 
As early as 1939, Sales-Gomes tested the effect of killed Leishmania in patients in 
Brazil.  He noticed a decrease in the size of lesions associated with this therapy 
(Genaro et al., 1996).  Mayrink in Brazil and Convit in Venezuela experimented with 
different vaccine formulations beginning in the 1980's.   
 
In Brazil, Mikhalick and Myrink compared  different vaccination protocols with a 
pentavalent vaccine (Leishvacin) and observed that immunotherapy could be a viable 
alternative to drug therapy in patients who can not tolerate Glucantime (Genaro et al., 
1996).  Machado-Pinto and Mayrink compared the monovalent L. amazonensis 
vaccine plus half does of the standard antimonial treatment against half dose of 
standard antimonial treatment alone.  Results suggested much faster cure in 100% of 
patients in the immunochemotherapy arm  (compared to 8.2% in the chemotherapy 
arm - figure 1.4) and fewer side effects (Machado-Pinto et al., 2002).   
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Figure 1.4 - Immuno-chemotherapy vs chemotherapy in Brazil,  after Machado Pinto 
et al., 2002  
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In Venezuela, Convit compared 3 injections of a combination of L. Mexicana 
promastigotes and BCG  without chemotherapy vs standard antimonial regimen in 94 
patients with localized CL.  Cure rate in both study arms were 94%, but with far fewer 
side effects in the vaccine arm (Convit et al., 1987).     
 
Subsequent studies by Convit and colleagues supported the therapeutic efficacy and 
safety of vaccine therapy of patients with various forms of leishmaniasis, including 
cases with severe ML and DCL (Convit, 1996;Convit et al., 2003;Convit et al., 2004).  
Figures 1.5 and 1.6 depict the results of Convit's 1996 investigation.   
 
Figure 1.5 - Side effects of Chemotherapy, immunotherapy and BCG alone, after 
Convit 1996 
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Figure 1.6 - Healing of localized leishmaniasis by chemotherapy, immunotherapy and 
BCG alone, after Convit 1996 
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The following figure shows a patient before and after immunotherapy in Convit et al, 
2004. 
 
Figure 1.7 - Mucosal leishmaniasis before and 6 months after immunotherapy in a 
patient non-responsive to chemotherapy (Convit et al., 2004) 
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Immunochemotherapy in Leishmania/HIV co-infection cases has had promising 
results (Genaro et al., 1996).  The latest therapeutic assessment by Mayrink et al 
(Mayrink et al., 2006) supports these earlier findings by Convit, Mayrink and their 
colleagues in Venezuela and Brazil.  Results demonstrate the effectiveness of 
immunotherapy with or without standard pentavalent antimonial treatment.  The 
effect in combination therapy was shorter  length of therapy  along with >98% cure.  
In immunotherapy alone, the same level of cure was achieved in slightly longer length 
of time. 
   
Recently in Sudan  two trials suggested the ability of immunotherapy with whole-
parasite, alum-precipitated autoclaved L. major promastigotes combined with BCG to 
induce quicker healing in chronic PKDL patients as compared to standard treatment 
with antimonial drugs (Pentostam) (Musa et al., 2008).  The fact that even suboptimal 
leishmaniasis vaccines could be effective in the therapeutic setting is encouraging 
support for the pursuit of a prophylactic vaccine (WHO/IVR, 2006).  
 
 
1.7.5  Modified antigen vaccines 
 
Modified antigen vaccines include second generation vaccines (sub-unit, purified 
protein, DNA, etc) and vaccines made with modified live parasites.  
 
1.7.5.1 Second generation vaccines 
 
Second generation vaccines encompass a number of different antigens and delivery 
systems and include purified protein, DNA's  or otherwise manipulated (genetically, 
chemically, etc) antigens with the goal to develop a well characterized vaccine with 
well defined effect on the immune system.  The common advantage of second 
generation vaccines is that they are well defined and easily standardized.  This is a 
major advantage and renders these vaccines better candidates for production and 
registration.  The development of well defined vaccine candidates against 
leishmaniasis has been the result of understanding the immunological mechanism that 
mediate protection as well as genome sequencing of L. major (Khamesipour et al., 
2006).  , subunit vaccines (purified, recombinant proteins), recombinant bacteria or 
viruses with leishmanial antigens, DNA vaccines, synthetic peptides (introducing the 
antigen protein's peptide rather than the entire protein) and non-protein antigens 
(parasite surface glycol-lipids such as lipophosphoglycan (LPG) (Handman, 
2001;Khamesipour et al., 2006;Modabber, 1995). 
 
Currently, the only second generation vaccine in clinical development is Leish-111f 
with MPL-SE which is the fusion of three leishmanial antigens: LmSTI1 (L. major 
Stress Inducible protein), TSA (Thiol-Specific Antioxidant) and LeIF (Leishmania 
elongation and initiation factor).   Leish-111f in its current formulation is injected 
after mixing with MPL-SE (monophosphoryl lipid A in squalene emulsifier) as 
adjuvant (Coler and Reed, 2005;Modabber and Reed, 2004).  A phase 1 trial in the US 
showed the safety, immunogenicity of the vaccine and therapeutic trials in Latin 
America have been conducted (Coler and Reed, 2005;Ghalib and Modabber, 2007).  
In dogs, however, multiple doses of Leish-111f did not protect against L. infantum 
infection (Gradoni et al., 2005) 
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Another approach has been based on the immune response to the sandfly salivary 
proteins inoculated into the host during a blood meal (Belkaid et al., 2000).  It has 
been observed that prior exposure of mice to the bite of uninfected sandflies is 
associated with reduced rate of infection (Kamhawi et al., 2000).  In endemic regions, 
many individuals are exposed to the bites of Leishmania-free phlebotomines before 
being bitten by an infected sand fly (Kamhawi et al., 2000).   In recent years there 
have been efforts for identifying salivary proteins that could lead to protection in 
humans (Handman, 2001;Valenzuela et al., 2001). 
 
1.7.5.2  Modified live parasite vaccines 
 
Modified live parasite vaccines consist of live parasites that are chemically or 
genetically attenuated or manipulated  (drug sensitized, suicide genes added, etc) to be 
infectious but not pathogenic (Handman, 2001).  Attenuated parasites are taken into 
the macrophage in the same way as the virulent organisms and persist long enough to 
induce an immune response (Kedzierski et al., 2006).  Persistence of the antigenic 
effect within the immune system is the main advantage of live attenuated parasites 
and could lead to a long lasting protection, much like live virulent parasites (Scott, 
2005;Selvapandiyan et al., 2006) methods of attenuation included long term culture, 
γ-irradiation, temperature sensitive mutations or random mutations induced by 
chemical agents(Selvapandiyan et al., 2006).  A major problem with these methods 
the possibility of reversion to the virulent state. Such reversion can occur 
spontaneously in healthy individuals or under conditions of weak host immune 
system(Selvapandiyan et al., 2006). 
 
These challenges can be met with newly developed live attenuated strains because 
they (i) possess genetically defined mutations; (ii) persist in the host without being 
virulent; (iii) have less chance  of reversion to the virulent phenotype because of 
irreversible genetic modifications; (iv) are amenable to further genetic manipulation if 
a candidate vaccine causes adverse reactions; (v) can be produced in large quantities 
in well defined conditions suitable for human vaccination; and (vi) can be tested along 
with new adjuvants or parasite antigens to enhance protective immune response or in 
combination with antileishmanial drugs to reduce pathogenesis, if 
needed(Selvapandiyan et al., 2006). 
 
 
1.7.6  Vaccines against canine leishmaniasis  
 
In parallel to vaccine development for humans, dog vaccines have been a focus of 
investigators.  Dogs play a major role as a reservoir in transmission in human 
communities (Gavgani et al., 2002).  Prevention in dogs could have significant effect 
on transmission reduction and incidence in humans within the same endemic focus 
(Gavgani et al., 2002;Saraiva et al., 2006).  A number of different dog vaccines with 
good results have been under investigation (Gradoni, 2001;Rafati et al., 2005). 
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1.7.7  Overview 
 
As suggested by the foregoing review, until now laboratory and clinical experiments 
have identified several vaccine candidates with the potential ability to produce the 
beneficial immune response against leishmanial infection.  Furthermore, those 
candidate vaccines that have undergone clinical trials, whether for prophylaxis or 
therapy, have been shown to be safe, without untoward systemic consequences, 
generally tolerable and immunogenic in humans.  Complications tend to be local and 
mostly associated with the use of adjuvant, particularly BCG which induces a lesion 
and leaves a scar.  The following points are central when considering the feasibility of 
an efficacious prophylactic vaccine against leishmaniasis: 
 
1. The natural model for protection against leishmaniasis exists: cured cases tend 
to be immune to new infection. This has been also demonstrated by LZ 
experiences. 
2. From a biological and immunological standpoint, a leishmaniasis vaccine 
seems to be feasible because the antigenic profile of the parasite in various 
stages of its life cycle (extra- and intra-cellular forms) undergoes little 
variation (Modabber and Reed, 2004).  In addition, the antigenic variation 
across different species of Leishmania is not extensive and cross protection in 
mice and monkeys has been observed(Vanloubbeeck and Jones, 
2004a;Vanloubbeeck and Jones, 2004b).   
3. There is only one target host cell for the parasite (the macrophage). 
4. In all clinical trials in healthy volunteers, the candidate vaccines have proven 
to be not only safe, but immunogenic. 
5. The therapeutic efficacy of various vaccine candidates has been demonstrated 
in several studies.  This indicates the ability of these vaccines in producing an 
effective Th1 immune response.   
6. In several trials where LST was performed to measure immune response to 
vaccination, lower rates of infection were observed in the subset of 
participants whose LST converted after vaccination.  
7. An affordable and efficacious leishmaniasis vaccine could be major addition 
to the armament for the control of the disease.   
 
Therefore, developing a vaccine against leishmaniasis is desirable and feasible.  Yet, 
long-term prophylactic efficacy in humans has not been clearly, consistently and 
reproducibly demonstrated.  Even vaccine candidates with therapeutic efficacy and 
immunogenicity in healthy subjects have not been shown to have prophylactic 
efficacy.  Improving the structure of these vaccines, by introducing new adjuvants or 
antigens, could potentially improve their efficacy (e.g., adding alum to ALM+BCG, 
as discussed earlier).  Another contributing factor to the failure of clinical trials in 
demonstrating prophylactic efficacy could be the limitations and conditions imposed 
by the design and conduct of phase 3 vaccine trials that could adversely affect the 
outcome.  This subject will be discussed later, since one of the objectives for this 
thesis is to address some of these limitations. 
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1.8  Rationale for the thesis 
 
Given the problems with existing methods of control, an affordable prophylactic 
vaccine would be a major step forward in the control of leishmaniasis.  First 
generation vaccines have the advantage that they can be produced relatively simply at 
low cost within endemic countries.  With one exception, results of clinical trials of 
first generation vaccines do not support their efficacy.  However, their safety and 
immunogenicity, as important requirements, have been demonstrated.  Additionally, a 
lower disease incidence has been repeatedly observed in individuals who responded to 
vaccination (LST converted).  Given the need for a cost effective method of 
prevention and observations that support at least partial effectiveness of the FGVs, it 
seems the idea of FGV efficacy can not be rejected without thorough analysis of the 
existing body of clinical trial data.  Therefore, in addition to continuing vaccine 
discovery and development efforts, it would be important to reassess the existing 
body of clinical trial data to further examine hypotheses related to prophylactic 
efficacy.  Such reanalysis seems even more necessary in light of the mostly 
unavoidable problems and shortcomings in the design and conduct of clinical trials.   
 
1.8.1  Potential problems with individual field efficacy trials 
 
Field efficacy trials for prophylactic vaccines are subject to certain conditions and 
limitations that could adversely affect their outcome. The design of field efficacy 
vaccine trials should allow the vaccine to demonstrate its true ability to reduce the rate 
of infection in those who are vaccinated.  For this to happen, a desirable statistical 
power (ability to detect a real difference) should be achieved.  Parameters that affect 
power calculation are  
a) disease incidence,  
b) expected vaccine efficacy,  
c) sample size 
For a given sample size, lower incidence or lower efficacy could adversely affect 
power.   
 
Certain aspects of vaccine efficacy trials can reduce the effective power of the study 
to less than its nominal value.  Problems arising from the design and conduct of 
efficacy trials with the ability to affect study power include: 
 
Problem 1:    Expected incidence of leishmaniasis could vary dramatically due to 
known or unknown reasons.  Examples of reduced incidence can be 
found in several of Mayrink's trials in Brazil (discussed).   
 
Problem 2: Vaccine efficacy trials must be done in endemic foci, so that infection 
can be observed and compared between study arms.  Any travelling out 
of the endemic foci by study participants (in either study arm) would 
reduce the effective incidence. 
 
Problem 3: Unlike drug trials, vaccine efficacy trials normally take a long time to 
allow study participants enough exposure and the expected incidence 
rate to take effect.  After several years, many of the original study 
participants could be lost to follow-up due to a variety of reasons, 
leading to a reduction of effective sample size. 
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Problems 5:  In endemic foci a subset of the population are immune due to either 
 
 genetic make up (Nylen et al., 2006;Ramirez and Guevara, 1997),  
 previous exposure to the bite of the uninfected vector which would 
not cause infection but could generate a certain level of immunity 
(Kamhawi et al., 2000) without affecting LST.  
 
Therefore, a certain number of those who would have otherwise been 
protected by the vaccine in the vaccine arm only, are protected due to 
other reasons.  More importantly, they have immune counterparts in the 
placebo arm since randomization guarantees that individuals with these 
types of undetected immunity are assigned to both study arms with equal 
probability.  Thus, some of the vaccine's potential for inducing immunity 
unilaterally in the vaccine arm would not be realized and would be 
wiped out by similar immunity in the control arm.  Study power for 
detecting vaccine efficacy will be reduced proportionately to the percent 
of such individuals in both arms.   
 
Problems 6:  In addition to the above, LST performance is subject to considerable 
variation due to a variety of other reasons.  This variability in 
performance could allow unintended inclusion of individuals who are 
immune due to previous infection in the study.  This, too, would allow 
inclusion of already immune participants in both trial arms.  
 
These and a number of other problems and inconsistencies between individual trials 
could have adverse effect on the study power and the ability to draw a correct 
conclusion.  Furthermore, they can not be prevented by randomization.   
 
 
1.8.2.  Analyses in thesis 
 
Combining and re-analysing clinical trial data would allow testing of new hypotheses 
in addition to re-examination of original hypotheses. It can bring about the advantages 
of a greater sample size and the ability to observe efficacy in various sub-groups 
(demographics, etc), identify new risk factors and shed light on ways to improve upon 
existing vaccine candidates or methods of assessment (e.g., trial designs).  This 
approach would also enable new hypotheses that could not be originally tested due to 
the requirement of adherence to randomization and intention to treat principle in the 
original trial analysis.     
 
Results could provide a different and enhanced view of the existing information and 
could lead to conclusions beyond what has already been made in individual trials, or 
confirm that new statistically significant results cannot be arrived at despite the 
greater power afforded by larger sample size.  
 
The re-examination of the data will enable re-evaluation of efficacy of FGV's for 
prophylaxis against leishmaniasis in different settings: various vaccine types, different 
causative parasites and the use of adjuvants.  A meta analytic approach will be used 
for this re-evaluation.  Efficacy should also be examined in demographic subgroups 
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via meta-analysis to study differences in response to vaccination due to demographics.  
Furthermore, the immunological response in various subgroups to vaccination and 
natural exposure should be assessed. Studying these differences could shed light on 
immunological distinctions between endemic and non-endemic populations. Finally, 
since LST is widely used in epidemiological and clinical studies, its merits to provide 
a marker of immunity should be assessed. A variety of analytical techniques will be 
used to address these objectives. 
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CHAPTER 2 
 
RESEARCH OBJECTIVES AND METHODS 
 
 
2.1  Goal and objectives 
 
The overall goal of the present study is to re-analyse the existing data of clinical trials 
of first generation leishmaniasis vaccine candidates with the view to re-examine the 
efficacy and immunogenicity (DTH response) of the most promising vaccines and to 
reassess LST as a correlate of immunity.  We will investigate whether the information 
from all these trials combined supports the feasibility of a first generation 
leishmaniasis vaccine and could shed additional light on the following specific 
objectives: 
 
Objective 1:  Re-evaluate the efficacy of FGV's for prophylaxis against leishmaniasis.   
 
Ho1: None of the FGV's for which there are trial data has the ability to confer 
protection in the population. 
 
A. Efficacy of all vaccines overall: This  will indicate the ability of leishmanial 
antigens, overall, in producing immunity and immune response, regardless of 
the species used in the vaccine.  
B. Efficacy of different vaccine candidates prepared by various methods 
(parasite killed by heat, merthiolate, etc): L. major (against L. major, L. 
tropica and L. donovoni), L. amazonensis (against ACL), and re-examination 
of 3-antigen cocktail of L. amazonensis, L. Guayanensis and L. Brasiliensis 
(against ACL).   
C. Contribution of adjuvant (comparison of vaccines with or without 
adjuvant(BCG or alum)  
 
Ho2: The studied FGV's are unable to confer immunity even in specific 
subgroups 
 
D. Comparison of efficacy in the subgroups identified by demographic and risk 
behaviour: age, gender, occupation, native origin (endemic vs non-endemic 
area native).  
  
Objective 2:  Assess immunological response as a result of vaccination and natural 
exposure.   
 
Ho: Inhabitants of endemic and non-endemic areas and various demographic 
groups do not differ in their immunological response to leishmanial antigens 
(introduced as a vaccine or natural exposure). 
 
A. Comparison of immunological response to leishmanial antigens (measured 
by LST) between various demographic groups (age and gender) and between 
inhabitants of endemic foci and those originally from non-endemic areas.  
This includes assessment and comparison of : 
- response in the vaccine arm (as a result of vaccination + natural exposure) 
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- response in the control arm (as a result of natural exposure) 
 
Objective 3:  LST as a marker of immunity 
 
Ho: LST does not constitute a surrogate marker of immunity (overall and in 
endemic area natives) 
 
A. Ability of LST to indicate the underlying immunological response to 
leishmanial antigens. 
B. Relationship between LST response and actual protection. This objective is 
to verify the suggestion by some studies that FGV's can confer immunity in 
LST converters.   
C. Comparison of this relationship between subgroups identified by 
demographic and risk behaviour: age, gender, occupation, native origin. 
 
2.2  Methods 
 
2.2.1  Data 
 
The data from the following leishmaniasis vaccine trials in Iran, Sudan and South 
America were used in this research (some from published articles and some provided 
by the principal investigators).  These trials constitute all randomized, blinded, 
controlled efficacy trials of leishmaniasis vaccines with the exception of Armijos' 
second trial in Ecuador (Armijos et al., 2004) (which did not reach conclusive results 
due to significantly lower rates of leishmaniasis than expected). 
 
A. Zav3: Phase 3 trial of 3 injections of ALM+BCG against L. major in Zavareh, 
Iran (Khamesipour, personal communication, not published) 
B. Bor3: Phase 3 trial of 3 injections of ALM+BCG against L. major in Borkhar, 
Iran (Khamesipour, personal communication, not published) 
C. Bam3: Phase 3 trial of 3 injections of ALM+BCG against L. tropica in Bam, 
Iran (Sharifi, personal communication, not published) 
D. Bam1: Phase 3 trial of single injection of ALM+BCG against L. tropica in 
Bam, Iran (Sharifi et al., 1998) 
E. Esf1: Phase 3 trial of a single injection of ALM+BCG against L. major in 
Esfahan, Iran (Momeni et al., 1999).  The study population included many 
who had moved from non-endemic areas to the trial site 
F. Sudan 2: Phase 3 trial of 2 injections of ALM+BCG against L. donovani in 
Sudan (Khalil et al., 2000a) 
G. Brazil 1981 and 1983: Efficacy trials of 2 injections of a 5-strain vaccine 
(composed of brasiliensis and mexicana complexes, including L. guyanensis 
and L. amazonensis) in Amazonas, Brazil (Antunes et al., 1986).  Exposure 
limited to military missions. 
H. Colombia3: Phase 3 trial of 3 injections of L. amazonensis vaccine in 
Colombia (Velez et al., 2005) Exposure limited to military missions. 
I. Ecuador2: Efficacy trial of 2 injections of a 3-strain vaccine (L. guyanensis, L. 
brasiliensis, L. amazonensis)+ BCG, in Ecuador (Armijos et al., 1998) 
 
Individual level data were available and were used to calculate relative risk for trials 
A-E above, while published information was used for F-I. 
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2.2.2  Analysis 
 
Examination of structure and distribution of the data obtained from above studies to 
ensure their suitability and compatibility.  
 
Analysis of the data to address the stated objectives, using appropriate statistical 
methods -- including conventional techniques (graphical analysis, cross tabulation, 
regression and tests of statistical significance) and meta analytic techniques for 
combined analysis of different trials.  If the original participant-level data for a given 
study were not available the analysis was based on published trial results (this was the 
case for South American and Sudan trials).  
 
The data used in this study represent trials that are different with respect to: 
1. Parasite species used in the vaccine (L. amazonensis in South American 
vaccines, L. major in Iran and Sudan trials),  
2. Parasite geographical origin; e.g., local parasites used in Equador vaccine 
3. Antigen preparation (merthiolate vs heat killed), 
4. Same antigen but different vaccine dose; e.g., single, double or triple injection 
of ALM+BCG in various trials,  
5. Disease causing parasite and its epidemiology; e.g., L. tropica in Bam.   
6. Study population; e.g., indigenous to an endemic area, age composition,  
 
2.2.2.1  Analysis methodology 
 
This study is a re-examination of previous efficacy vaccine trials and relies on 
conventional analytic techniques as well as meta-analysis as a technique to ascertain 
underlying relationships not observable in individual trials.  Reviews provide an 
important tool for access to the results of multiple investigations.  Systematic reviews 
are believed by many to allow more objective appraisal of previous research(Egger et 
al., 2005a).  In addition to confirming previous results, systematic re-evaluation of 
studies could identify new findings and generate new research questions to be 
addressed in the future.  Randomized, controlled clinical trials of the prophylactic 
efficacy of leishmaniasis vaccine candidates have been conducted since the 1970's.  
The results of these studies vary from trial to trial, owing to the particular 
circumstances, disease epidemiology and immunology, the vaccine candidate, etc.  
Meta-analysis would enable studying the results of these studies in concert, thus 
minimizing the "noise" due to the specific limitations of individual trials and helping 
to resolve if there are conflicting findings in some studies. 
 
Internal validity and sources of bias in clinical trials and the present investigation:   
 
Internal validity implies that differences between groups in a clinical trial are 
attributable to the treatment of interest, plus some random error (Juni and Egger, 
2005).  In conducting systematic reviews and meta analyses it is important to ensure 
that the design and implementation of the original studies were appropriately done to 
maximize internal validity and minimize selection bias, bias due to outcome 
assessment and attrition bias(Egger et al., 2005b;Juni and Egger, 2005). 
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By design, and in contrast to observational studies, double blind randomized 
controlled clinical trials, when well conducted, have an important safeguard against 
bias (Egger et al., 2005b).   
 
The trials used in the present investigation have all been randomized, double blind 
controlled studies.  Therefore, appropriate measures for minimizing bias have been 
taken in their design and conduct.  In addition, most of these trials were done with 
collaboration and monitoring of WHO/TDR for adherence to protocol and measures 
of GCP (good clinical practice).  Data management, progress reports and monitoring 
reports by TDR monitors were retrieved from WHO archives and studied to ensure 
trials were done appropriately according to the approved protocol.   
 
The study in Zavareh (unpublished) was not done with formal sponsorship of TDR.  
However, TDR staff in charge of leishmaniasis were informed of the progress of the 
trial and maintained involvement.  The conduct and procedures of this trial were 
discussed with the Center for Training and Research in Skin Diseases and Leprosy, 
Medical University of Tehran, Iran and the staff involved in performing and data 
management of the trial.  The 1981 and 1983 studies by Mayrink were done 
independently of TDR.  However they are accepted as landmark trials of 
leishmaniasis vaccines and generally accepted as having been appropriately designed 
and conducted.  The second Armijos trial, also conducted with TDR involvement, 
suffered a lower than expected incidence rate which rendered the results inconclusive 
(since the power was calculated based on a much higher incidence rate).  This trial 
was, therefore, not used in the present analysis. 
 
Statistical approaches and considerations in meta-analysis: 
 
Note - In the following explanation of meta-analysis models and effect estimation, 
reference will be made to a usual 2 by 2 table such as the following: 
 
Study i Event
No 
event Group size
Vaccine ai bi n1i
Control ci di n2i  
 
where i identifies clinical trial.  In the present study, as in the original trials, "effect" is 
presented as relative risk (RR), where RR = (ai/n1i) / (ci/n2i). 
 
     * * *  
 
Two general approaches to processing data for meta-analysis include random effect 
and fixed effect models.  
 
1) Fixed effect model:  The fixed effect model assumes that individual studies 
measure a single (hence, "fixed"), true effect, θ, which will be estimated by the meta-
analysis pooled effect.  Consequently, the differences between effects in individual 
trials should be due to random errors of measurement -- rather than a real difference 
in what they measure.  Therefore, it is expected that variation in the measurement of 
the effect in different studies be comparable and reflect only chance.  If variation 
between and within different studies are comparable and not widely different (i.e., 
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studies are homogeneous), the fixed effect assumption is expected to hold.  As a result, 
in calculating the common, or pooled, effect, the average of the statistic of interest 
(e.g., relative risk) is calculated by simply weighting individual study effects 
according to their trial size (i.e., weighting by the relative quantity of information 
provided by the trial).  These weights can be calculated using a variety of methods, 
including inverse variance (I-V) and Mantel Haenszel (M-H) methods (Deeks et al., 
2005).  
 
Pooled effect estimation in the fixed effect model (inverse variance and Mantel-
Haenszel methods):  
 
The inverse variance method uses the inverse of the standard error (SE) of the effect 
measured in a study "i".  With RR being the effect of interest where 
 
θi = Ln(RRi) = Ln( (ai/n1i)/(ci/n2i)) 
 
SE of the logarithm of RRi (or LnRRi) is obtained by 
 
SE(Ln RRi) = √(1/ai)+(1/ci)-(1/n1i)- (1/n2i) 
 
The weight calculated for individual effects is 
 
ωi = 1 / SE(θi)2 
 
Thus, since n1i  and n2i  in the denominator of SE transfer to the numerator of the 
weight, weighting by ωi is equivalent of weighting individual effects by their 
respective sample size.   
 
The pooled effect size is given by 
 
Pooled θ = ∑ ωi θi / ∑ ωi     
 
With SE given by 
 
SE (pooled θ) = √1/ ∑ ωi 
 
The heterogeneity statistic is given by 
 
Q = ∑ ωi (θi - pooled θ)2  
 
Mantel-Haenszel Method is another fixed effect method of estimation.  In this method, 
similar to the inverse variance method, for each study, the effect size from each trial 
θi is given weight and the pooled effect is estimated as:    
 
Pooled θ = ∑ ωi θi / ∑ ωi   
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Unlike inverse variance method, relative effect measures are combined in their natural 
scale, although their standard errors and confidence intervals are computed on the log 
scale.  Weights for RR's are calculated as: 
 
ωi = cin1i/Ni  
  
Standard error of log RR is given by: 
 
SE(ln(RR) = √P/(R*S) 
 
Where 
 
P = ∑ ((n1i n2i)(ai + ci)-(ai ci Ni) / N2i); R = ∑ ((ai n2i) / Ni); S = ∑ ((ci n1i) / Ni) 
 
                                            
2) Random effect model: This model assumes the "true" effect to be not fixed, but an 
overall average effect with a normal distribution.  Each individual study is assumed to 
measure a point in this distribution. Therefore, individual studies could vary due to 
where they target in this distribution.    Consequently, compared to the fixed effect 
model, more heterogeneity between various studies is expected.  Therefore, a greater 
variation than attributable to chance (i.e., greater variation between studies compared 
to the variation within studies) would indicate heterogeneity and the appropriateness 
of a random effect model.  Due to the heterogeneity and the assumption that 
individual studies may not measure exactly the same thing, less emphasis (compared 
to the fixed effect model) is placed on size alone in weighting individual study results.  
This will place more emphasis on the differences between studies.  A common 
method for calculation of the pooled effect in random effect analysis is the 
DerSimonian-Laird method as described below (Deeks et al., 2005).  
 
Pooled effect estimation in the random effect model: 
 
The random effect model assumes a normal distribution for the treatment effect with 
mean θ and variance τ2.  The DerSimonian-Laird estimate of τ2 is as follows 
 
τ2 =  (Q-(k-1)) / (∑ ωi - (∑ ωi2 / ∑ ωi )') 
 
Where Q is the heterogeneity statistic, with τ2 set to zero if Q<k-1.  The ωi 
are calculated as in the inverse variance method, described above.  As in the fixed 
effect model, the natural logarithm of the effect size (if the effect size is RR or OR) is 
used.   
 
Individual study weights are given by 
 
ωi = 1/ (SE(θi )2 + τ2 ) 
 
As can be seen the main difference between the DerSimonian-Laired and the inverse 
variance methods is in the inclusion of τ2 in the former.  If τ2 is zero, the two models 
would be equivalent.  The pooled effect is given by  
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Pooled θ = ∑ ω'i θi / ∑ ω'i     
 
with its standard error being   
 
SE (pooled θ) = 1/ ∑ ω'i  
 
A measure of Heterogeneity in meta-analysis is I-squared that is based on Cochrane's 
Q. I-squared measures the amount of heterogeneity not explainable by chance (i.e, 
variablilty between studies) (Huedo-Medina et al., 2006).  Values of I-squared range 
from 0% to 100%. 
 
2.2.3  Thesis structure 
 
This study is organized in the following chapters:  
 
CHAPTER 1 - Background  
CHAPTER 2 - Research objectives and methods  
CHAPTER 3 - Efficacy of killed whole-parasite vaccines in prevention of 
leishmaniasis - a meta-analysis 
CHAPTER 4 - Prophylactic efficacy of whole-parasite killed vaccines in 
demographic subgroups 
CHAPTER 5 - Immunological response (measured by LST) in demographic 
subgroups to the leishmanial antigen introduced by vaccine or 
natural exposure  
CHAPTER 6 - LST response as a correlate of immunity 
CHAPTER 7 - Discussion 
CHAPTER 8 - Conclusions and recommendations for further research 
 57
CHAPTER 3 
 
EFFICACY OF KILLED WHOLE-PARASITE VACCINES IN PREVENTION 
OF LEISHMANIASIS - A META-ANALYSIS2 
 
 
Most trials of leishmaniasis vaccines have demonstrated no prophylactic efficacy 
when comparing the vaccine and the control arms.  However, the trial by Armijos et 
al (Armijos et al., 1998) suggested efficacy when comparing the two arms of the 
randomized trial of a locally produced tri-valent vaccine.  In addition, reduction in 
infection rate in a subset of the randomized sample (in the vaccine arm) has been 
demonstrated in several trials.  Studies by Antunes/Mayrink et al, Momeni et al and 
Khalil et al (Antunes et al., 1986;Khalil et al., 2000a;Momeni et al., 1999) have 
shown reduced incidence in the subset of participants whose LST results converted as 
a result of vaccination.  Additionally, Sharifi (Sharifi et al., 1998) showed a 
significant protection in boys, but not in girls. On the therapeutic side, several trials 
have demonstrated the efficacy of these vaccines for treatment of leishmaniasis 
patients. 
 
The objective of this analysis is to examine the results of all of these trials combined 
so that the effect of any possible specific adverse conditions or limitations associated 
with individual trials could be minimized.   This objective will be addressed by first 
examining the data from all previous efficacy trials and continuing with the analysis 
of more homogenous subsets of trials to study efficacy in groups that are 
homogeneous with respect to a given factor (such as the parasite species used in the 
vaccine).  The following 3 sets of analysis will be undertaken: 
 
A. Efficacy of all vaccines overall: This  will indicate the ability of leishmanial 
antigens, overall, in producing immunity and immune response, regardless of 
the species used in the vaccine. 
B. Efficacy of different vaccine candidates prepared by various methods (parasite 
killed by heat, merthiolate, etc): L. major (against L. major, L. tropica and L. 
donovoni), L. amazonensis (against ACL), and re-examination of 3-antigen 
cocktail of L. amazonensis, L. Guayanensis and L. Brasiliensis (against ACL).   
C. Contribution of adjuvant (comparison of vaccines with or without 
adjuvant(BCG or alum)  
 
3.1 Description and comparison of trials 
 
Tables 3.1a and 3.1b provide a summary description and comparison of various trials 
used in this study. 
 
 
 
 
                                                   
2 This chapter has been submitted in part for publication in th Vaccine (see Annex) 
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Table 3.1a - Leishmaniasis first generation vaccine trials 
Author
Sharifi           Momeni         Sharifi            
Khamesi-
pour            
Khamesi-
pour              Khalil             
Antunes, 
Mayrink          
Antunes, 
Mayrink         Velez             Armijos      Armijos         
Year Published 1998 1998 N/P N/P N/P 2000 1986 1986 2005 1998 2004
Study designation Bam1 Esf1 Bam3 Bor3 Zav3 Sudan2 Brazil 1981-2 Brazil 1983-2 Colombia3 Ecuador2 N/A
Background
Country,                                                           
Area
Iran,           
Bam
Iran,     
Esfahan
Iran,           
Bam
Iran,    
Borkhar
Iran,    
Zavareh
Sudan, 
Gedaref
Brazil, 
Amazonas
Brazil, 
Amazonas Colombia Ecuador Ecuador
Year(s) study conducted 1994-1997 1994-1997 1997-2000 1997-2000 1997-2000 1997-1999 1981 1983 2001-2003 1995-6? 2002?
Targetted parasite causing local disease
L. tropica L. major L. tropica L. major L. major L. donovani
L. pnamensis,     
L. braziliensis
L. panamensis, 
L. basiliensis, 
L.amazonensis
L. panamensis, 
L. basiliensis, 
L.amazonensis
Expected annual  incidence in controls 2% 5% 2% 6% 6% ? 9% 10%-25% 10%-25% 5% 7.5% 3%
Number of volunteers screened 12156 4712 6524 5869 a 2053 5093 ? ? 3018 ? 4164
Trial Design
Number of volunteers accepted and 
randomized 3637 2453 4217 2191 2008 2306 1312 1274 2597 b 1042 1995
N in vaccine arm (original, received 
complete vaccination schedule ---if known) 1839 1256, 1118 2149, 2082 1107, 964 945 1155 667 658 1302, 1252 552, 438 1009, 750
N in control arm (original, final) 1798 1197, 1122 2068, 2008 1084, 956 1063 1151 645 616 1295, 1251 487, 406 986, 756
originally planned (nominal) power 80% 80% 90% 90% 90% 90% 90% 90% 80% 90% 90%
Hypothesized vaccine effectiveness 
(expected %reduction in annual incidence)
50% 50% 50% 50% 50% 50% 50% 50% 50% 50% 50%
LST requirement for inclusion (LST=0 mm, 
LST<5 mm , etc) LST=0 mm LST=0 mm LST=0 mm LST> 0 mm LST> 0 mm LST=0 mm LST negative LST negative LST<3 mm LST< 5 mm LST< 5 mm
Length of time post vaccination for LST 
testing 80 days, 1 yr 80 days, 1 yr 80 days, 1 yr
80 days, 1yr, 
1yr+80 days Not done 42 days, 1 yr 40-45 days 40-45 days Not done 1 month 2 months
Number of vaccine injections 1 1 3 3 3 2 2 2 3 2 2
Time between vaccine injections single dose single dose 30 days 75 days, 1 yr 30 dqys 28 days 7 days 7 days 20 days 30 days 56 days
Dose of Leishmania  antigen injected (each 
injection) 1 mg ALM 1 mg ALM 1 mg ALM 1 mg ALM 1 mg ALM 1 mg ALM
240 ug 
Nitrogen
240 ug 
Nitrogen
11.11 mg 
protein/mL 72 mill promast. 240 ug Nitrogen
Injection method ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) IM (1 mL) IM 1(mL) IM (1 mL) ID (0.1 mL) ID (0.1 mL)
Control treatment
BCG BCG BCG BCG BCG BCG
PBS + 
merthiolate
PBS+ 
mrthiolate Saline (ph=7.4) BCG BCG
Duration of follow up (months) 12+12 12+12 36 24 24 12 12 12 12+48 12+14
Type of case detection during follow up 
(A=active, I=inactive) A/I A/I A/I A/I A/I A/I A A A A A  
a 2671 of 5869 were qualified for randomization but 492 participated in phase I/II trial. 
b Recruitment was done in 3 groups:  Sept-Nov/01 (989), Jan-March/)2 (1131), Jul-Aug/02 (477)  
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 Table 3.1a (continued) - Leishmaniasis first generation vaccine trials 
Author
Sharifi           Momeni         Sharifi            
Khamesi-
pour            
Khamesi-
pour              Khalil             
Antunes, 
Mayrink          
Antunes, 
Mayrink          Velez             Armijos      
Year Published 1998 1998 N/P N/P N/P 2000 1986 1986 2005 1998
Product Profile
Parasite species in vaccine L. major L. major L. major L. major L. major L. major 5 Leishmania 
strains g
5 Leishmania 
strains g
L. amazonensis L. braziliensis,  
L. guyanensis,  
L. amazonensis
Parasite killing method Heat Heat Heat Heat Heat Heat Merthiolate Merthiolate Merthiolate Phenol
Antigen origin Iran Iran Iran Iran Iran Iran Brazil Brazil Brazil Ecuador
Adjuvant BCG BCG BCG BCG BCG BCG None None None BCG
Vaccine Antigen manufacturer Razi, Iran Razi, Iran Razi, Iran Razi, Iran Razi, Iran Razi, Iran Local Local Biobras Local
Adjuvant (BCG) manufacturer Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran N/A N/A N/A Tokyo
BCG concentration/injection
1/10 normal 
dose
1/10 normal 
dose
1/10 norm al 
dose
1/10 normal 
dose
1/10 normal 
dose
1/10 normal 
dose N/A N/A N/A
1/2 normal dose 
(500,000 
organisms)
Leishmanin manufacturer
Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran ? ?
Colombian Nat'l  
Inst. of Health Local
Leishmanin composition
L. major L. major L. major L. major L. major L. major ? ?
L. amazonensis, 
L. panamensis sam e as vaccine
Findings
Yr 1: Observed incidence in controls
2.17% c N/A d 3.77% 1.75% 1.70% N/A f
11.07% (gr 1),  
1.40% (gr 2) 1.30% 6.80% 7.60%
Yr 1: Observed incidence in vaccine arm
2.01% c N/A d 3.16% 1.36% 1.40% N/A f
8.70% (gr 1), 
1.16% (gr 2) 0.61% 7.76% 2.10%
Yr 1: Efficacy (= 1-(% case vaccine 
arm/%case control arm) 7.4% N/A 16.2% 22.3% 17.6% N/A
21.4% (gr 1),    
17.1% (gr 2) 53.1% -14.1% 72.4%
Yr 2: Observed incidence in controls 1.2% c N/A d 1.76% 4.04% e 10.70% N/A f N/A N/A N/A 9.19% h
Yr 2: Observed incidence in vaccine arm 0.83% c N/A d 1.68% 4.67% e 11.40% N/A f N/A N/A N/A 4.41% h
Yr 2: Efficacy 30.8% N/A 4.5% -15.6% -6.5% N/A N/A N/A 52.0%
Volunteers endemic origin
Low endemic
Mixed (army 
base) Low endemic Endemic New endemic
different 
villages
Mixed (army 
concripts)
Mixed (army 
conscripts) Mixed (army) Endemic
Age (range, mean) 6-15, 9.1 5-72, 18.2 6-12, 7.41 6-13, 8.45 5-59, 19.12 1-65, 6.9 18.6 18.6 >18, 19.8 approx mean 5.6
Sex (% male) 50.60% 47.40% 50.80% 50.70% 46.80% 45.70% 100% 100% 100% 44.16%
Protection observed in the overall sample No No No No No No No No No Yes
Protection  in those with converted  LST 
after vaccination No Yes No No Not done Yes Yes No Not done N/A
LST conversion rate (per protocol) 40-80 
days post vaccination (vaccine arm, 
Controle arm) 16.5%, 3.2% 36.2%, 7.9% 18.2%, 2.0% 
29.9%, 6.1% 
(Received 2 
doses year 1) Not done 30%, 7% 33% 70% Not done 85.1%, 20.1%       
(Footnotes on the next page) 
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Bor3, Zav3, Bam3 findings are ITT. Other trials from published information.
c Cumulative 2-year incidence: Vacc=2.8%, BCG=3.3%, overall efficacy=15%
d Annual rate not reported. Cumulative 2-year incidence: vacc=18.0%, BCG=18.5%, overall efficacy=3%
e Third year incidence in Bor3: 6.64% (Control), 6.44% (Vaccine)
f Annual rate not reported. Cumulative 2-year incidence: vacc=11.5%, BCG=12.3%. Overall efficacy=6%
g Brasiliensis and mexicana complexes
h Reported by Armijos 2003  
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3.1.1  Demographic composition 
 
The demographic make up of trials used in this analysis are presented below: 
 
Table 3.1b - Age and sex distribution in clinical trials used in the meta-analysis 
Study
Trial arm V * C * V C V C V C V C V C V C V C V C V C
N 1838 1795 1190 1124 2149 2068 1107 1084 941 1055 1155 1151 667 644 658 616 1302 1295 438 406
Age (yrs)
Minimum 6 6 5 5 6 6 6 6 5 5 <3 <3
Maximun 15 15 67 72 12 12 13 13 59 59
Mean 9.1 9.1 18.0 18.8 7.4 7.4 8.2 8.7 19.0 19.2 6.5 7.2 18.6 18.6 18.6 18.6 19.8 19.8 5.4 5.7
P value  
(Kruskal-
Wallis H)
SEX
% Female 47.1 51.8 52.7 52.6 48.8 49.6 46.3 52.4 50.2 48.9 53.3 55.3 0.0 0.0 0.0 0.0 0.0 0.0 57.5 54.3
P value 
(Fisher 
Exact)
N/A 0.349
-- 0.271
0.003 0.496 0.302 0.002 0.323 0.599 N/A N/A
0.822 0.118 0.132 0.000 0.666 0.010 -- --
Colombia3 Ecuador2Zav3 Sudan2 Brazil1981 - 2 Brazil 1983 - 2Bam1 Esf1 Bam3 Bor3
 
*   V=vaccine arm, C=control arm 
Note: The Kruskal-Wallis test and associated probabilites test the equality of mean for age 
 
Trials in Brazil and Colombia (4 out of 11 trials), were done strictly in male soldiers, leaving the Ecuador trial as the only South American study 
with female+male participants.  Other trials include a mix of gender and age.
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3.1.2  Vaccine immunogenicity (DTH) in various trials 
 
LST measured 42 to 80 days post-vaccination (depending on the trial) in vaccine and 
control arms in various trials are displayed in the table 3.2.  LST induration is an 
inexact indication of the intensity of immune response (DTH) to the antigen--i.e., the 
ability of the vaccine to produce a cell mediated immune response.  LST induration 
equal to or greater than 5 mm is generally accepted as positive response and an 
indication of significant immunogenicity.   
 
The table indicates that LST conversion is more frequently observed in the vaccine 
arms of trials.  It is also observed in control arms in a small percentage of participants 
as a result of BCG injection (if BCG is used as placebo) or possibly natural exposure.   
As can be seen, post vaccination LST was not conducted in all trials.   
 
It should be pointed out that the Brazil study in 1981 by Mayrink, Antunes et al 
(results reported along with 1983 trial results by Antunes et al. 1986), was conducted 
in two separate cohorts.  These cohorts were different with respect to observed 
incidence, duration of exposure, previous vaccination history, etc.  In the present 
analysis, these two cohorts are treated as two separate studies (identified as Brazil 
1981A-2 and Brazil 1981B-2) due to the differences in trial conditions and 
participants' vaccination history (Antunes et al., 1986).  This is reflected in the 
following table. 
 
Table 3.2 - LST conversion 42-80 days post-vaccination in initially LST negative 
individuals 
Post 
vaccination 
LST Trial arm N
% LST  
≥5 mm
V * 1807 16.5
C * 1761 3.3
V 1168 36.2
C 1104 7.9
V 1980 18.2
C 1935 2
V 608 29.9
C 538 6.1
V 772 --
C 901 --
V 1919 30
C 1005 7
V 311 33
C -- --
V 338 37
C -- --
V 611 68
C -- --
V -- --
C -- --
V -- --
C -- --
Brazil 1983-2
Colombia3
Bam1
Esf1
Ecuador2
Zav3
Sudan2
Brazil1981A-2
Brazil1981B-2
Bam3
Bor3
 
*   V = vaccine arm, C = control arm 
-- = LST not measured 
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Note: In most of the listed trials an exclusion criterion of LST>0 mm or, at least, LST 
negative (e.g., LST>3 in Colombia) was used.  However, in Bor3 and Zav3, LST was 
not an exclusion criteria and volunteers with any values of LST were enrolled in order 
to compare the vaccine effect in those with or without previous exposure.  To address 
the current objective of overall vaccine efficacy, participants in Bor3 and Zav3 with 
LST>0 mm were excluded for consistency with other trials and to be able to isolate 
the effect of the vaccine from that of previous natural exposure.  
 
3.2  Efficacy of all vaccines overall 
 
This analysis combines previous trials, regardless of vaccine formulation (e.g., the 
species of the parasite used as the antigen, the use of adjuvants, etc), or the 
epidemiology of the local disease (species of the parasite causing the disease, 
incidence rate, etc).  As mentioned, Zav3 and Bor3 participants with pre-vaccination 
LST>0 mm were excluded from this analysis (12.2% of Zav3 and 40% of Bor3).  
Trial results are summarized in table 3.3. 
 
Table 3.3 - Results of efficacy clinical trials over the entire follow-up period    
 
Study 
Follow-up 
(months)
Vaccine 
Total N
Vaccine 
Cases 
Control 
Total N
Control 
Cases
% Case 
(vaccine)
% Case 
(control)
Vaccine 
efficacy
Bam1 24 1838 52 1795 60 2.83 3.34 15%
Esf1 24 1190 214 1124 208 17.98 18.51 3%
Bam3 24 2082 81 2008 93 3.89 4.63 16%
Bor3 36* 604 64 561 63 10.60 11.23 6%
Zav3 24 742 102 868 109 13.75 12.56 -9%
Sudan2 24 1155 133 1151 141 11.52 12.25 6%
Brazil 1981A-2 12 322 28 289 32 8.70 11.07 21%
Brazil 1981B-2 12 345 4 356 5 1.16 1.40 17%
Brazil 1983-2 12 658 4 616 8 0.61 1.30 53%
Colombia3 12 1302 101 1295 88 7.76 6.80 -14%
Ecuador2 12 333 7 316 24 2.10 7.60 72%  
* Although there were 3 years follow up, only cases from years 2 and 3 are included in this 
analysis because vaccination was completed end of yr 1. 
 
 
More details about the conduct of these trials are available in tables 3.1a and 3.1b, 
presented earlier (table 3.1a).   
 
3.2.1  Meta-analysis results 
 
The hypothesis to be tested: 
 
H0: RR(in pre-vaccination LST=0 participants, all trials combined) = 1 
H1: RR(in pre-vaccination LST=0 participants, all trials combined) ≠ 1 
 
To test this hypothesis, the "metan" program in Stata 9 was used to calculate relative 
risk estimates and corresponding 95% confidence intervals.  The inverse variance (I-V) 
and the Mantel-Haenszel (M-H) methods were used separately to fit the fixed effect 
model and the DerSimonian-Laird (D+L) method to fit the random effect model.  The 
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RR values, associated confidence intervals and the weights assigned by each 
estimation method are presented in the following table.   
 
Table 3.4 - Relative risks, 95% confidence intervals and meta-analysis weights  
Study N RR I-V M-H D+L
Bam1 3633 0.846 0.587 1.22 6.32 7.26 8.33
Esf1 2314 0.972 0.818 1.155 28.37 25.59 19.66
Bam3 4090 0.84 0.628 1.124 9.94 11.32 11.41
Bor3 1165 0.944 0.679 1.31 7.84 7.81 9.72
Zav3 1610 1.095 0.851 1.408 13.34 12.02 13.66
Sudan2 2306 0.94 0.753 1.174 17.08 16.89 15.63
Brazil 1981A-2 611 0.785 0.485 1.271 3.64 4.03 5.39
Brazil 1981B-2 701 0.826 0.224 3.049 0.49 0.59 0.86
Brazil 1983-2 1274 0.468 0.142 1.547 0.59 0.99 1.02
Colombia3 2597 1.142 0.867 1.503 11.15 10.55 12.27
Ecuador2 649 0.277 0.121 0.633 1.23 2.95 2.05
100 100 100
95% Conf. Int
Weight (%)
 
 
The weight assigned to the Ecuador trial varies substantially (by about 100%) from 
the IV method to the D+L.  This reflects the tendency of the fixed effect model to give 
smaller weights to smaller trials.  
 
The heterogeneity statistics estimated by the three methods are very similar, as 
indicated by the following table.  The p values associated with the heterogeneity chi 
square statistics in all methods are >0.05.  These results suggest that the heterogeneity 
among the trials is minimal and results are consistent with a fixed model.  Comparing 
the RR's (table 3.4) from the Old World trials with those of the New World trials 
shows that most of the heterogeneity is due to the latter group. However as the 
weights in table 3.4 indicate, there is very little difference in the estimation of the 
pooled RR by the three methods.  
 
Table 3.5 - Heterogeneity statistics in the 3 methods of meta-analysis 
Method
Heterogeneity 
Chi square d.f. p I-squared
I-V 14.59 10 0.148 31.50%
M-H 14.62 10 0.146 31.60%
D+L 14.62 10 0.146 31.60%  
I-square is a measure of heterogeneity not explainable by chance, ranging from 0% to 100% 
 
Pooled RR estimates and the 95% CI estimated by the 3 methods (table 3.6) are very 
similar regardless of the model used and lead to similar conclusions.   Overall, the 
hypothesis of RR=1 (i.e., no efficacy) can not be rejected. 
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Table 3.6 - Meta-analysis pooled estimates of RR and confidence intervals 
Pooled 
Method RR z value P
I-V 0.947 0.864 1.038 1.16 0.246
M-H 0.939 0.857 1.029 1.34 0.179
D+L 0.928 0.821 1.049 1.2 0.231
95% Conf. Int
Test of RR=1 
 
 
Therefore, the hypothesis that the overall effect is not different from 1, i.e.,  
 
H0: RR(in pre-vaccination LST=0 participants, all trials combined) = 1  cannot be rejected. 
 
The "forest plot" in figure 3.1 presents a graphical comparison of the results of these 
trials and the pooled effect.  Gray square boxes represent the relative size of each trial 
with the centre dot and the line in the centre of each square representing the RR and 
its 95% CI. The overall RR is depicted by two blank diamond boxes, representing the 
M-H and the D+L estimates.   
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Figure 3.1 - Forest plot of vaccine efficacy measure in different leishmaniasis vaccine trials  
M-H Overall  (I-squared = 31.6%, p = 0.146)
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0.93 (0.82, 1.05)
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0.94 (0.75, 1.17)
0.47 (0.14, 1.55)
0.79 (0.49, 1.27)
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The forest plot summarizes the information in the previous tables. While Old World 
trials are clustered around the vertical line of RR=1 (i.e., homogeneous but with 
minimal efficacy), South American trials tend to be scattered on the left of that line, 
suggesting more heterogeneity but also more efficacious results.  The Ecuador trial, 
the only trial with significant results, is located in the far left of the forest plot.  
Despite their lower individual RR values, these trials have limited impact on the 
pooled RR due to their smaller sample sizes. Other statistics, such as the 
heterogeneity statistics and the pooled RR (with 95% CI) are also depicted on the 
graph.   
 
A graphical display of the influence of individual trials on the pooled RR is presented 
in the following figure.  This graph shows the values of the pooled RR, when studies 
are omitted one at a time. The reference line in the centre is the overall, pooled RR.   
Thus, the pooled RR when Esf1, Zav3 or Colombia3 trials are omitted tends to the left 
of the overall estimate. In other words, these trials have relatively strong influence on 
bringing the overall  RR closer to 1.  Both Bam trials, Brazil1981A-2 and Ecuador2 
have a favourable influence on the pooled estimate. 
 
Figure 3.2 - Influence of individual trials on pooled RR 
 
Another graphical representation of the variability in meta-analysis is provided by a 
"funnel plot" which is constructed by plotting RR against the standard error of RR 
(SE(RR) represents size and variability in each trial); both axes are in logarithmic 
units (Sterne et al., 2005).  The centre line of the graph is the estimated pooled RR 
while the two oblique lines indicate the expected limits of the confidence band for RR 
for any given standard error. The CI becomes larger as SE(RR) increases; hence the 
funnel shape.  Values outside the funnel represent out of range RR for a given SE(RR).  
Values of RR that are within the expected range for the given SE(RR), form a 
triangular plot symmetrically scattered around the centre line.  An asymmetrical, 
triangular scatter of RR's around the centreline would point at possible problems (or 
bias) in the selection of the trials - i.e., individual study RR's should be over and under 
the pooled RR, with roughly equal frequency.  In other words, they should not 
systematically be missing from either side and outside the oblique lines (which would 
represent a bias).  The funnel plot for the present meta-analysis is presented below  
 
Figure 3.3 - Funnel plot of leishmaniasis vaccine trials 
 
 
 
 
The above graph and the funnel plot in figure 3.3 suggests the RR from the Ecuador 
trial to be somewhat out of range for its given study size and variability. Additionally 
figure 3.3 Additionally, the downward trend of all points in figure 3.3 may indicate a 
small bias (better vaccine effect in smaller studies).  
 
A statistical analogue of a funnel plot is Egger's test which is a regression-based 
approach to assessing bias (symmetry of the plot).  It consists of a weighted 
regression of the effect size on standard error:  RR = b0+ b1s  where weights are 
inversely proportional to the variance of the effect. However, simulations by (Sterne 
et al., 2005)  have demonstrated low sensitivity for this test when the number of trials 
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is less than 20 or the bias is not substantial.  Therefore, the results of Egger's test are 
not reported here.  
Figure 3.3 - Funnel plot of leishmaniasis vaccine trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3  Efficacy related to different vaccine formulations and causative parasite  
 
In further analysis of these vaccine trials it should be considered that they were 
conducted to test the efficacy of different vaccines based on different antigens, against 
different causative agents and with or without BCG.  It is reasonable allow for these 
sources of difference by studying groups of more similar trials with a common 
vaccine formulation and/or epidemiological setting.  
 
Two sets of analyses will be conducted in groups of trials that are similar with respect 
to antigen/vaccine formulation and causative parasite. 
 
 
3.3.1  Subgroup analysis 
 
3.3.1.1  Analysis based on vaccine formulation:  
 
The candidate vaccines that were in trial in the Old World and the New World were 
different on a number of characteristics.  Chemical inactivation of the parasite was the 
common method in vaccine preparation in the New World trials.  In contrast, those in 
the New World were all heat killed (see the trial comparison table).   Another 
distinction between the Old World and the New World vaccines was the parasites 
species used as the antigen in the vaccine. L. amazonensis was the common parasite 
used in all South American vaccines (in Ecuador it also included L. braziliensis and L. 
guyanensis) usually without adjuvant (except in Ecuador), while L. major plus BCG 
constituted the Old World vaccines.  Consequently, differences in the results of the 
Old World and the New World trials could be due to one or more of such factors that 
are in effect simultaneously.  Due to this confounding, it is not practical to separately 
Begg's funnel plot with pseudo 95% confidence limits
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assess the effect of parasite species and the method of inactivation.  But it is possible 
to study the two effects in combination.  In this analysis, the symbols NW (New 
World) and OW (Old World) will be used to identify the two groups of trials. 
 
As an exploratory step, a regression analysis was conducted to investigate whether the 
effect size in the OW vaccines is significantly different from that in the NW (metareg 
command in Stata's metan program).  The regression model was set up as: LnRR= 
f(vaccine formulation), i.e., natural log of RR regressed on a binary variable 
indicating Old World and New World.  Results, presented below, suggest no 
significant difference in RR due to vaccine formulation. 
 
Table 3.7 - Regression results: LnRR= f(vaccine formulation) 
Coef. Std. Err. z p
Vacc formulation 0.04 0.12 0.34 0.73 -0.20 0.29
Constant term -0.09 0.11 -0.79 0.43 -0.31 0.13
95% Conf. Int.
 
 
At the next step, OW and NW trials were meta analysed separately to investigate RR 
in each set of trials. 
 
 
3.3.1.1.1  New world (NW) trials:  
 
The hypothesis to be tested is formulated as: 
 
H0: RR(in pre-vaccination LST=0 participants, NW trials combined) = 1 
H1: RR(in pre-vaccination LST=0 participants, NW trials combined) ≠ 1 
 
The following table present the results of NW trials: 
 
Table 3.8 - South American trial results and meta-analysis weights 
 
Study N RR
I-V D+L
Brazil 1981A-2 611 0.785 0.485 1.271 21.28 26.77
Brazil 1981B-2 701 0.826 0.224 3.049 2.89 10.85
Brazil 1983-2 1274 0.468 0.142 1.547 3.46 12.22
Colombia3 2597 1.142 0.867 1.503 65.16 31.71
Ecuador2 649 0.277 0.121 0.633 7.21 18.45
Weight (%)95% Conf. Int.
 
 
The heterogeneity observed in the results of these trials is as follows:   
 
Table 3.9 - Heterogeneity in South American trials 
Method
Heterogeneity Chi 
sq p I - squared
I-V 12.12 0.017 0.67
D+L 12.18 0.016 0.672  
 
These statistics point at the significant heterogeneity in NW trials.  This heterogeneity 
stems primarily from the Colombian trial with the smallest effect and largest sample 
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size.  This heterogeneity is demonstrated by the following table.  As a result of its 
sample size, in the meta-analysis of these trials, the Colombia trial sways other trial 
results in its own direction.   
 
Figure 3.4 - Influence by Colombia trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the sizeable difference between Colombia and other trials' results, the overall 
RR is not statistically significant based on the random effect model (which is the 
appropriate model, given the large heterogeneity) or even the fixed effect model (table 
3.10).  Therefore, the hypothesis that the RR in all NW trials is not different from 1 
can not be rejected. 
 
Table 3.10 - Meta-analysis results for South American trials (all trials) 
Pooled 
Method RR z p
I-V pooled RR 0.914 0.732 1.142 0.79 0.43
D+L pooled RR 0.688 0.41 1.156 0.141 0.158
Test of RR=1 
95% Conf. Int.
 
 
Excluding the Colombia trial reduces the heterogeneity to non-significant levels and 
leads to statistically significant pooled RR based on the trials in Ecuador and Brazil, 
as follows: 
 
Table 3.11 - Meta-analysis results for South American trials (Colombia excluded) 
Pooled 
Method RR z p
I-V 0.604 0.414 0.88 2.63 0.009
M-H 0.576 0.398 0.834 2.93 0.003
D+L 0.551 0.315 0.966 2.06 0.037
Test of RR=1 
95% Conf. Int.
 
 
Brazil 1983-2
Colombia3
Ecuador2
Brazil 1981A-2
Brazil 1981B-2
Study omitted
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As indicated by the above results of three estimation models, exclusion of the large 
trial in Colombia renders the combined result of other trials in South America 
significant.  This approach is directed by the heterogeneity stemming from the 
Colombia trial.  However, it should be kept in mind that this trial was a large, well 
managed, internationally sponsored trial and its exclusion could introduce an 
unknown bias.  Furthermore, it could be argued that in most circumstances, by 
exclusion of trials with effect values in the opposite direction of other trials, one could 
finally reach a subset with statistically significant combined effect; an unjustifiable 
approach.  One trial-specific situation that could provide an explanation for the 
difference between Colombia and other trials may be the possibility of ineffectiveness 
L. amazonensis in creating cross immunity with L. panamensis, an important 
causative species in Colombia.  There is some evidence epidemiologically that those 
infected with L. amazonensis are still susceptible to infection by L. panamensis (R. 
Killick-Kendrick, personal communication). Another explanation may be that in the 
Colombia trial, by design, volunteers with LST<3 mm at the time of screening were 
enrolled.  To the extent that such reactive LST (LST>0) is linked to endemic 
immunity, the study power would be compromised and efficacy estimate biased 
downward. This extent is unknown and the individual level data to identify the 
number of LST reactive participants was not available for verification.   Therefore, at 
the current level of information, this analysis provides some basis for further 
exploration of the difference between Colombia and other trials. 
 
 
3.3.1.1.2   Old world (OW) Trials:  The OW trial set was studied to see if a strong 
homogeneity and/or influence of a particular trial is a possible source of overall low 
efficacy.  No evidence of significant heterogeneity or influence was observed, with 
the M-H heterogeneity chi square of 2.36 (p= 0.797).  H-M Pooled RR = 0.951 
(p=0.330).  Therefore, no further breakdown of the OW trials into more homogeneous 
sets seems to change the results.  
 
 
3.3.1.2  Analysis based on causative Leishmania species:   
 
The causative parasite between South America trials (L. braziliensis, L. Mexicana or 
L. Peruviana complexes), Iran trials (L. major or L. tropica) and the Sudan trial (L. 
donovani) are distinct.   Multiple parasite species could cause the disease in each 
location in South American trial sites and there is not enough information to separate 
the trials into homogeneous subsets with respect to the causative parasite.  Therefore, 
the NW set can not be analysed.  The OW trials, on the other hand provide a better 
opportunity for this analysis since there are multiple trials with the same parasite 
species causing the disease:  two trials in Bam, where the majority of cases are due to 
L. tropica, and three in Esfahan, Borkhar and Zavareh, where the disease is due to L. 
major.  Since there is only one trial of L. donovani in Sudan, it can not be further 
analysed.  
 
Tables 3.12 and 3.13 display the results of pooling of Bam and Esfahan/trials: The 
heterogeneity chi square for the both sets of analysis have p>0.05.  
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Table 3.12 - Bam1 and Bam3 trials 
Pooled 
Method RR z p
M-H pooled RR 0.843 0.671 1.058 1.47 0.141
Test of RR=1 
95% Conf. Int.
 
 
 
Table 3.13 - Esf1, Bor3, Zav3 trials 
Pooled 
Method RR z p
M-H pooled RR 0.999 0.877 1.139 0.01 0.993
95% Conf. Int.
Test of RR=1 
 
 
 
From the above analyses, it is concluded that the breakdown of the data into sets with 
common causative parasite does not improve efficacy results, although the RR in Bam 
trials seems to be slightly better.   
  
Consistent results are reached by a regression analysis of lnRR regressed on a binary 
variable with 0 for L. major and 1 for L. tropica, as follows (table 3.14): 
 
Table 3.14 - Regression results of Bam1, Bam3, Bor3, Esf1, Zav3 trials 
Coef. Std. Err. z p
parasite -0.17 0.13 -1.27 0.20 -0.43 0.09
constant 0.00 0.07 -0.02 0.99 -0.13 0.13
95% Conf. Int.
 
 
 
3.4  Contribution of adjuvant ( analysis based on adjuvant)  
 
The role of BCG in induction of the Th1 immune response is well known and its 
presence in leishmaniasis vaccines is believed to play a role in the vaccine 
immunogenicity (Alimohammadian et al., 2002).  Although BCG led to LST 
conversion in a percentage of trial participants, the conversion was generally not long 
lasting.  The down side of using BCG as an adjuvant is the requirement to use it as the 
control treatment if double blinding is desired.  Double blinding with BCG and the 
effect of BCG in LST conversion and (possibly) a certain level of resulting protection 
could make it difficult to see the relationship between LST conversion and vaccine 
induced immunity (Armijos et al., 1998).  To address the question of the role of BCG 
in protection, trials with and without BCG adjuvant will be compared for induced 
protection. 
 
Table 3.15 depicts the results of regressing the LnRR on a binary variable named 
"adjuvant" with 0 for trials without BCG and 1 for those with it.  A significant model 
coefficient would indicate a relationship beyond chance: 
 
  Table 3.15 - Meta regression results of Bam1, Bam3, Bor3, Esf1, Zav3 trials 
Coef. Std. Err. z p
adjuvant -0.07 0.13 -0.53 0.59 -0.32 0.18
constant 0.00 0.12 0.03 0.98 -0.23 0.23
95% Conf. Int.
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As the table demonstrates, neither the model slope nor the constant are statistically 
significant (p > 0.05).  Therefore the hypothesis of "no relationship" cannot be 
rejected. 
 
3.5  Summary:  As discussed in Chapter 1, with the exception of the trial in Ecuador 
no other efficacy trials had shown significant protection attributable to any of the 
leishmaniasis vaccines, when comparing the entirety of the two randomized trial arms.  
The forgoing analysis combines the results of all efficacy trials to go beyond 
limitations of individual trials.  Potentially, many problems and limitations could 
adversely affect the results of individual trials.  Problems such as lower-than-expected 
incidence, misclassification of exposed/protected people as unexposed and occasional 
problems with the conduct of a trial could have a negative impact on a given trial's 
statistical power.  Other problems such as the length of the required follow-up period 
could also affect the final sample size and power.  Combining the results of trials in a 
meta-analysis framework and simultaneously analysing them could help bypass 
problems with individual trials.  
 
All studies were first combined for an overall analysis without accounting for 
differences in their vaccine antigen, use of adjuvant, causative parasite, etc.  Next 
more homogeneous trials (based on the vaccine type and causative parasite species) 
were grouped and analysed separately.  The efficacy results of the overall analysis of 
all trials combined were not different from the results of individual studies; i.e., no 
efficacy.  Similarly, grouping trials by their antigenic content (separately for L. major 
and L. amazonensis vaccines) did not suggest significant protection.  However, when 
considering L. amazonensis vaccine trials (i.e., all those in South America), the 
exclusion of the largest clinical trial, a TDR-sponsored study conducted in Colombia,  
and leaving the Ecuador and the Brazil trials in the analysis, yielded significant 
efficacy results.  This approach could be disputed since it ignores the information 
from the largest trial in South America. Additionally, it could be viewed as an 
arbitrary exclusion of a trial.  The argument in favour of this approach is that, the 
Colombia trial could act as the centre of gravity to all trials, drawing their results in its 
own direction by imposing possible trial specific limitations. This, coupled with the 
possible ineffectiveness of L. amazonensis in producing cross immunity against L. 
panamensis provide a justification for excluding the Colombia trial. Additionally, the 
Colombia trial included a number of participants with pre-vaccination LST between 0 
and 3 mm.  If any protection could arise as a result of the pre-vaccination LST>0, 
then this would have had an effect on the study power.  In light of this observation, it 
may be worthwhile to further explore the Colombia trial results and possibly the L. 
amazonensis potential for vaccine development. 
 
Grouping trials by other factors such as the causative parasite (L. tropica or L. major) 
or inclusion of BCG as adjuvant did not lead to significant efficacy results. 
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CHAPTER 4 
 
INCIDENCE AND PROPHYLACTIC EFFICACY OF KILLED WHOLE-
PARASITE VACCINES IN DEMOGRAPHIC SUBGROUPS 
 
 
It is generally believed that in the context of leishmanial infection, immunity is 
correlated with previous/repeated exposure.  This is also seen in other diseases such as 
malaria where, in endemic areas, a form of acquired immunity develops with 
continuous/repeated exposure. Demographic characteristics, primarily age and gender, 
are associated with behaviour that could augment the risk of exposure and/or infection. 
Playing and working outdoors, sleeping habits, coverage of the body and so on, are all 
age/gender related behaviour and can affect risk in an endemic area.  Additionally, 
age is directly related to the length of exposure and accumulated likelihood of 
infection or immunity. Genetic differences between males and females could also 
have an impact on response to the leishmanial antigen.  Consequently, it is important 
to investigate vaccine efficacy separately in demographically homogeneous sub-
groups.  The demographic variables of primary importance which have been 
measured in all leishmaniasis vaccine trials are age and gender.  Other variables such 
as school and grade, also collected in some studies, highly correlate with these two. 
The focus of this analysis is assessing efficacy in various groups of age and gender. 
 
The studies in Colombia and Brazil included only male participants of around 18-20 
years old (soldiers) and did not present age/gender variety.  The Sudan trial data were 
not available for individual participant level analysis and consequently was not used 
in the analyses in this chapter.  Because participant-level data were available for trials 
conducted in Iran, including Bam1, Bam3, Bor3, Esf1 and Zav3, these trials were 
used to address the objectives of this and subsequent chapters.  Additionally, these 
trials provided a better mix of age and gender.  The added advantage was that they all 
evaluated the efficacy of the same vaccine (ALM+BCG) against BCG. 
 
The overall hypothesis is formulated as: 
 
H0: The studied FGV's are not able to confer protection even in specific subgroups 
H1: The studied FGV's lead to reduction in incidence in certain sub-groups 
 
This hypothesis will be tested by assessing vaccine (ALM+BCG) efficacy in the 
subgroups identified by demographic variables age, gender and endemic/non-endemic 
origin of participants. 
 
Three of the trials used in this analysis (Bam1, Bam2, Bor3) included school age 
participants, 6-13 or 15 years.  Zav3 and Esf1 included participants as young as 5 or 
as old as 59 or 72 years.  Tables 4.01 and 4.02 show the distribution of age and gender 
in these trials combined.   
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Table 4.01 - Age distribution in Iran trials combined 
Age category Frequency %
1 =  (5-6 yrs) 1420 10.3
2 =  (7 yrs) 2711 19.6
3 =  (8 yrs) 2797 20.2
4 =  (9-10 yrs) 3142 22.7
5 =  (11-15 yrs) 2169 15.7
6 =  (16-25 yrs) 517 3.7
7 =  (> 26 yrs) 1069 7.7
Total 13825 100        
 
 
Table 4.02 - Gender in Iran trials combined 
Gender Frequency %
F 6898 49.9
M 6937 50.1
Total 13835 100  
 
Although all trials were conducted in Leishmania endemic areas, they did not all 
include participants from endemic origins, as explained below.   
 
Esf1: Esfahan is an L. major endemic area. However, participants in the trial consisted 
not of native residents but of army families in an airbase.  Their origins, therefore, 
were from diverse areas, many coming from non-endemic areas.  
 
Zav3: Participants were Zavareh residents.  Zavareh is a new L. major endemic focus 
(or possibly the site of recent epidemics). Its endemicity started with an epidemic, 
after which cases have been identified on a regular basis.  Therefore, residents are 
essentially from a non-endemic background, though living in a newly endemic area.  
 
Bor3: Borkhar is an established L. major focus and participants were native area 
residents. 
 
Bam1, Bam2: Bam is an established endemic focus of L. tropica.  Trial participants 
were native area residents.   
 
The distribution of the endemic/non-endemic origin of participants for the combined 
sample is as follows: 
 
Table 4.03 - Endemic origin in Iran trials combined 
Endemic Origin Frequency %
No 3992 28.9
Yes 9843 71.1
Total 1385 100  
 
4.1  Age, incidence and vaccine efficacy 
 
It would be helpful to explore the age-incidence relationship before addressing the 
age-efficacy question.   
   *  *  * 
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To study the effect of age on incidence data from all trials are combined in Figure 4.E 
(below).  However, the apparent increased incidence with age may be spurious. 
Combining the data in this form is misleading since Zav3 and Esf1, the only trials 
with participants older than 16, were also the trials with highest incidence.  Incidence 
in higher ages would only reflect the overall high incidence in these two trials.  For 
this reason, combining all data, would lead to the significant, but biased, relation 
between efficacy and age (with significance level < 0.000).   
 
Figure 4.E - Spurious relationship: % Case by age of participants 
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The appropriate method for this analysis would be comparing age-incidence 
distribution within the different trials.  For estimating the age-related vaccine efficacy 
a meta analytic approach, similar to the overall efficacy analysis described in Chapter 
3 could be used.  
 
   *  *  * 
 
In studying the age/incidence distribution, it is important to note that two factors work 
against detecting the effect of age on incidence: 
 
 Exposure (and resulting endemic immunity) increases with time/age and is 
manifested by pre-vaccination LST>0 (as will be indicated in the next chapter).  
As a result, eliminating LST>0 volunteers would minimize or remove from the 
trial sample the effect of age on exposure, endemic immunity and consequently 
incidence (in participants of endemic background).   By design, LST>0 volunteers 
were not enrolled in Bam1, Bam3 and Esf1.  In this chapter, to be able to see the 
effect of age on incidence, participants with pre-vaccination LST>0 in Bor3 and 
Zav3 have been included in most analyses.   
 Similarly, limiting age to less than 15 years (Bam1, Bam3, Bor3) would take away 
from the effect of age on incidence since older individuals would be the ones with 
longer exposure and higher endemic immunity.   
 
Figure 4.1 demonstrates the age/incidence distribution in the 5 trials.  The 
age/incidence distribution in Bam1, Bam3 and Bor3 trials is not significant; possibly 
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partially due to age restriction in these trials.  Statistically significant distributions  are 
observed in Zav3 (chi sq=16.66, p=0.011) and Esf1 (chi sq=14.73, p=0.022), the two 
trials with participants' age ranging from 5 to 59 or 72.  These significant values show 
the dependence of incidence on age, but trend tests do not suggest a significant linear 
downward trend in these trials.  A downward age/incidence relationship would be 
consistent with exposure-induced immunity in endemic populations.  In Zav3, where 
exclusion criteria did not impose a limitation on age or LST status of participants,  
lack of a significant downward trend confirms that participants do not have the 
age/incidence characteristics expected of endemic populations.   
 
Despite the difference in the endemic origin of participants and average incidence, 
incidence distribution by age in Esf1 resembles Bor3 within their common age range.  
In Bor3, age/incidence distribution is not significant (p=0.067), but the downward 
trend in incidence with age can be recognized after age 7 (see the following graph=).  
Trends in Bam trials are not significant and possibly consistent with the exclusion of 
pre-vaccination LST>0. 
 
Overall incidence in Esf1 and Zav3 were the highest of all trials.  This is attributable 
to participants' non-endemic origin (leishmania-naive).  
 
Figure 4.1 - Average annual incidence and age distribution in the 5 trials in Iran 
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Trend tests not significant for any of the trials 
 
 
To further explore the relationship between age and infection, logistic regression was 
used to test whether age had a direct effect on incidence within each trial.  In table 4.1 
the OR (odds ratios) of incidence by age are displayed. The OR indicates for a one 
year increase in age the change in log odds (logarithm of the probability of being case 
divided by the probability of not being case). A larger OR indicates generally larger 
incidence at higher ages.  OR is not significant in Bor3, even when including those 
with pre-vaccination LST>0.  This is partially an effect of the age limitation to 13 in 
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this trial which restricts the effect of age on immunity and consequently incidence.  
Zav3 results are not significant and this is not as surprising since participants were not 
from endemic origin and therefore endemic immunity (a direct downward trend with 
age) was not expected.  When considering different trials separately, the odds ratio of 
incidence/age is significant only in Esf1.  This relationship though significant is not 
very strong and, as figure 4.1 indicates, is not linear, as will be discussed later.   
 
Table 4.1 - Odds ratio for the effect of age on incidence in separate trials 
OR of incidence by age 
in: N OR Std. Err. P>|z|
Bam1 3633 0.988 0.060 0.85 0.877 1.114
Bam3 4087 1.073 0.083 0.36 0.922 1.248
Bor3 (all pre-vac LST) 2123 0.989 0.042 0.80 0.989 0.042
Bor3 (pre-vac LST=0) 1275 1.000 0.057 1.00 0.894 1.118
Esf1 2314 1.009 0.004 0.04 1.001 1.017
Zav3 (all pre-vac LST) 1659 0.997 0.007 0.61 0.984 1.009
Zav3 (pre-vac LST=0) 1454 1.000 0.007 0.95 0.987 1.014
95% Conf. Int.
 
 
To observe the age/incidence distribution in trials with endemic and non-endemic 
participants, these trials were combined as shown in table 4.2.  Results did not show a 
significant difference in age-based incidence in either group: 
 
Table 4.2 - Odds ratio for the effect of age on incidence in endemic and non-endemic 
areas (pre-vaccination LST=0) 
OR of incidence by 
age in: N OR Std. Err. P> | z|
Non-endemic 3768 1.007 0.004 0.07 1.00 1.01
Endemic 8995 0.982 0.032 0.57 0.922 1.046
95% conf. Int.
 
 
Breaking these groups further down to separate the effect of vaccine from BCG 
within endemic/non-endemic participants (table 4.3) did not yield significant results: 
 
Table 4.3 - Odds ratio for the effect of age on incidence in trials arms in endemic and 
non-endemic participants (pre-vaccination LST=0) 
OR of incidence by 
age in: N OR Std. Err. P> | z|
Control/non-endemic 1909 1.009 0.005 0.077 0.999 1.019
Control/endemic 4419 0.984 0.044 0.726 0.902 1.075
Vaccine/non-endemic 1859 1.004 0.005 0.406 0.994 1.014
Vaccine/endemic 4576 0.977 0.045 0.612 0.892 1.070
95% Conf. Int.
 
 
The age/incidence relationship in Esf1was further studied by breaking down the Esf1 
data into vaccine and control arms.  Resulting odds ratio in the control arm is 
marginally significant (table 4.4) and does not demonstrate a strong linear relationship 
(as demonstrated in figure 4.2 below with trend test p=0.318 for BCG, p=0.229 for 
vaccine).  Moreover, the same relationship is not observed in Zav3, the other trial 
with non-endemic participants.  Therefore, it is likely that the marginally significant 
OR is due to chance.   
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Table 4.4 - Esf1 odds ratio for the effect of age on incidence in trial arms  
OR of incidence by 
age in: N OR Std. Err. P> | z|
control arm 1124 1.012 0.006 0.042 1.000 1.024
vaccine arm 1190 1.005 0.006 0.373 0.994 1.018
95% Conf. Int.
 
 
 
Figure 4.2 - Incidence in trial arms in Esf1 
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   *  *  * 
 
Before proceeding with the meta-analysis, it is noteworthy that in the Bam3 trial, the 
number of cases in participants 9 years or older is significantly smaller in the vaccine 
arm than the control arm, as demonstrated in table 4.5.  Since the difference in 
efficacy between the age groups were not significant and the same observation was 
not made in the other Bam trial data, or any other trials, this finding will not be further 
considered.  
 
Table 4.5 - Bam3: significant vaccine arm protection in >9 yrs participants 
Bam 3-inj
% case in age group 0 1 Total Fisher Exact
< 9 yrs 0.04 0.04 0.04 p =  0.368
N = 1723 1844 3567
9 yrs or older 0.07 0.03 0.05 p =  0.036
N = 282 238 520
To t al 0.05 0.04 0.04
N = 2005 2082 4087
Vaccine
 
 
   *  *  * 
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4.1.1  Meta-analysis to investigate age/efficacy relationship  
 
4.1.1.1  Estimating the pooled RR for all age categories simultaneously  
 
If due to any age-related reasons (such as immunological differences between ages), 
vaccine effectiveness in different age groups varies, this relationship could be 
explored by examining efficacy in various age groups. Furthermore, if all relationship 
between age and exposure/immunity are not removed by excluding LST>0, then some 
interrelationship between age and vaccine effectiveness could be present, if the 
vaccine is in fact efficacious.  The hypothesis to be tested via meta-analysis is: 
 
H0: Overall RR(estimated based on all age- and trial-specific RR's) = 1  
H1: Overall RR(estimated based on all age- and trial-specific RR's) ≠ 1 
 
This analysis initially estimates RR's separately for each age category within each 
trial.  Next, a meta analytic approach is taken to estimate the pooled RR for all of 
these estimates using a fixed or random effect model.  In this way, age-specific RR's 
are first estimated within the homogeneity of a given age group in a given trial.  These 
group-specific RR's would represent the pure effect within a homogeneous age/trial 
group, without being averaged down by other age/trial groups.  The pooled RR would 
then be based on these individually more reliable estimates.   
 
Additionally, this approach allows studying whether RR's in a given age category are 
systematically different from those in other age categories.  This can be visually 
examined in the graphs in the following pages.   
 
Tables 4.6 and 4.7 and figure 4.3 demonstrate the results of the age/trial meta-analysis 
estimation of overall RR.  As discussed in the previous chapter, large variability in 
individual RR's would lead to significant heterogeneity in the model.  Therefore, if 
variation in RR's due to age and/or trial were substantial, significant heterogeneity and 
between-group variation, indicated by a significant τ2, would be expected.    
 
 
Table 4.6 - Meta-analysis results for age-specific/trial specific RR's 
Pooled 
Method RR z p
M-H pooled RR 0.957 0.855 1.072 0.76 0.45
D+L pooled RR 0.960 0.851 1.084 0.65 0.513
Test of RR=1 
95% Conf. Int.
 
 
Table 4.7 - Heterogeneity statistics for meta-analysis of age/trial RR's 
Method
Heterogeneity Chi 
sq p I - squared
D+L or M-H 29.93 0.367 0.64  
 
As indicated by the above tables, heterogeneity and its associated chi square statistic 
are not statistically significant (τ2 estimate is 0.007 and its associated heterogeneity 
chi sq.=29.93, p=0.367).  This lack of significant heterogeneity suggests that RR 
within age/trial groups do not vary greatly; i.e., age/trial combination is not a 
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significant determinant of RR.  This does not provide support for age specific vaccine 
effect.  
 
The forest plot in the next page (figure 4.3) indicates the deviations of individual RR's 
from the pooled estimate (represented by the dashed centre line).  In this graph, RR's 
have been sorted by age-category.  Thus, all age-based RR's for various trials are 
displayed one after another.  In case of meaningful/systematic differences between 
age groups RR's for the same age category would cluster around the same value on 
the same side of the overall estimate line.  Such clustering is not observed in the graph.  
Therefore, the visual examination of forest plots does not support the notion that there 
is a relationship between vaccine efficacy and age.   
 
Age categories are defined as in previous figures (e.g., figure 4.1 and 4.2) as follows: 
 
Age category       Age range (yrs) 
 1   5-6  
 2   7  
 3   8  
 4   9-10  
 5   11-15 
 6   16-25 
 7   >26 
 
 
Grouping age into these categories was based on assumed behavioural differences 
between them coupled with large enough sample size in each group.  For example, the 
5-6 years category was believed to be different enough from the 7 years category in 
that 7 years of age is the official age for entering elementary school.  Therefore, it is 
conceivable that 7 year olds are different in their exposure patterns from 5-6 year olds.  
Similarly, 7 and 8 year olds could be assumed to have some systematic differences in 
their behaviour since at that young age one year of difference could translate into 
measurable difference sin behaviour and exposure.  Additionally, enough sample size 
was available for separating the two to observe possible differences.  The same logic 
was behind separating 9-10 years and then 11-15 years categories.  The 15-25 year 
group was separated from 25+ years mainly so that a young adults could be 
distinguished from all older ages.      
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Figure 4.3 - Forest plot of the age-specific RR's in all trial, sorted by trial within the same age 
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Results of diagnostic measures including are presented below and do not show any 
biasing effect or significant influence by any of the age/trial combinations on the 
overall estimate.  The following 2 graphs indicate these results. 
 
Figure 4.4 - Funnel plot: checking for out of range RR values 
 
 
Figure 4.5 - Influence of individual age categories on the pooled RR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall, the meta-analysis of all age-specific effects in all trials does not lead to the 
rejection of the null hypothesis of RR=1.  Furthermore, visual inspection of forest 
plots does not suggest systematic differences between age groups.    
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4.1.1.2  Estimating RR within each age category separately 
 
With the above approach of estimating the pooled RR over all age categories failing 
to show a significant age/efficacy relationship, an alternative approach of estimating 
vaccine efficacy within each age group separately was used.  The difference between 
age group RR's would then show the effect of age.  The hypothesis tested was:  
 
H0: Age-specific RR(estimated based on age-specific RR's in all trials) = 1 
H1: Age-specific RR(estimated based on age-specific RR's in all trials) ≠ 1 
 
To estimate the vaccine efficacy within each age category, a series of meta analyses 
were conducted, estimating pooled RR's separately for each age category.  Individual, 
age-specific RR's are the same those as used in the previous analysis.  What contrasts 
this analysis is that RR's for the seven age categories are separately estimated (pooled 
over the 5 trials).  Estimation is done within groups that are homogeneous with 
respect to age, without allowing the effect of the other age-groups to average down 
the results.  Assuming that the RR is systematically and significantly different 
between some of the age groups, this would allow observing the pure effect within 
each age category.  In this way, it would become clear if the vaccine were more 
effective in a certain group but not in others.  Results are presented below.   
 
5-6 years old:  The RR in Bam3 is significant (as indicated by the 95% confidence 
interval that does not contain 1), while in other trials it is not significant.  In Zav3 and 
Bor3, in fact, the direction of the effect is unexpected (higher incidence in the vaccine 
arm).  However, these reverse RR's have minimal impact on the overall RR due to 
their small weights which reflects their relatively few participants in this age group 
(table 4.8). 
 
Table 4.8 - Meta-analysis results in the 5-6 year old category 
Age=  5-6 years
Study RR % Weight
Bam1 0.35 0.02 6.70 3.76
Bam3 0.48 0.24 0.98 46.37
Bor3 2.84 0.62 13.09 4.84
Esf1 0.98 0.56 1.72 43.03
zav3 2.17 0.21 22.39 1.99
M-H pooled RR 0.84 0.56 1.25 100.00
Test of RR= 1 : z=    0.87 p =  0.384
Heterogeneity chi-squared =    6.03 (d.f . =  4) p =  0.197
I-squared (variat ion in RR attributable to heterogeneity) =   33.7%
95% Conf. Int.
 
 
7 years old category:  The RR in none of the trials is statistically significant.  
Similarly, the overall RR is also not significant.  The direction of the RR in both Bam 
trials is opposite expectation but not significant (table 4.9). 
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Table 4.9 - Meta-analysis results in the 7 year old category 
Age=  7 years
Study     RR % Weight
Bam1 1.84 0.65 5.24 7.06
Bam3 1.22 0.73 2.04 33.01
Bor3 0.61 0.34 1.09 34.33
Esf1 0.70 0.37 1.29 23.14
zav3 2.78 0.57 13.62 2.46
M-H pooled RR 0.97 0.72 1.31 100.00
Test of RR= 1 : z=    0.19 p =  0.846
Heterogeneity chi-squared =    7.46 (d.f . =  4) p =  0.113
I-squared (variat ion in RR attributable to heterogeneity) =   46.4%
95% Conf. Int.
 
 
8 years old: Similar to the 7 years old category, all trial RR's and the overall RR are 
not statistically significant, showing no vaccine effect (table 4.10). 
 
Table 4.10 - Meta-analysis results in the 8 year old category 
Age=  8 years
Study RR % Weight
Bam1 0.57 0.25 1.32 18.54
Bam3 1.04 0.63 1.72 37.08
Bor3 1.05 0.53 2.08 19.54
Esf1 0.88 0.44 1.73 18.68
zav3 1.04 0.31 3.43 6.16
M-H pooled RR 0.92 0.68 1.26 100.00
Test of RR= 1 : z=    0.51 p =  0.612
Heterogeneity chi-squared =    1.66 (d.f . =  4) p =  0.798
I-squared (variat ion in RR attributable to heterogeneity) =    0.0%
95% Conf. Int.
 
 
9-10 years old category:  also shows no significant effect by the vaccine in any of the 
individual trials or overall (table 4.11). 
 
Table 4.11 - Meta-analysis results in the 9-10 year old category 
Age=  9-10 years
Study RR % Weight
Bam1 0.72 0.40 1.29 26.29
Bam3 0.46 0.19 1.07 16.46
Bor3 1.25 0.73 2.17 21.15
Esf1 1.12 0.69 1.81 25.31
zav3 1.69 0.87 3.27 10.79
M-H pooled RR 0.99 0.76 1.29 100.00
Test of  RR= 1 : z=    0.05 p =  0.959
Heterogeneity chi-squared =    7.77 (d.f . =  4) p =  0.100
I-squared (variat ion in RR attributable to heterogeneity) =   48.5%
95% Conf. Int.
 
 
11-15 years old: Similar results to younger age groups are seen in the 11-15 year olds 
(table 4.12).   
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Table 4.12 - Meta-analysis results in the 11-15 year old category 
Age=  11-15 years
Study RR % Weight
Bam1 1.21 0.55 2.66 10.28
Bam3 0.56 0.03 11.57 1.04
Bor3 0.55 0.15 2.02 6.02
Esf1 1.13 0.76 1.68 36.58
zav3 0.82 0.56 1.20 46.07
M-H pooled RR 0.96 0.74 1.23 100.00
Test of  RR= 1 : z=    0.36 p =  0.721
Heterogeneity chi-squared =    2.48 (d.f . =  4) p =  0.648
I-squared (variat ion in RR attributable to heterogeneity) =    0.0%
95% Conf. Int.
 
 
16-25 years old:  Esf1 and Zav3 were the only trials with volunteers older than 
school age.  The RR in Esf1 and Zav3 in the 16-25 years group are in the opposite 
direction, leading to an overall RR that is not significant (table 4.13).  
 
Table 4.13 - Meta-analysis results in the 16-25 year old category 
Age=  16-25 years
Study RR % Weight
Esf1 1.07 0.57 2.03 48.56
zav3 0.68 0.33 1.43 51.44
M-H pooled RR 0.87 0.54 1.41 100.00
Test of  RR= 1 : z=    0.56 p =  0.573
Heterogeneity chi-squared =    0.83 (d.f . =  1) p =  0.363
I-squared (variat ion in RR attributable to heterogeneity) =    0.0%
95% Conf. Int.
 
 
25 years and older:  Similar to the previous age group, the RR's in the two trials are 
in reverse direction (table 4.14).  Moreover, their direction is reverse of that in the RR 
in the same trial in the 16-25 year category.   This is not a problem since these RR's 
are not statistically significant.  The overall RR is, again, not significant. 
 
Table  4.14 - Meta-analysis results in the >25 year old category 
Age>  25 years
Study RR % Weight
Esf1 0.91 0.69 1.21 82.43
zav3 1.56 0.89 2.74 17.57
M-H pooled RR 1.03 0.80 1.32 100.00
Test of  RR= 1 : z=    0.21 p =  0.834
Heterogeneity chi-squared =    2.75 (d.f . =  1) p =  0.098
I-squared (variat ion in RR attributable to heterogeneity) =   63.6%
95% Conf. Int.
 
 
The only significant RR in this analysis is that in the 5-6 year olds in Bam3 -- which 
is therefore, more likely the product of chance.  The pooled RR in none of the age 
groups is significantly different from 1; indicating that the vaccine efficacy (1-RR) is 
not significantly different from 0, even when considering the effect in homogeneous 
age groups separately.  These results do not contradict the findings in the previous 
analysis where the pooled RR for all age groups and all trials was not significant.  In 
summary, the data do not support the notion that vaccine efficacy is age related.   
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4.2  Gender, incidence and vaccine efficacy 
 
Overall, in all trials, there are 8.11% cases among males compared to 8.92% among 
females (Fisher Exact p=0.088) without any significant difference in distribution in 
endemic/non-endemic participants or L. major/L. tropica trials.  The following graph 
shows the distribution of infection by gender within each trial: 
 
Figure 4.6 - Average annual incidence in male/female participants by trial (study arms 
combined) 
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Zav3 is the only trial with a statistically significant difference (p < 0.05) in % cases 
among males and females.  
 
4.2.1    Vaccine efficacy in males and females 
 
Trial by trial efficacy results in males and females are given in the following tables.  
The only significant relationship  is the significantly lower incidence in boys in the 
Bam1 trial (p = 0.006).  This is not observed in girls in the same trial.  .  Furthermore, 
The same magnitude of difference was not observed in any other trial.  In Zav3, 
where male participants experienced significantly lower overall incidence compared 
to women (p < 0.05), the difference was not significant between study arms.  Male 
and female incidence rates in various trials are depicted in tables 4.15a and 4.15b. 
 
Table 4.15a - Percent infection in male/female participants in vaccine trials (endemic) 
in participants with pre-vaccination LST=0 
SEX C V C V C V
F 3.01% 4.16% 4.53% 3.04% 12.33% 9.67%
929 865 994 1019 300 319
M 3.70% 1.64% 4.75% 4.70% 10.66% 11.63%
866 973 1011 1063 269 387
Total 3.34% 2.83% 4.64% 3.89% 11.47% 10.82%
1795 1838 2005 2082 569 706
Bam 1 Bam 3 Bor 3
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Table 4.15b - Percent infection in male/female participants in vaccine trials (non-
endemic) in participants with pre-vaccination LST=0 
SEX C V C V
F 18.10% 18.18% 14.29% 15.99%
591 627 385 344
M 18.95% 17.76% 10.59% 10.98%
533 563 406 328
Total 18.51% 17.98% 12.39% 13.54%
1124 1190 791 672
Zav 3Esf 1
 
 
For all trials combined, the overall efficacy results for male and female participants 
are not statistically significant (table 4.16).  
 
Table 4.16 - Percent infection in male/female participants (all trials combined) in 
participants with pre-vaccination LST=0 
SEX C V Total P
F 8.50% 8.39% 8.45% 0.87
3199 3124 6323
M 8.23% 7.45% 7.83% 0.26
3135 3314 6449
Total 8.37% 7.91% 8.13%
6334 6438 12772
Overall
 
 
Regressing infection rate on a binary variable (0= control, 1=vaccine), separately in 
males and females shows similar results, i.e., the hypothesis of no difference in 
protection between males and females cannot be rejected (Table 4.17). 
 
Table 4.17 - Vaccine odds ratio by gender in participants with pre-vaccination LST=0 
Odds ratio p
Female 0.98 0.854 0.83 1.17
Male 0.90 0.262 0.75 1.08
95% conf. Int.
 
 
4.2.1.1  Meta-analysis to investigate gender/efficacy relationship  
 
To address the effect of gender on efficacy, the following hypothesis will be tested: 
 
H0: RR(estimated based on  sex- and trial-specific RR's) = 1  
H1: RR(estimated based on  sex- and trial-specific RR's) ≠ 1 
 
A meta analytic approach was adopted to test the hypothesis. This approach is similar 
to the one used in assessing efficacy in age groups.  In this analysis, RR's for male and 
female participants were first estimated separately within each trial.  The pooled RR 
was then estimated based on these gender-based RR's.  Results are presented in table 
4.18 and figure 4.7. 
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Table 4.18 - Gender-based analysis of vaccine RR in vaccine trials (0 = F, 1 = M) 
Study RR % Weight
Bam1-SEX= 0 1.381 0.85 2.243 4.96
Bam1-SEX= 1 0.445 0.246 0.805 6.22
Bam3-SEX= 0 0.672 0.429 1.053 8.37
Bam3-SEX= 1 0.991 0.673 1.458 9.04
Bor3-SEX= 0 0.78 0.479 1.268 6.44
Bor3-SEX= 1 1.169 0.761 1.795 6.63
Esf1-SEX= 0 1.004 0.791 1.275 20.23
Esf1-SEX= 1 0.937 0.73 1.203 19.06
zav3-SEX= 0 1.086 0.793 1.487 11.52
zav3-SEX= 1 1.007 0.668 1.518 7.54
M-H pooled RR 0.952 0.851 1.066 100
Test of RR= 1 : z=    0.85 p =  0.397
Heterogeneity chi-squared =   13.41 (d.f . =  9) p =  0.145
I-squared (variat ion in RR attributable to heterogeneity) =   32.9%
95% Conf. Int.
 
 
As table 4.18 indicates, the heterogeneity calculated via the Mantel-Haenszel method 
is not significant (p= 0.145), implying the appropriateness of the fixed effect model.  
The random effect model was nevertheless estimated for comparison with the above.  
However, regardless of the method of estimation, the overall effect is not statistically 
significant.  As indicated, the only significant RR is in boys in Bam1.  No other 
gender/trial group shows a significant effect.  Furthermore, the overall RR is not 
significant.  In light of these meta analytic results, a correlation between gender and 
incidence cannot be ascertained.  These results are summarized in the forest plot in 
figure 4.7. 
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Figure 4.7 - Forest plot of gender-based meta-analysis 
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4.3  Endemic origin, incidence and efficacy 
 
Residents of endemic areas are routinely exposed to sandfly bites.  Although exposure 
to the infected sandfly bite leads to some level of infection, a large percentage of 
exposed individuals never develop clinical symptoms.  Recovery from clinical disease 
normally is synonymous with immunity.  Even in individuals who do not develop 
clinical infection, the constant exposure, which resembles a prime/boost vaccination 
method, is normally associated with LST reactivity and increased chances of 
immunity.  Such immunity is expected to increase with exposure and age - since more 
frequent exposure for a longer period of time should increase the immunization effect 
(Davies and Mazloumi Gavgani, 1999).  Due to this mechanism, one would expect 
lower infection rates in populations from endemic origin compared to those from non-
endemic origin residing in endemic foci.  Although endemic immunity that is 
manifested by LST can be identified in both arms, if it is not associated with LST>0 
(for example in people who are genetically non-responsive to the antigen), then it 
cannot be identified.  In such cases, the LST=0 inclusion criteria would be less 
effective and leave some exposed individuals in the study.  By extension, if the 
vaccine is in fact efficacious, one could observe lower vaccine-attributable protection 
in clinical trials with endemic participants, since endemically immune participants 
would be present in both study arms with equal probability leaving fewer participants 
to be protected by the vaccine in the vaccine arm and more individuals already 
protected without the vaccine in the control arm.  Therefore, to the extent that 
endemic immunity exists in both arms, vaccine-induced protection will be 
underestimated since those who would otherwise be protected only in the vaccine arm 
by vaccination are now already immune and present in both arms; thus reducing the 
statistical power of the study through reducing the difference in protection observed 
between study arms (since a percentaqge of those already protected in the control arm 
by endemic immunity would otherwise succumb to infection during the follow up).   
 
As described earlier, two of the Iran trials, Zav3 and Esf1 were trials in endemic (or 
high incidence) areas with participants of non-endemic origin.  Comparison of the 
much higher incidence in these trials with relatively lower incidence in Bam1, Bam3 
and Bor3 (with local endemic area residents as trial participants) points partially at the 
difference due to the endemic make-up of study subjects (as displayed in figure 4.8 
and table 4.19).  Although total incidence is not significantly different between Zav3 
and Esf1 (p=0.626), it is different between Bor3 and Zav3 (p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92
  Figure 4.8 - Average annual incidence in trials with participants of endemic/non-
endemic origin by age 
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As expected, incidence in the non-endemic participants in Esf1 and Zav3 exceeds that 
among endemic participants -- even after excluding all ages >15 in Esf1 and Bor3 to 
make them consistent with other trials.  This observation is consistent with the large 
number of Leishmania-naive participants in non-endemic populations who are 
expected to experience higher disease rates upon introduction to endemic conditions.  
The lower incidence in endemic participants in Bam1 and Bam3 reflects the 
epidemiology of the local ACL disease but potentially is also partially driven by the 
endemic immunity among the endemic participants.  The lower rate in Bor3, however, 
probably reflects site differences as well as endemic immunity which would not be 
present in Esf1 and Zav3.   
 
Table 4.19 compares incidence in vaccine and control arms in endemic and non-
endemic participants.  It is clear that despite the higher incidence in the latter, 
response to the vaccine is not significantly different between the two.  
 
Table 4.19 - Incidence in vaccine and control arms, endemic and non-endemic  
C V Total P
Non-endemic 15.83% 16.11% 15.97% 0.42
2022 1961 3983
Endemic 5.75% 5.25% 5.50% 0.27
4855 4988 9843
Total 8.71% 8.32% 8.51%
6877 6949 13826
Treatment
 
 
Odds ratios (vaccine/control) for endemic and non-endemic participants are given in 
the table 4.20 and suggest no vaccine efficacy in either of groups of endemic origin. 
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Table 4.20 - Odds ratios of vaccine to control, endemic and non-endemic  
N OR Std. Err. P>|z|
Non-endemic 3983 1.022 0.088 0.80 0.86 1.21
Endemic 9843 0.909 0.080 0.28 0.764 1.081
95% conf. Int.
 
 
The result of this study suggests that there is no difference in vaccine efficacy 
between the endemic and the non-endemic trials.  Neither group of trials shows 
protection in the vaccine arm.  Despite the higher incidence and the favourable 
conditions in the Esf1 and Zav3 trials for detecting protection due to vaccine, vaccine 
efficacy cannot be observed.  
 
4.4  Summary: Immunity to leishmaniasis could be related to genetic and 
demographic characteristics.  Demographic characteristics, including age and gender, 
correlate with risk behaviour and exposure patterns.  Exposure could lead to two 
outcomes: clinical or sub-clinical infection; both of which increase the likelihood of 
immunity to future infection.  There are two ways in which age can influence 
incidence and immunity:  1) dissimilar risk behaviour in different age groups which 
leads to higher exposure in certain age categories, 2) cumulative chance of exposure 
by age.  
 
The present analysis did not confirm a strong relationship between incidence with age 
or gender.  Moreover, it did not suggest efficacy for the ALM+BCG vaccine in any of 
the demographic groups.  
 
Since demographics were expected to be related to incidence and immunity in 
endemic foci, lack of such relationship in the data was unexpected.  However, 
consideration of the data collection procedures sheds some light on this question.  
When demographic variables are used as exclusion criteria, to the extent that these 
variables are correlated with immunity and incidence the natural relationship between 
incidence and demographics may be concealed.  In the clinical trials analysed in the 
present study, one of the factors with potential impact on observing age/incidence 
relationship was age limitation of 6-13 or 15 years in Bam1, Bam3 and Bor3.  It has 
been argued that endemic immunity settles in at an early age, perhaps by 5 or 6 years.  
Whether this is the case or if immunity prevalence continues to increase with age, the 
6-15 age limitation in these trials could have compromised the effect of age.   
 
Another factor in the way of observing the effect of age and other demographic 
variables on incidence was exclusion of pre-vaccination LST>0 volunteers in Bam1, 
Bam3 and Esf1.  Endemic immunity is expected to be associated with LST>0.  At the 
same time, prevalence of LST>0 and endemic immunity increases with age.  
Excluding volunteers with LST>0 may have reduced the effect of age on immunity 
and consequently on incidence in these clinical trial samples.  Three of the trials used 
for the forgoing analysis (Bam1, Bam3, Esf1) used LST>0 as an exclusion criterion.  
Zav3 is the only trial where neither age nor LST limitations were used as exclusion 
criteria.  However, Zav3 participants were chiefly not from endemic background and 
therefore are unlikely to show the effect of age on endemic immunity and incidence.  
Together these factors seem to be the explanation for lack of a strong relationship 
between demographics and incidence.   
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In this analysis, vaccine efficacy could not be confirmed in any of the demographic 
groups, when considering all data combined.  Although significantly greater vaccine 
related protection was observed in boys in Bam1, this observation could not be 
confirmed in other trials.   
 
In summary, the results presented in this chapter do not in general support the notion 
that demographic characteristics affect vaccine efficacy significantly: none of the 
demographic factors discussed were found to directly and strongly correlate with 
vaccine efficacy across all trials and demographic groups, although greater vaccine-
related protection in a subgroup in one trial was observed.  These findings are subject 
to limitations in the age range of trial participants.  Certain effects may be observable 
only in very high or very low values of a variable such as age.  In this regard, the Esf1 
trial provided the ideal combination of endemic foci + Leishmania-naive participants 
+ a wide age range. Perhaps this was the reason why Esf1 was the only Iranian trial 
that showed lower incidence among vaccination-sensitized participants (those with 
converted LST, 80 days after vaccination, in both arms combined, as discussed in 
Chapter 1). 
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CHAPTER 5 
 
IMMUNOLOGICAL RESPONSE (MEASURED BY LST) IN DEMOGRAPHIC 
SUBGROUPS TO THE LEISHMANIAL ANTIGEN INTRODUCED BY 
VACCINE OR NATURAL EXPOSURE 
 
In this chapter the immune response to the antigen (as measured by LST), the 
development of immune response over time (from before vaccination to the end of 
one year follow-up) and the effects of demographic factors, gender, age and endemic 
origin are assessed.   
 
The vaccine trials used in this analysis are the 5 trials in Iran which provide 
participant-level data.  All of these trials, with the exception of Zav3, provide LST 
measurements 80 days and one year post-injection.  Zav3 and Bor3 provide LST 
measurement prior to the vaccine injection.  Esf1 and Zav3 include participants of 
non-endemic origin (i.e., originally from non-endemic areas) while others include 
chiefly participants originally from the endemic trial site.  Figure 5.1 summarizes 
these trial design elements: 
 
Figure 5.1 - Timing of vaccination and LST in Iran trials 
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A non-zero leishmanin skin test could indicate cellular response due to exposure to 
the leishmanial antigen naturally or via immunization. To a limited degree, it could 
also indicate exposure to other immunomodulating agents such as BCG.  However, it 
is also possible that a certain percentage of people in endemic foci are non-responsive 
to the antigen.  LST in such people is expected to stay negative. 
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The dogma maintains that previous infection or repeated exposure, common in 
endemic foci, is detectable via LST≥5 and is associated with immunity (endemic 
immunity).  In other words, LST≥5 (generally accepted as "positive"), if not 
indicative of a developing infection, would be associated with protection (Ben Salah 
et al., 2005).  Pre-vaccination LST could provide some information about existing 
levels of immunity in the study sample.  
 
However, partially because of this reason, normally pre-vaccination LST> 0mm (or in 
some trials LST>5mm) is used as an exclusion criterion in leishmaniasis vaccine trials.  
This has the desirable consequence of allowing the assessment of the vaccine effect in 
Leishmania-naive individuals without confounding by the potentially protective effect 
of previous exposure.  However, this disallows estimating the vaccine effectiveness in 
those with previous exposure; who constitute a large part of the populations in 
endemic areas.   
 
As indicated, in Bor3 and Zav3, by design, LST>0 was not an exclusion criterion and 
volunteers with LST>0 (but no disease history) were admitted.  This allowed  a more 
representative cross section of endemic residents with respect to exposure and enabled 
assessing the correlation between pre-vaccination LST>0 and:  disease incidence (thus, 
testing the dogma), post-vaccination immunological response and vaccine efficacy.  
On the negative side, this introduced potentially immune individuals to both arms of 
these trials, thus reducing statistical power. 
 
Pre- and post-vaccination LST measurements indicate the degree of stimulation in the 
immune response at various points in time and could be linked to vaccine efficacy.  
LST measurements over time are inter-related; immune response at one point in time 
is probably not independent of it at an earlier time.  Therefore, it is important to study 
different LST readings, their inter-relationship and their link to vaccination.   More 
over, LST and immune response should be studied in connection to potentially risk-
related characteristics such as demographics and endemic origin.  
 
The overall hypothesis of this chapter is: 
 
H0: Inhabitants of endemic and non-endemic areas and various demographic groups 
do not differ in their immunological response (measured by LST) to leishmanial 
antigens introduced as a vaccine or natural exposure. 
H1: Demographic differences are associated with different immunologic responses in 
inhabitants of endemic and non-endemic areas. 
 
 
5.1  Overall observations: LST results, before and after vaccination 
 
5.1.1 Pre-vaccination LST 
 
Pre-vaccination LST in Bor3 and Zav3 are presented below.  Compared to Zav3, a 
significantly higher percentage of LST>0 was observed in Bor3, suggesting greater 
prevalence of exposure in the already well established endemic area of Borkhar 
compared to the newly endemic area of Zavareh.  This is depicted in the graph below. 
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Figure 5.2 - Pre-vaccination LST distribution in Bor3 and Zav3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By contrast, the size of the LST reaction in those with LST>0 is greater in Zav3 than 
in Bor3 (right side of the table below), suggesting that in Zav3 with participants of 
non-endemic origin the lower prevalence is accompanied with more acute reaction. 
 
Table 5.1 - Pre-vaccination LST induration in Bor3 and Zav3 
Study Obs Mean Std. Dev. Obs Mean Std. Dev.
Bor3 2123 1.09 2.07 848 2.72 2.51
Zav3 1690 0.48 1.71 210 3.91 3.22
t= 9.664 t= -5.765
p=  0.00 p= 0.00
Overall sample LST>0 only
 
 
It should be noted that the prevalence of LST>0 in either of these areas is smaller than 
that observed in other endemic areas previously studied(Sassi et al., 1999).   
 
 
5.1.2 Post-vaccination LST 
 
The following graphs and tables depict LST results 80 days and one year after 
vaccination in participants with pre-vaccination LST=0.  Findings are discussed in the 
sections 5.1.2.1 and 5.1.2.2.  Zav3 is excluded because there was no post vaccination 
LST measurement in that trial.   
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Figure 5.3 - Day 80 LST in vaccine and control arms (pre-vaccination LST=0) 
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Figure 5.4 - One-year LST in vaccine and control arms (pre-vaccination LST=0) 
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Table 5.2 - Mean LST induration on day 80 and one year after vaccination  
      --- Pre-vaccination LST=0 
Study BCG Vaccine BCG Vaccine
Bam1 mean 0.70 2.73 0.52 1.45
std. dev. 1.46 1.94 1.49 1.64
N 1761 1807 1654 1681
Bam3 mean 0.50 2.49 0.76 2.29
std. dev. 1.12 2.09 1.51 1.99
N 1932 1980 1855 1899
Bor3 mean 0.90 3.33 0.59 2.53
std. dev. 2.19 2.73 1.73 2.21
N 538 608 516 542
Esf1 mean 1.05 3.43 2.71 4.08
std. dev. 2.03 2.98 3.86 3.84
N 1104 1168 888 922
Day  80 LST One-year LST
 
All paired comparisons between same-arm day 80 and one-year LST are significant at 0.000; 
except Bor3 in BCG arm at p=0.0314 
 
Table 5.3 - Mean LST induration (if LST>0 in each evaluation) on day 80 and one 
year after vaccination --- pre-vaccination LST=0 
Study BCG Vaccine BCG Vaccine BCG Vaccine
Bam1 mean 2.58 b  3.39 2.18 2.38
std. dev. 1.73 1.56 2.38 1.48
% LST> 0 27.2% 80.4% 24.0% 61.0% 0.020 0.000
N (LST> 0) 479 1452 396 1024
Bam3 mean 2.03 b  3.27 c  2.85 d  3.42
std. dev. 1.41 1.79 1.58 1.44
% LST> 0 24.5% 76.3% 26.8% 66.9% 0.105 0.000
N (LST> 0) 473 1511 497 1271
Bor3 mean a  3.08 4.14 c  3.70 d  3.61
std. dev. 3.12 2.43 2.71 1.75
% LST> 0 29.1% 80.4% 15.9% 70.1% 0.000 0.000
N (LST> 0) 157 489 82 380
Esf1 mean a  3.19 4.71 5.17 5.33
std. dev. 2.38 2.48 3.97 3.55
% LST> 0 32.9% 72.8% 52.5% 76.7% 0.000 0.042
N (LST> 0) 363 850 466 707
P Day  80 LST One-year LST
 
 
1. Day 80 LST: All differences between vaccine and BCG arms within the same trial/same 
evaluation are significant at p<0.001.  
2. One-year LST: Differences between arms in Bam1 and Bam3 are significant at p<0.0001; 
in Bor3 at 0.33; in Esf1 at p=0.0549. 
3. All pairs of differences between trials are significant at 0.00 or lower except those indicated 
a: p=0.951, b: p=0.061, c: p=0.095, d: p=0.506 
 
5.1.2.1  LST 80 days after vaccination 
 
As expected, LST response is significantly larger in the vaccine arm than the BCG 
arm in all trials; in both size and frequency.  A certain level of LST response is 
 100
observed in BCG-alone arms of all trials, possibly due to the BCG-stimulated Th1 
response and DTH.   
 
A common pattern of LST response is not shared by trials with the same number of 
vaccine doses (Bor3 and Bam3 vs Esf1 and Bam1).  Of note is Bam3 trial where after 
3 doses of BCG or vaccine, the mean day 80 LST tends to be lower than in Bam1 or 
Bor3.   
 
However, trial site (which encompasses the effect of endemic origin, incidence and 
causative species) seems to be a distinguishing factor:  in both treatment arms, 
conversion to LST≥5 is more frequent in Esf1 and Bor3 (L. major endemic areas with 
5-6% annual disease incidence) compared to Bam1 and Bam3 (L. tropica endemic 
area with 2% annual incidence).   
 
Although Esf1 participants are largely from non-endemic origin, their intensity of 
LST response 80 days after vaccination is somewhat but not substantially greater than 
that in Bor3. However, in the course of the follow up, LST response becomes more 
frequent and stronger in both arms (particularly BCG) in Esf1, whereas they drop in 
Bor3.  
 
5.1.2.2  LST one year after vaccination 
 
As observed in other studies (Alimohammadian et al., 2002) some erosion in the 
vaccine-induced immune response is manifested by an increase in the number of 
participants with LST=0 in the vaccine arms in Bam1, Bam3 and Bor3 trials.  At the 
same time, natural exposure during study follow-up were not able to maintain day 80 
LST levels in endemic participants (or these endemic participants did not respond 
strongly to such exposure). By contrast, in Esf1 with non-endemic participants, the 
frequency of LST>0 and the average LST size in both arms increased from day 80 to 
the one year evaluation (particularly in the BCG arm).   
 
In contrast to Bam1, LST response after the 3 doses in Bam3 trial did not decrease; 
rather, LST reactivity and magnitude increased particularly in the BCG arm.  Despite 
the drop in the LST response in Bam1 and Bor3 trials, a certain level of LST response 
is maintained, particularly in Bor3.  
 
In Esf1, unlike the other trials, an increase is observed in the percentage of one-year 
LST>0 and its magnitude compared to day 80 - this increase is observed in both arms, 
but it is substantial in the BCG arm.  This could be attributable to the non-endemic 
background of participants and their resulting sensitivity to the natural exposure 
during the trial follow-up.   
 
The greater increase in the frequency of one year LST>0 in the BCG compared to 
vaccine arm in Esf1 may indicate a natural limit for the number of people who can 
become LST reactive. This observation cannot be verified in Zav3 since post 
vaccination LST was not measured.  However, examining the change in LST from 
day 80 to one year after vaccination in all other trials reveals the following: 
 
 The change is very little in the BCG arm of Bam1 and Bam3 trials with endemic 
participants (stays at about 25%). Contrary to Bam trials, in Bor3, the endemic 
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area with a high annual incidence, the percent of LST>0 in the BCG arm almost 
halves (29.1% to 15.9% - see previous table).  The change is in the opposite 
direction (increase significantly) in the BCG arm in Esf1 with non-endemic 
participants (table below).   
 A point of maximum (a ceiling) may exist for the percent of individuals who 
become LST reactive.  In the vaccine arm of trials by day 80 between 72-80% 
became LST>0.  Over the next several months, a point of equilibrium was reached 
as the effect of the vaccine eroded and at the same time participants received the 
infected bites of sandflies.  While in endemic participants the percent of LST>0 
diminished during the follow up (from 78.7% to 65%), in non-endemic 
participants it grew (from 72.8% to 76.7%).  
 
Table 5.4 - LST reactivity in endemic and non-endemic participants in vaccine and 
BCG arms: before, 80 days after and one year after vaccination  
Pre-vac 
Total BCG Vaccine Total BCG Vaccine Total
Non-endemic (% LST> 0) 12.4 32.9 72.8 53.4 52.5 76.7 64.8
N 1690 1104 1168 2272 888 922 1810
Endemic (% LST> 0) 39.9 27.6 78.7 53.6 25.2 65.4 45.4
N 2123 4630 4775 9405 4377 4437 8814
Total (% LST> 0) 27.7 28.7 77.6 53.5 29.8 67.3 48.7
N 3796 5734 5943 11677 5265 5359 10624
Day 80 One-year
 
Note: Pre-vac LST observed only in Zav3 (non-endemic) and Bor3 (endemic)  
  
5.1.3  Pre- and post-vaccination LST (in Bor3) 
 
Bor3 trial provides the only opportunity to study the relationship between pre- and 
post-vaccination LST.  Figures 5.5 and 5.6 display changes in pre-vaccination LST 
after 80 days and one year of vaccination, respectively. 
 
Figure 5.5 - Day 80 LST in Bor3                                   
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Figure 5.6 - One-year LST in Bor3                                   
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Tables 5.5 and 5.6 present changes in LST over the study period in Bor3.  Among 
those with pre-vaccination LST<5, more of the vaccinated compared to BCG 
participants maintained their LST>0 status 80 days after vaccination.  Vaccination led 
to one year LST reactivity even if day 80 LST values were non-reactive.  As table 5.6 
indicates, vaccination caused a sharper jump in LST in individuals with pre-
vaccination LST=0 compared to LST>0.  An important observation in table 5.5 is that 
there is a notable percentage of participants whose LST measurement changed from 
non-zero at screening to zero on day 80.  Over one third (300/779=38.5%) of Borkhar 
participants with pre-vaccination LST had LST=0 on day 80.   
 
Table 5.5 - Mean values of one-year LST associated with LST on day 80 and pre-
vaccination in Bor3 for vaccine and BCG arms 
Pre-vac 
LST 0 1 2 Total 0 1 2 Total
0 mean LST 1yr 0.33 0.74 4.17 0.62 1.72 2.52 3.17 2.56
std. dev. 1.15 1.69 4.50 1.82 1.63 2.23 2.40 2.23
N 322 103 23 448 99 250 151 500
% of total 71.9% 23.0% 5.1% 19.8% 50.0% 30.2%
> 0and< 5 mean LST 1yr 0.56 1.02 4.83 1.13 2.26 2.44 3.24 2.65
std. dev. 1.73 1.64 4.37 2.51 1.81 2.16 3.17 2.48
N 176 62 29 267 50 111 72 233
% of total 65.9% 23.2% 10.9% 21.5% 47.6% 30.9%
≥5 mean LST 1yr 0.33 3.33 7.22 6.29 3.00 2.86 5.98 4.72
std. dev. 0.82 1.26 4.20 4.47 3.55 2.04 4.19 3.89
N 6 3 48 57 7 14 30 51
% of total 10.5% 5.3% 84.2% 13.7% 27.5% 58.8%
Total mean LST 1yr 0.41 0.89 5.83 1.22 1.95 2.51 3.52 2.72
std. dev. 1.38 1.70 4.49 2.77 1.82 2.20 3.02 2.50
N 504 168 100 772 156 375 253 784
% of total 65.3% 21.8% 13.0% 19.9% 47.8% 32.3%
Vaccine
Day 80 LST categories Day 80 LST categories
BCG
 
LST categories are  0: 0mm, 1: >0mm up to 5mm, 2: LST≥5mm  
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Table 5.6 - Mean LST induration 80 days and one year post vaccination in pre-
vaccination LST reactive participants in BCG or vaccine arm in Bor3 
Pre-vac LSt BCG Vaccine BCG Vaccine
LST= 0 mean 0.90 3.33 0.59 2.53
std. dev. 2.19 2.73 2.99 2.21
N 538 608 516 542
LST> 0 mean 2.73 4.15 2.08 3.08
std. dev. 4.60 4.00 12.77 3.00
N 399 380 352 315
Day 80 One-year 
 
Differences between LST=0 and LST>0 are significant in BCG arm in both evaluations 
(p<0.0005); in the vaccine arm: day 80 p= 0.03, one-year p=0.10. 
 
The following regression models summarize the effect of earlier LST reaction and 
vaccination on day 80 LST measurement.  The first model (table 5.7a) estimates the 
effect of prevaccination LST and the vaccine (vs BCG alone) on day 80 LST.  The 
variable named Vaccine in the model is a dichotomous variable with 1 = vaccine and 
0 = BCG.  This model does not include an interaction term and tests the effect of the 
two independent variables Vaccine and Pre-vac LST independently of one another.  
Results indicate a significant direct relationship between both of these variables and 
the magnitude of day 80 LST.  The beta values suggest that the pre-vaccination is the 
more important driver of day 80 LST.  
 
 
Table 5.7a - Regressing day 80 LST on pre-vaccination LST and vaccine 
Dependant: Day 80 LST Coef. Std. Err. t P> | t| Beta
Pre-vac LST 0.78 0.03 23.76 0.000 0.46
Vaccine 2.02 0.14 14.73 0.000 0.28
CONST 0.79 0.11 7.54 0.000 .
R-squared 0.286
Adjusted R-sq 0.285
P (F test) < 0.001  
 
To see the effect of prevaccination LST>0 in the two study arms separately, the 
second model (table 5.7a1) also includes an interaction defined as the product of 
Vaccine and Pre-vac LST variables (multi-collinearity was not a problem in the model, 
with the multiple correlation between the interaction term and its components around 
0.5).  For the BCG arm, the value of the interaction term is 0.  In the vaccine arm, 
when the value of pre-vaccination LST>0 the interaction term is non-zero (and equals 
the pre-vaccination LST measurement).  
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Table 5.7a1 - Regressing day 80 LST on pre-vaccination LST, vaccine and their 
interaction 
 
Dependant: Day 80 LST Coef. Std. Err. t P> | t| Beta
Pre-vac LST 1.05 0.05 22.68 0.000 0.61
Vaccine 2.60 0.15 17.00 0.000 0.36
Interaction (Vaccine by Pre-
vac LST) -0.52 0.06 -8.06 0.000 -0.23
CONST 0.49 0.11 4.47 0.000
R-squared 0.309
Adjusted R-sq 0.308
P (F test) < 0.001  
 
In table 5.7a1, the significant, negative coefficient for the interaction term suggests 
that in the vaccine arm, non-zero pre-vaccination LST is associated with relatively 
smaller day 80 LST as compared to the BCG arm.  This can also be verified via table 
5.6.  Since a non-zero prevaccination LST is necessary for the interaction term to also 
be non-zero, this observation may also indicate the role of previous exposure in 
keeping day 80 LST at moderate levels despite vaccination.    
 
Table 5.8 presnts a similar model to that discussed above but has the one-year LST 
value as the dependent variable.   This model estimates the effect of previous LST 
measurement ( both prevaccination LST and day 80 LST) as well as vaccination in the 
two study arms.  Results are similar to those seen for day 80 LST discussed above 
with a negative coefficient for the interaction term.  Overall, the model indicates a 
greater association between pre-vaccination LST than day 80 LST with one-year LST 
measurement.  
 
Table 5.8 - Regressing one-year LST on day 80 LST, pre-vaccination LST, Vaccine 
and their interaction 
Dependant: One-year LST Coef. Std. Err. t P> | t| Beta
Day 80 LST 0.30 0.03 8.56 0.000 0.23
Pre-vac LST 0.33 0.02 17.44 0.000 0.42
Vaccine 1.14 0.14 8.19 0.000 0.21
Interaction (Vaccine by Pre-
vac LST) -0.63 0.19 -3.38 0.001 -0.09
CONST 0.33 0.09 3.81 0.000
R-squared 0.368
Adjusted R-sq 0.366
P (F test) < 0.001  
 
From above data presentations (tables 5.5 through 5.8), it is clear that LST reaction at 
any stage is related to both, previous immune response and vaccination status.  
Primarily, however, natural exposure (boosted by BCG or vaccine) plays a major role 
in a lasting (one year) LST response.   These observations are summarized below: 
 
Strong immune response to natural exposure, manifested by pre-vaccination LST≥5, 
influences post-vaccination LST results: in the BCG arm, both 80 days and one year 
after vaccination, LST response is more frequent and stronger if pre-vaccination 
LST≥5.  Vaccination also plays a significant role in increasing LST.   
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Based on table 5.5, larger pre-vaccination LST in the BCG arm leads to larger day 80 
LST.  In the vaccine arm this relationship is more moderate.  This is demonstrated in 
tables 5.7a1 and 5.8, where the negative interaction term suggests vaccination in 
participants with reactive pre-vaccination LST leads to lower day 80 and one-year 
LST results than in those with pre-vaccination LST=0. 
 
It should be noted that of those with pre-vaccination LST>0 nearly 19% in the vaccine 
arm and over 57% in the control arm reverted to LST=0 by day 80 (64% and 28% 
respectively reverted in one year).  This demonstrates the volatility inherent in LST 
and its implication for vaccine clinical trials:  had the volunteers been screened 80 
days later, 38.5% of those with pre-vaccination LST>0 would have been accepted into 
the trial as having LST=0, and assumed unexposed, a source of misclassification. 
 
5.1.3.1  Estimation of the number of non-responsive participants in the sample 
 
The design of the Bor3 study which includes a number of LST tests including pre-
vaccination, allows a rough estimate of the prevalence of lack of 
sensitivity/responsiveness to the leishmanial antigen in Bor3.  The subset of the 
sample who received the vaccine, whose LST stayed at 0 from pre-vaccination until 
after the final dose of the vaccine (4 LST evaluations overall), and who did not 
develop the clinical disease would include non-responders; i.e., the percentage of such 
individuals would be the upper limit for the vaccine arm prevalence of those whose 
immunology does not respond to the parasite.  A total of 28 participants with these 
qualifications could be identified. This suggests 3.72% (95% CI: 2.37%-5.07%) of all 
vaccinated trial participants with complete LST profile (753 individuals) potentially 
lack sensitivity to the antigen.  Furthermore, if they indeed lack sensitivity to the 
antigen, they could be potentially immune.   
 
This estimate has an upward bias due to: a) during the follow up some of these 
participants may not have been exposed to the infected sandfly bite in the first year; 
some such individuals could have responded to natural exposure had there been 
another LST test at the end of the 3 year follow up, and b) LST imperfect sensitivity 
and (for example, the BCG within the vaccine mix may have not been effective, 
leading to LST's inability to identify exposure).   
 
 
5.2  LST results in demographic groups 
 
5.2.1  Pre-vaccination LST 
 
As indicated earlier, the naturally acquired pre-vaccination LST>0 is more prevalent 
but with generally smaller induration in Bor3.  LST prevalence and induration (among 
those with LST>0) in both trials is age dependent.  This is indicated in the following 
table and figure 5.7.  In ages up to 13 years, the relationship is equally significant in 
both trials. 
 
 
 
 
 106
Table 5.9 - Mean values of pre-vaccination LST (including all LST values) in Bor3 
and Zav3 and ANOVA* results 
Age categories Mean Std. Dev. Freq. Mean Std. Dev. Freq.
5-6 yrs 0.86 1.60 236 0.20 0.99 50
7 yrs 0.87 1.93 445 0.04 0.41 94
8 yrs 1.02 2.01 461 0.34 1.19 93
9-10 yrs 1.23 2.21 764 0.32 1.06 170
11-15 yrs 1.41 2.35 217 0.60 1.71 592
16-25 yrs -- -- -- 0.57 1.75 321
> 26 yrs -- -- -- 0.52 2.28 360
Total 1.09 2.07 2123 0.49 1.72 1680
Bor3 Zav3
 
ANOVA results: Bor3: F=4.36, Pr>F=0.001;  Zav3: F=2.21, Pr>F=0.040 
 
 
Figure 5.7 - Age-based pre-vaccination LST>0 in endemic and non-endemic 
participants (by design, Endemic participants were limited to school age 
children)                                   
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(Trend test in Bor3: Z=4.36, p<0.001; in Zav3: Z=2.33, p=0.020) 
 
The relationship between age and prevalence of naturally developed LST up to the 11-
15 yr age group shows age-dependence in both Bor3 and Zav3.  However, when 
considering age groups above 11-15 years (figure 5.7) this relationship is non-linear in 
Zav3.  This is a deviation from the expected linear LST/age relationship in endemic 
foci, where longer exposure leads to more prevalent LST>0 in older residents.   
 
The regression results in table 5.10 (based on participants with pre-vaccination LST>0 
only) demonstrate the age-dependence of pre-vaccination LST induration in Bor3 
(endemic) and Zav3 (non-endemic).  The coefficient for participants' endemic origin 
is negative; indicating significantly smaller average LST induration in endemic 
participants in Bor3.  Age is a statistically significant predictor, although the 0.049 R 
squared indicates that other factors than age are stronger determinants of LST 
induration.  
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Table 5.10 - Regression results of pre-vaccination LST on age in Bor3 and Zav3 
 LST=f (age+endemic) -- including only those with pre-vaccination LST>0 
Coef. Std. Err. t P> | t| Beta
age 0.07 0.02 4.74 0.00 0.18
endemic -0.48 0.26 -1.86 0.06 -0.07
CONST 2.55 0.34 7.47 0.00 .  
Adjusted R squared=0.049 
 
The relationship between pre-vaccination LST and gender in Bor3 and Zav3 is 
presented in table 5.11.  In Bor3 a significantly higher percent of girls (45.4% vs 
34.7% boys) had non-zero pre-vaccination LST. By contrast, in Zav3, no significant 
relationship between gender and pre-vaccination LST could be observed. 
 
Table 5.11 - Distribution of pre-vaccination LST by Gender  
Study F M
Bor3 N 1042 1081
% w ith LST= 0 54.6 65.3
% w ith LST> 0 45.4 34.7
Zav3 N 831 859
% w ith LST= 0 88.0 87.2
% w ith LST> 0 12.0 12.8  
Fisher's exact: Bor3 p<0.001, Zav3 p=0.342 
 
Although the percentage of pre-vaccination LST>0 is greater in females in Bor3, the 
average LST induration in both trials is larger in males (the significant difference in 
Zav3 holds true even when age is limited to <15, p=0.0001). This is indicated in the 
table 5.12. On average, pre-vaccination LST size in males in both trials (all ages) is 
significantly higher than in females. 
 
Table 5.12 - Mean values of pre-vaccination LST in males and females with pre-
vaccination LST>0 in Bor3 and Zav3 
Obs Mean Std. dev. t p> t Obs Mean Std. dev. t p> t
Female 473 2.48 2.20 -3.11 -0.002 100 3.10 2.60 -3.71 0.000
Male 375 3.02 2.83 110 4.69 3.52
Bor3 Zav3
 
 
To see the interaction between age and gender, graph 5.8 below breaks the age/LST 
relationship further down by gender.  Trend tests and tests of LST mean differences 
between male and female participants (presented below) confirm age-LST 
relationship in both males and females in Bor3. 
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Figure 5.8 - Age-based pre-vaccination LST>0 in endemic (Bor3) and non-endemic 
(Zav3), male and female participants                                   
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Trend test in Bor3: females: Z=3.82, p<0.001, males: Z=1.84, p=0.066 (Z=2.10, p=0.036 if 
mean LST is used instead of %LST>0); no significant trend in Zav3 (females: p=0.135, males: 
p=0.073) 
 
In Bor3, pre-vaccination LST is linearly age-related in males and females, as 
indicated in table 5.13. The same relationship in Zav3 (marginally significant at p 
=0.049) does not show gender-dependence.  The initial high LST in Bor3 may 
indicate disease while the subsequent drop and gradual rise may indicate LST due to 
building up of immunity.  
 
Table 5.13 - Male female comparison on mean pre-vaccination LST in Bor3 and Zav3 
Age categories 
Male Female Male Female
5-6 yrs 0.83 0.91 0.40 0.00
7 yrs 0.89 0.84 0.09 0.00
8 yrs 1.11 0.93 0.22 0.43
9-10 yrs 1.25 1.22 0.12 0.55
11-15 yrs 1.55 1.27 0.48 0.74
16-25 yrs -- -- 0.39 0.67
> 26 yrs -- -- 0.39 0.60
Bor3 Zav3
 
 
 
In Zav3, the difference between males and females is mainly in ages 8-10 and, 
assuming this reflects a real difference, it may be due to greater exposure in 8-10 year 
old boys in this newly endemic area (girls may be more covered or spend less time 
outdoors particularly during peak hours of sandfly activity).  However, as stated, other 
than this difference there is no consistent trend with age.   
 
Overall, these findings suggest that in an established endemic area, as expected, most 
people eventually are exposed (i.e., increased chance of exposure with age), 
regardless of gender and, as a result, pre-vaccination LST is age-related. On the other 
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hand, in a newly endemic area pre-vaccination LST may be more related to the 
differences in exposure for male and female participants, in childhood (ages 8-10) 
without a continuous trend with age. 
 
5.2.2  Day 80 LST 
 
Trend tests for day 80 LST over age categories are significant for all except vaccine 
arm, non-endemic participants.  Nonetheless, these relationships are not very strong or 
consistent (figure 5.9) and do not seem to have immediate epidemiological 
explanation.  The finding for the Esf1 BCG arm is consistent with the finding in 
Chapter 4 (table 4.4) that in the BCG arm in Esf1 there is a positive but borderline 
significant relationship between age and incidence.  The increased percentage of 
LST>0 in higher ages in the BCG arm in Esf1, therefore, may show developing 
infection due to natural exposure. This is, however, unlikely since the study start was 
selected so that the 80 days after vaccination would fall within the non-transmission 
period.     
 
Figure 5.9 - Age-based day 80 LST>0 in participants from endemic or non-endemic 
origin (Endemic participants were limited to school age children-- all pre-vac LST=0)     
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Trend test for age:  Non-endemic BCG: z = 2.29, p=0.022, vaccine: z = -1.05; p=0.292; 
Endemic BCG: z = 2.74, p=0.006, vaccine: z = 7.28, p<0.001        
 
Graph 5.10 shows the relationship between gender and LST. The only interaction 
between gender and age is the difference observed between male and female 
participants in the 16-25 year age category, both in the vaccine and the BCG trial 
arms.  The only immediate explanation is that local customs and risk behaviours 
promote such differences. 
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Figure 5.10 - Age-based day80 LST>0 in male and female participants in vaccine and 
control arms (endemic participants were limited to school age children-- all pre-vac LST=0)                             
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Trend test for age:  Females BCG: z = 3.86 p< 0.001, vaccine: z = 1.40, p=0.161; Males BCG: 
z = 3.63, p<0.001, vaccine: z = 1.65, p=0.099 
 
In Bor3 male participants in the BCG arm with pre-vaccination LST>0 have a 
significantly greater tendency to maintain their LST levels after 80 days and after one 
year (table 5.14).   This is probably independent of further natural exposure in these 
male participants since by day 80 the re-exposure to the sandfly bites has presumably 
not yet started (study start date was chosen  so that day 80 would be before the start of 
the transmission season). 
 
Table 5.14 - Post-vaccination LST in control arm participants with pre-vaccination 
LST>0 in Bor3 
LST Female Male
Day 80 N 217 182
% w ith LST= 0 62.7 50.5
% w ith LST> 0 37.3 49.5
One-year N 191 161
% w ith LST= 0 72.3 53.4
% w ith LST> 0 27.7 46.6  
Fisher's exact: day 80 p=0.019, one-year p<0.0005 
 
5.2.3 One year LST 
 
Graph 5.11 below, depicts changes in LST from day 80 to the one-year evaluation.  
Overall, the change does not seem to be age-dependent, regardless of the endemic 
origin of participants, or study treatment.  For all age groups combined, the frequency 
of LST response in the BCG arm of Esf1 (non-endemic participants) increased 
significantly from day 80 (as discussed earlier, tables 5.2 and 5.3).  In Bor3 (endemic 
participants) other than a slight drop in day 80 LST measurements, no sizeable change 
was observed in LST from day 80.  This observation points at a state of equilibrium 
with respect to LST response in endemic participants.  This state of equilibrium is 
missing in non-endemic participants who respond massively to natural exposure. 
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Figure 5.11 - Age-based one-year LST>0  in participants of endemic and non-
endemic origin in vaccine and control arms (Endemic participants were limited to 
school age children-- all pre-vac LST=0)    
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Trend test for age: all p> 0.3 
 
5.3  Summary 
 
Immune response and LST development over time as a result of vaccination and 
natural exposure was assessed overall and in demographic groups.  As expected, 
ALM+BCG vaccine is a significantly greater immune response stimulator than BCG 
alone, as demonstrated by day 80 and then one-year LST evaluation (which do not 
differ significantly in endemic participants, but an increase from day 80 to one-year is 
observed in non-endemic participants due to natural exposure). 
 
Overall, the hypothesis of no difference in immune response being associated with 
demographic characteristics can be rejected.  
 
Naturally developed LST (pre-vaccination LST) was not an exclusion criterion  in 
Bor3 and Zav3; therefore, participants with screening LST>0 were included in these 
trials.  In comparison to Bor3 LST is less prevalent but has larger average induration 
among the non-endemic participants in Zav3.  By contrast, in Bor3 naturally induced 
LST is observed more frequently but with moderate induration.   
 
LST due to natural exposure is, as expected, age dependent, both in its prevalence and 
induration.   In Zav3, where participants were as old as 59 years, the prevalence of 
pre-vaccination LST>0 peaks at the 11-15 age group and drops thereafter.  This 
phenomenon may be confirmation that the site in Zav3 is a new endemic area and the 
population do not demonstrate the same age/exposure characteristic as in an endemic 
focus (where LST prevalence is expected to increase with age).  In Bor3 the more or 
less linear age/LST correlation is expected since the trial site had been an endemic 
focus for many years.  However, this could only be demonstrated within the trial age 
range (6-13 years). Therefore, it can not be compared with Zav3 for ages above 13 
years.    
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Pre-vaccination LST is more frequent in females in Bor3; however, induration is 
significantly larger in male participants in both trials.  Additionally, male participants 
in the control arm tend to maintain their LST reactivity more than females.   
 
An interesting observation with respect to pre-vaccination LST in Borkhar was that 
some of the participants with pre-vaccination LST>0 had LST=0 readings on day 80.  
This suggests that LST has a volatile nature and not always a reliable indicator of 
exposure.   
  
Post-vaccination LST was measured in most trials in 80 days and then one year after 
vaccination.  As mentioned, stronger LST response was observed in the vaccine arms 
of trials.  In general, the one-year LST results diminished slightly but did not change 
dramatically from day 80 except that the average induration in vaccine and BCG arms 
converged somewhat.  In trials in L. major foci, in Esf1 with non-endemic participants 
average day 80 LST results were similar to Bor3 with endemic participants; one-year 
LST results however, were much stronger in Esf1, presumably due to leishmania-
naive participants' response to the natural exposure during the year.  The fact that 
LST>0 proportion among endemic participants does not continue growing during the 
follow up (despite continuous exposure) may indicate a point of equilibrium (or 
maximum) for LST conversion in a population.  
 
A common pattern of LST response could not be identified for trials with multiple 
doses of the vaccine/BCG. 
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CHAPTER 6 
 
LST RESPONSE AS A CORRELATE OF IMMUNITY 
 
 
Immunization with leishmanial antigen, BCG injection and natural exposure could, to 
varying degrees, stimulate cellular response to Leishmania and increase LST 
(Modabber and Reed, 2004).  Exposure to the parasite in populations of endemic foci 
is generally life-long and repeated.  In a newly endemic area (or during an epidemic in 
a non-endemic area) exposure is not repeated over a long period of time.  The dogma 
maintains that significant immune system stimulation (DTH) due to natural exposure 
(and the ensuing positive LST response) is linked to protection.   
 
Repeated exposure (i.e., asymptomatic, subclinical infection) and previous clinical 
infection are common in leishmaniasis endemic foci and are believed to be detectable 
via LST≥5 (Jumaian et al., 1998;Weigle et al., 1993), which in turn is believed to be 
associated with immunity (endemic immunity) (Ben Salah et al., 2005;Davies et al., 
1995;Guirges, 1971).  In other words, LST≥5 (generally accepted as "positive"), if not 
indicative of a developing current infection, would be associated with protection. 
 
Bor3 and Zav3 provide pre-vaccination LST measurements and the opportunity to test 
the dogma; i.e., protection associated with pre-vaccination LST>0 or LST>5 in 
endemic and non-endemic populations (after boosting with BCG alone or ALM+BCG 
vaccine).   The opportunity is also provided to assess LST as a reliable/lasting 
indicator of pre-vaccination exposure by assessing the change in LST measurement 
during the follow-up. 
 
It has been observed in some of the trials (Antunes et al., 1986;Khalil et al., 
2000a;Momeni et al., 1999) that LST≥ 5mm measured 40-80 days after vaccination is 
associated with a reduced incidence of disease.  However, this has not been suggested 
by all vaccine trials -- either because this effect was not present or because different 
trials were not equally able to indicate it, owing to their differences in incidence rate, 
levels of endemic immunity, etc.  It is of interest to further test whether disease 
incidence is reduced in LST responsive participants using the large combined sample 
size of the present study and to observe whether it holds in various subgroups.  
 
In this chapter incidence and vaccine efficacy will be studied in connection with the 
DTH response as measured by LST at different points in time, before and after 
vaccination, in the vaccine or the BCG arm.   
 
The overall objective is to evaluate the association between LST response and 
immunity (due to intervention or natural exposure) and examine LST's merits as a 
correlate of immunity. 
 
 
6.1   Naturally developed (pre-vaccination) LST and protection 
 
To test that LST≥5 due to natural exposure is associated with immunity, the incidence 
in participants with pre-vaccination LST≥5 or LST<5 in the Bor3 and Zav3 trials were 
compared.  The important caveat is that all participants received either BCG or the 
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vaccine, ALM+BCG.  Therefore, the comparison of the clinical outcome between 
LST<5 and LST≥5 groups does not show the pure effect of naturally acquired LST≥5 
but rather its joint effect with BCG (which could augment the effect of previously 
activated DTH).   
 
The hypothesis to be tested should take BCG into account, as follows:  
 
H0: % cases among those with pre-vaccination LST≥5+BCG equals % cases among 
those with pre-vaccination LST<5+BCG 
H1: % cases among those with pre-vaccination LST≥5+BCG is less than % cases 
among those with pre-vaccination LST<5+BCG 
 
The following table displays the % cases in the two studies associated with pre-
vaccination data: 
 
Table 6.1 - Incidence in pre-vaccination LST groups (BCG and vaccine arms) in Zav3 
and Bor3, combined 
Pre-vaccination LST
Bor3+ Zav3
LST < 5 12.9%
N 3595
LST ≥5 4.4%
N 210
TOTAL 12.5%
N 3805
Fisher ex. p < 0.001  
 
This analysis leads to the rejection of the hypothesis as formulated; i.e., it leads to the 
conclusion that LST≥5 due to natural exposure is in fact associated with significant 
protection, when considering the data from both trials combined (keeping in mind that 
all participants had received BCG either with or without ALM antigen and these 
results could partially reflect its effect) 
 
 
6.1.1  Further observations in relation to naturally developed LST 
 
Further examination of the number of cases at LST<5 and LST≥5, reveals that in Bor3, 
LST≥5 was associated with significant protection, regardless of vaccination status; in 
Zav3, LST≥5 is associated with borderline significant protection.   This is depicted in 
the table 6.2 below.  This difference is linked to the smaller prevalence of LST≥5 in 
Zav3 (55 compared to 148) in spite of the higher annual incidence rates in Zav3 
(figure 4.8).  Although the difference in % cases among LST+ participants between 
the two trials is not statistically significant, the difference in the % of LST≥5 between 
Bor3 and Zav3 is quite significant (p< 0.001).  This difference probably reflects the 
difference in endemicity between the two trial sites: Zavareh, a new endemic area, has 
smaller overall prevalence of exposure.   The are further differences between Bor3 
and Zav3 in their patterns of exposure and incidence.  These differences will be 
discussed in the next section. 
 115
 
Table 6.2 - Cases in pre-vac LST groups in Zav3 and Bor3 
Pre-vaccination LST Zav3 Bor3
LST<5 13.2% 12.6%
N 1620 1975
LST≥5               4.8% 4.1%
N 62 148
TOTAL     12.9% 12.0%
1682 2123
Fisher's exact p 0.053 0.001  
 
 
6.1.1.1  Differences in endemic exposure and immunity between Bor3 and Zav3 
 
As discussed in Chapter 5, pre-vaccination exposure (detectable by LST) is age 
related in both Bor3 and Zav3 (up to age 13 - see figure 5.7).  In Bor3, as suggested 
by figure 6.1, the protective effect of endemic exposure (detectable by pre-vaccination 
LST) appears age-based, as would be expected of an endemic focus.  However, this is 
not the case in Zav3, the endemic focus with non-endemic population (figure 6.2). 
 
Figure 6.1 - Pre-vaccination LST and incidence by age in Bor3 
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Trend test significant for LST (p<0.0005) but not for incidence 
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Figure 6.2 - Pre-vaccination LST and incidence by age in Zav3 
Zav3
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Trend test significant for LST (p=0.020) but not incidence 
 
This observation should be considered in conjunction with another finding discussed 
in Chapter 5 in relation to the induration and prevalence of pre-vaccination LST.  As 
discussed in Chapter 5, compared to Zav3, pre-vaccination in Bor3 is more prevalent 
but with more moderate induration, on average (see table 5.1).  Together these 
findings suggest distinct profiles associated with naturally developed, protective DTH 
and LST results in endemic and non-endemic populations under high incidence 
conditions. 
 
 
6.2  Post vaccination LST and protection 
 
6.2.1 Day 80 LST and protection 
 
In some of the previous vaccine trials, LST conversion to ≥5 in 40-80 days after 
vaccination has been linked to lower incidence in the vaccine arm.  In these trials, 
lower incidence was observed in the subset of participants whose immune system was 
stimulated by the vaccine (evident by the LST≥5).  To test whether the current data 
support the notion that vaccine induced immune system stimulation could lead to 
protection, the following hypothesis is formulated: 
 
H0: % case in participants with day 80 LST conversion to ≥5 in the vaccine arm 
equals % case in participants in the BCG arm or those with day 80 LST<5 in the 
vaccine arm 
H1: % case in participants with day 80 LST conversion to ≥5 in the vaccine arm is 
less than % case in participants in the BCG arm or those with day 80 LST<5 in 
the vaccine arm 
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The hypothesis formulated above is in line with and addresses the same question as in the 
study by Antunes and Mayrink (Antunes et al., 1986).  Khalil (Khalil et al., 2000a) and 
Momeni (Momeni et al., 1999) tested somewhat different hypotheses.  In Esf1, Momeni 
et al limited their analysis to the first year follow up results.  Furthermore, both Momeni 
and Khalil included with the LST≥5 group not only participants from the vaccine arm but 
also the LST converted participants from the control arm.   Effectively, they tested the 
efficacy of LST conversion rather than the vaccine.  The hypothesis formulated above 
tests the reduction in incidence associated with the ALM+BCG vaccine in LST converted 
vaccine arm participants against all others.  The group of interest is not defined by LST 
conversion but LST conversion due to the vaccine. 
 
Examining incidence in individual trials, after excluding those with pre-vaccination 
LST>0, does not provide statistically significant evidence that vaccine was efficacious 
in conjunction with day 80 LST≥5.  These results are presented below. 
 
Bam1: Reduced incidences observed in the vaccine arm (in all LST categories and 
overall) are not statistically significant, as demonstrated in the following table. 
 
Table 6.3 - Incidence in day 80 LST groups in vaccine and BCG arms in Bam1 
Bam1 LST= 0 0< LST< 5 LST≥5 Total
BCG 3.0% 4.5% 5.2% 3.4%
N 1282 421 58 1761
Vaccine 2.8% 2.9% 2.7% 2.8%
N 355 1154 298 1807
Total 2.9% 3.3% 3.1% 3.1%
N 1637 1575 356 3568
Fisher ex.  p 0.526 0.074 0.260 0.212
Vaccine arm 
LST≥5 All others Fisher Ex.
% 2.7% 3.1% p=0.411
N 298 3270  
 
 
Bam3:  Similar to Bam1, differences are not significant, as depicted in the table 6.4.  
The only difference between the design of  Bam1 and Bam2 trials was the number of 
study injections which may be the reason for higher incidence in LST>5 in the 
vaccine arm (possibly due to stronger stimulation of cases in incubation by the 
vaccine compared to BCG alone -- this will be discussed later). 
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Table 6.4 - Incidence in day 80 LST groups in vaccine and BCG arms in Bam3 
 
Bam3 LST= 0 0< LST< 5 LST≥5 Total
BCG 4.9% 4.6% 2.6% 4.8%
N 1459 434 39 1932
Vaccine 3.6% 3.5% 5.8% 3.9%
N 469 1150 361 1980
Total 4.6% 3.8% 5.5% 4.3%
N 1928 1584 400 3912
Fisher ex.  p 0.160 0.182 0.346 0.134
Vaccine arm 
LST≥5 All others Fisher Ex.
% 5.8% 4.2% p=0.099
N 361 3551  
 
 
Bor3: In Bor3, similar to Bam3, results are not significant (table below).  However, 
when comparing LST positives and LST negatives, significant protection is associated 
with the former, regardless of vaccine arm. 
 
Table 6.5 - Incidence in day 80 LST groups in vaccine and BCG arms in Bor3 
Bor3 LST= 0 0< LST< 5 LST≥5 Total
BCG 12.3% 11.3% 3.0% 11.5%
N 381 124 33 538
Vaccine 9.2% 13.4% 8.2% 11.0%
N 119 307 182 608
Total 11.6% 12.8% 7.4% 11.3%
N 500 431 215 1146
Fisher ex.  p 0.228 0.342 0.260 0.390
Vaccine arm 
LST≥5 All others Fisher Ex.
% 8.2% 11.8% p=0.098
N 182 964  
 
Esf1: Similar to Bor3, results are not statistically significant, as displayed in the 
following table. 
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Table 6.6 - Incidence in day 80 LST groups in vaccine and BCG arms in Esf1 
Esf1 LST= 0 0< LST< 5 LST≥5 Total
BCG 19.2% 18.5% 14.9% 18.7%
N 741 276 87 1104
Vaccine 16.7% 20.1% 17.5% 18.2%
N 318 427 423 1168
Total 18.4% 19.5% 17.1% 18.4%
N 1059 703 510 2272
Fisher ex.  p 0.191 0.329 0.344 0.393
Vaccine arm 
LST≥5 All others Fisher Ex.
% 17.5% 18.7% p=0.315
N 423 1849  
 
 
Overall, no significant reduction in incidence can be observed in individual studies among 
the immunologically responsive (LST≥5) vaccine arm participants compared to others or 
between vaccine and BCG arms within the same LST group.  
 
The next step in this analysis is to estimate via meta-analysis the reduction in incidence in 
all Iran trials associated with both ALM+BCG vaccine and subsequent day 80 LST≥5.  
As stated earlier, this analysis is directed at testing reduction in incidence associated with 
the vaccine.  Therefore, it focuses on the effect on incidence of LST response associated 
with ALM+BCG vaccine but not with BCG alone. Including day 80 LST conversion in 
the BCG arm would test not LST conversion due to the vaccine but rather LST 
conversion, regardless of the stimulus.  Incidence rates and risk ratios in different trials 
are presented in table 6.7 and 6.8.  Figure 6.5 displays the forest plot for this analysis. 
 
Table 6.7 - Incidence in the treatment/LST groups 
Study
BCG or 
LST< 5 
Total N
BCG or 
LST< 5 
Cases
Vaccine & 
LST≥5 
Total N
Vaccine 
Cases
% Case 
(BCG or 
LST< 5)
% case 
(Vaccine & 
LST≥5)
Bam1 3270 103 298 8 3.15 2.68
Bam3 3551 149 361 21 4.20 5.82
Bor3 964 114 182 15 11.83 8.24
Esf1 1849 345 423 74 18.66 17.49  
 
Table 6.8 - Meta-analysis of RR results between (LST≥5 in vaccine) and all others  
Study RR % Weight
Bam1 0.852 0.419 1.733 8.22
Bam3 1.386 0.889 2.161 13.13
Bor3 0.697 0.417 1.166 17.29
Esf1 0.938 0.747 1.177 61.36
M-H pooled RR 0.948 0.79 1.137 100
  Heterogeneity chi-squared =   4.29 (d.f. = 3) p = 0.232
  I-squared (variation in RR attributable to heterogeneity) =  30.0%
  Test of RR=1 : z=   0.58 p = 0.565
95% Conf. Interval
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Figure 6.3 - Forest plot of effect in LST responsive vs non-responsive subsets in Iran 
clinical trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meta-analysis results (overall RR=0.948, p=0.565) do not lead to the rejection of the null 
hypothesis; i.e., they do not support the notion that significant protection is associated 
with vaccination even when LST converts on day 80.  It should be emphasized, however, 
that a reformulated hypothesis (for example first year follow up results only, etc) could 
potentially lead to different results.  
 
 
6.2.1.1  Day 80 LST response and protection 
 
Increased LST after vaccination (80 days) could be due to different reasons.  Just as a 
raised LST could show immune system stimulation by vaccine or BCG, it could also 
show a developing infection destined to become a case.   As a result, compared to those 
with LST<5, the pool of LST≥5 participants would include a larger percentage of those 
who would later be identified as clinical cases. Due to the stronger stimulation by the 
ALM+BCG compared to BCG alone, this imbalance would be more pronounced in 
the vaccine arm, leading to the observation that LST stimulation by the vaccine that 
would lead to LST<5 could lead to protection.  In fact, such an imbalance should not 
be viewed as indicative of protection by the study treatment but rather the result of the 
LST≥5 classification criterion.  
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Accordingly, caution should be exercised in analysing the association between day 80 
LST of  0<LST<5 and protection when combining the data from all clinical trials. 
This is indicated in the following table. As mentioned previously (tables 6.3 to 6.6), 
comparison of the two arms within the same LST group in each trial separately does 
not lead to significant findings.  However, when combining the data from different 
trials, vaccination appears to be linked with a significant reduction in cases in the LST 
response group of 0<LST<5, as indicated in the table below.   
 
Table 6..9 - Incidence in day 80 LST groups in vaccine and BCG arms in all trials 
combined (pre-vaccination LST=0) 
All trials LST= 0 0< LST< 5 LST≥5 Total
BCG 7.7% 8.3% 8.3% 7.9%
N 3863 1255 217 5335
Vaccine 7.2% 6.6% 9.3% 7.4%
N 1261 3038 1264 5563
Total 7.6% 7.1% 9.2% 7.6%
N 5124 4293 1481 10898
Fisher ex. 0.304 0.029 0.366 0.306  
 
In the above table, incidence in the BCG arm is the same in both 0<LST<5 and 
LST≥5 groups while in the vaccine arm, it is significantly lower in the medium LST 
group compared to: 
 Vaccine arm LST≥5 group (p=0.002) 
 BCG arm LST<5 (0.047) 
 Entire BCG arm combined (p=0.030) 
 All other cells in the table (BCG or vaccine), combined (0.012) 
 
The difference is not significant between the 0<LST<5 and LST=0 groups in the 
vaccine arm. 
 
Initially, this observation may appear to indicate protection among those whose LST 
on day 80 was minimally stimulated by the vaccine.   However, this finding may be at 
least partially explainable by the LST-based grouping of study subjects: cases who 
received the vaccine have higher LST than healthy individuals who received the 
vaccine.  Therefore, in the vaccine arm, more cases end up in the high LST group and 
fewer in the medium LST group.  This is not because more individuals have been 
protected but because they have been grouped into the high LST category.  
  
This can be seen by observing the distribution of cases in the LST groups in the BCG 
and vaccine arms (% LST group within case/healthy participants), indicated below: 
 
Table 6.10 - Day 80 LST distribution among healthy and infected in four trials 
(throughout the follow-up duration)  
Day 80 LST Healthy Case Total Healthy Case Total
N 4,915 420 5,335 5,154 409 5,563
0 72.5% 71.0% 72.4% 22.7% 22.3% 22.7%
0<  and < 5 23.4% 24.8% 23.5% 55.1% 48.9% 54.6%
≥5               4.1% 4.3% 4.1% 22.2% 28.9% 22.7%
Fisher's Exact p: 0.755 0.008
BCG Vaccine
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As can be seen in the above table, an imbalance of about 6-8% of cases is observed 
between the medium and the high LST groups only in the vaccine arm and not in the 
BCG arm.  This imbalance leads to a lower proportion of cases in the medium LST 
group in the vaccine arm that is statistically significant and could be interpreted as 
protection. 
  
    
6.2.1.2  Lower first year  incidence in day 80 LST positive participants in L. 
major foci 
 
In Esf1, the L. major foci with non-endemic participants, stimulation by day 80 of the 
immune system (LST≥5) is associated with significantly reduced number of cases 
compared to those not stimulated (in the first year of follow-up only). This effect is 
observed in both study arms (table 6.11).   
 
Table 6.11 - Incidence (first year of follow-up) in Esf1 (L. major focus with non-
endemic participants) 
Day 80  LST BCG Vaccine Total
< 5 10.03% 11.28% 10.56%
N 1017 745 1762
≥5               3.45% 7.33% 6.67%
N 87 423 510
Total 9.51% 9.85% 9.68%
N 1104 1168 2272
P (incidence diff) 0.0446 0.0296 0.0089  
 
Bor3, conducted in endemic participants in another L. major focus, shows identical 
trends but with much smaller incidence in all cells of the table (possibly due to left 
over endemic immunity, even after excluding all pre-vaccination LST>0).  As a result, 
Bor3 results are not significant.  However, combining first year follow up results in 
Bor3 and Esf1 leads to highly significant results consistent with Esf1, as displayed in 
tables 6.12 and 6.13. 
 
Table 6.12 - Incidence (first year of follow-up) in Bor3 (pre-vaccination LST=0)  
Day 80  LST BCG Vaccine Total
< 5 1.98% 1.41% 1.72%
N 505 426 931
≥5               0.00% 0.55% 0.47%
N 33 182 215
Total 1.86% 1.15% 1.48%
N 538 608 1146
P (incidence diff) 0.4145 0.3632 0.1706  
 
Combined Bor3 and Esf1 results are presented in table 6.13. 
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Table 6.13 - Combined incidence (first year of follow-up) in Bor3 and Esf1  
Day 80  LST BCG Vaccine Total
< 5 7.36% 7.69% 7.50%
N 1522 1171 2693
≥5               2.50% 5.29% 4.83%
N 120 605 725
Total 7.00% 6.87% 6.93%
N 1642 1776 3418
P (incidence diff) 0.0447 0.0584 0.0119  
 
Overall, these observations share an important aspect: reduced incidence is not 
observed only in the vaccine arm, but also in the BCG arm.  This points at the 
possibility that BCG could be an important protective component of the vaccine.   
 
It is noteworthy that the two L. major foci show similar results of reduced first year 
incidence not seen in Bam trials. This is consistent with the fact that Bam is a focus of 
L. tropica which a typically longer period of latency and disease duration. Therefore, 
first year incidence could not be expected to show the effect of BCG, as most cases 
could not be identified until the second year of follow-up.     
 
Further examination of incidence over the entire follow up period in Bor3 reveals that 
after removing those with pre-vaccination LST>0, the number of cases is significantly 
smaller among those with day 80 LST≥5, when combining the two study arms 
(difference between BCG and vaccine not significant), as presented in table 6.14. This 
finding was not observed in any other trial and may in fact show the effect of 
sensitization due to natural exposure or vaccination in the first year + subsequent 
booster effect by BCG or vaccine at the end of the first year. 
 
Table 6.14 - Incidence associated with day 80 LST (in pre-vaccination LST=0) 
Bor3 Day 80 LST BCG Vaccine Total
< 5 12.1% 12.2% 12.1%
N 505 426 931
≥5 3.0% 8.2% 7.4%
N 33 182 215
Total 11.5% 11.0% 11.3%
N 538 608 1146  
P (comparison of LST groups in the total column) = 0.0496  
 
In summary, evidence of protection associated with LST≥5 is observed in the two 
trials in L. major foci in both study arms (ALM+BCG or BCG alone). 
 
6.2.2  One year LST and protection 
 
The likelihood of the LST reactivity one year after vaccination correlates with  
1) vaccination status (longer lasting LST reaction in the vaccine arm due to ALM) 
2) chance of sub-clinical infection 
3) chance of clinical infection.  
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There is a higher chance of infection among LST reactive participants because 
infection leads to LST response.  It is therefore not surprising that in both study arms, 
incidence is higher in higher LST groups (see the table below).  In this context, a 
reactive one-year LST works as a partial retrospective proxy for infection over the 
first year of follow-up period.   
 
At the same time, given equal chances of natural exposure in the BCG and vaccine 
arms during the first year of follow-up, the percent of LST reactivity should be greater 
in the vaccine arm.  This has been pointed out previously (chapter 5) and can be 
verified in the following table.   
Table 6.15 - First year incidence in one year LST groups in Bam1, Bam3, Bor3 and 
Esf1 (in pre-vaccination LST=0) 
LST= 0 0< LST< 5 LST≥5 Total
BCG 0.9% 5.6% 28.7% 3.8%
N 3472 1124 317 4913
Vaccine 1.2% 2.1% 14.3% 3.4%
N 1662 2717 665 5044
Total 1.0% 3.1% 18.9% 3.6%
N 5134 3841 982 9957
P (BCG vs Vacc): 0.346 0.000 0.000 0.314  
 
The important observation in the above table is that within LST reactive groups 
(0<LST<5 and LST≥5) the incidence among vaccine participants is significantly 
lower than that among BCG participants (this observation was verified in L. major 
and L. tropica trials separately but is not indicated here).  This could be interpreted as 
the ability of the vaccine to confer protection among those with high LST reaction.  
However, the overall incidence in the two study arms, regardless of LST, are not 
significantly different.  This observation raises the following question: given the 
random assignment to the study arms and the expectation for roughly equal incidence, 
does the vaccine really confer protection if it cannot reduce the overall incidence in 
the vaccine arm? 
 
To answer this question one should consider the LST-based classification rule in table 
6.16.  The reduced incidence in the vaccinated LST reactive groups may reflect the 
mixing of participants with similar LST measurement without regard for the reason 
for their LST reactivity: vaccine or exposure.  In calculating incidence within each 
LST group, those not infected but with the raised LST (due to natural exposure, 
vaccine or BCG) all contribute to the denominator but only those infected due to 
natural exposure contribute to the numerator.  Given equal exposure in both arms, the 
number of such participants is far greater in the vaccine arm, since the vaccine has a 
greater ability than BCG to raise LST response for one year. As a result, for roughly 
equal number of cases (which would be expected if the vaccine was not effective), a 
larger denominator in the vaccine arm leads to lower calculated incidence in LST 
reactive groups, while the overall incidence in the two arms are the same.   
 
6.2.2.1  One-year LST and protection in the second year of follow up 
 
When considering second year incidence in different one-year LST groups, a lower 
relative reduction in incidence among those with 0<LST<5 is observed (table 6.17).  
This is a similar situation to that explained earlier for the day 80 LST; i.e., classifying 
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based on LST result would place infected cases out of the 0<LST<5 group and in the 
LST≥5 group.  LST in this case is a prospective marker. 
 
Table 6.16 - Second year incidence in one year LST groups (in pre-vaccination 
LST=0) 
LST= 0 0< LST< 5 LST≥5 Total
BCG 3.7% 5.5% 4.1% 4.1%
N 3472 1124 317 4913
Vaccine 3.4% 3.8% 4.8% 3.8%
N 1662 2717 665 5044
Total 3.6% 4.3% 4.6% 4.0%
N 5134 3841 982 9957
P (BCG vs Vacc): 0.644 0.019 0.618  
   
6.2.3  Incidence associated with LST reactivity both, 80 days and one year post 
vaccination 
 
Continuous stimulation of the immune system has been stated as a requirement for 
protection  (Breton et al., 2005;Scott, 2005;Selvapandiyan et al., 2006;Zinkernagel et 
al., 1996).   In mice, it is clear that persistent parasite stimulation (with live parasite) 
maintains the effector CD4+ T cell pool which in turn mediates DTH and contributes 
to protection (Scott, 2005).  It could, therefore, be hypothesized that for protection 
during the first year of follow-up, neither the LST response after 80 days nor that after 
one year would be individually sufficient.  Rather, a continuous immune stimulation 
over the follow-up period would be necessary.   For protection, therefore, LST>0 both 
on day 80 and one year post vaccination would be a minimum requirement.   
 
Table 6.17 indicates incidence (entire follow-up) in various day 80 and one year LST 
groups.  Restricting to first year cases does not significantly change these findings: 
 
Table 6.17 - Incidence in day 80 and one year LST groups (pre-vaccination LST=0) 
d 80 
LST= 0
d 80 
LST> 0
d 80 
LST= 0
d 80 
LST> 0
d 80 
LST= 0
d 80 
LST> 0
BCG 6.0% 6.8% 40.4% 23.8% 7.7% 8.7%
N 3275 1168 171 143 3446 1311
Vaccine 5.0% 5.6% 28.7% 18.1% 7.0% 7.4%
N 1010 3232 94 552 1104 3784
Total 5.8% 5.9% 36.2% 19.3% 7.5% 7.8%
N 4285 4400 265 695 4550 5095
Within treatment pairs of difference between day 80 LST groups in the 
one year LST≥5 are significant as follows: BCG: p=0.0018, vaccine: p=0.0168, 
overall: p=0.0000.  Pairs of difference between BCG vs Vacc are not significant.
One year LST≥5 TotalOne year LST< 5
 
 
The table above indicates lower incidence in the subset of participants with one year 
LST≥5 whose day 80 LST>0 (either by BCG or vaccine).  An argument, similar to the 
one presented above, suggesting that the abundance of healthy LST-positive 
individuals (due to vaccine or BCG) augmented the denominator in the positive LST 
groups, thereby lowering their calculated incidence, would not hold in this case since 
the reduced incidence is observed in both the vaccine and the BCG participants.  
Unlike the vaccine, BCG tends not to produce a long lasting immune stimulation.  
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Therefore, many of the one-year LST positive individuals in the BCG arm (and a 
similar number of their vaccine counterparts) must have received additional 
stimulation through natural exposure; i.e., a natural boost for the priming with BCG or 
vaccine.  Such a prime-boost approach could be a practical method of immunization 
in endemic foci. 
 
The above table also provides support for the notion that a continuously stimulated 
immune system (evidenced by both day 80 and one year LST) is associated with 
lower incidence.  At the same time, it is important to note that there is no significant 
difference between vaccine and BCG.  Therefore, the lower incidence which could be 
indicative of protection, could be attributed to the BCG in both study treatments.  
Although, as pointed out before, the ALM in the vaccine leads to significantly higher 
LST response, this form of stimulation does not bring about a significantly larger 
protection in comparison to the BCG.  It was also observed that some cases in the 
vaccine arm had values of LST in excess of 5 mm or 10 mm or higher.  
 
The idea that ALM+BCG and BCG alone both resulted in protection in participants is 
also suggested by the following table.  The two treatments were for the most part 
indistinguishable with respect to their protectiveness: they appear to have both 
protected study participants against their immediate risk of infection.  The natural 
development of the disease is that in L. major infection clinical manifestation usually 
occurs in less than one year after exposure while in L. tropica infection clinical 
manifestation takes over one year (figure 6.6).  As table 6.19 indicates, in Iran clinical 
trials in L. major foci (except in Esf1), in the first year (year of vaccination) incidence 
was significantly lower than the second year.  By contrast, in L. tropica foci, the 
second year incidence was lower (table 6.19).  , it appears that immunization by BCG 
or ALM+BCG may have been protecting against the immediate risk of infection (first 
year in L. major and second year in L. tropica) by a overall factor of roughly RR= 
0.55, or efficacy of about 45%.   This effect may have been strengthened by multiple 
injections of BCG (alone or in vaccine) as suggested by the significantly lower first 
year incidence in Bor3 and Zav3 (3 injections) but not in Esf1 (1 injection).  
 
Figure 6.4 - Expected exposure/infection during follow up in ZCL and ACL trials 
Clinical  
manifestation
Clinical manifestation
Vaccination
Vaccination
ZCL
ACL
Exposure
Year 1 Year 2
Exposure
 
 127
 
 
Table 6.18 - Protection by BCG and vaccine against the immediate risk of infection 
in pre-vaccination LST=0 
Incidence in: Bam1 Bam3 Bor3 Esf1 Zav3 Overall
First year 1.90% 2.54% 1.33% 9.59% 1.23% 3.36%
Second year 1.18% 1.71% 9.80% 8.64% 11.69% 4.76%
N 3633 4087 1275 2314 1463 12772
p (1st yr-2nd yr) 0.013 0.009 0.000 0.261 0.000 0.000  
Note: second year incidence in Bor3 represents second and third year combined 
 
 
6.2.4  LST as a marker of immunity 
 
LST provides an accessible and simple diagnostic tool and is widely used for 
identifying exposure to leishmanial exposure.  Nevertheless, LST is not an exact 
measure of immune response and can not be considered a highly sensitive or specific 
tool.  The problems with LST include:  
 
 LST could change dramatically over multiple measurements in a period of a few 
weeks and thus could be a source of misclassification.  This was pointed out 
earlier in the discussion of pre-vaccination LST>0 in Bor3 which changed to zero 
by day 80 in about one third of those with pre-vaccination LST>0.  Therefore, at 
any point in time, LST measurement is subject to a certain level of unexplainable 
variability and unreliable sensitivity and specificity.  In fact, it is not known how 
many endemically exposed participants were missed in the screening evaluation in 
Bor3 or in other trials where screening criteria called for LST=0.    
 Additionally, LST could rise in response to different stimuli: inactivated 
leishmanial antigen, immune stimulation by the adjuvant (in this case BCG), 
natural exposure without subsequent disease, or clinical infection.  Therefore, it 
seems impossible, without other forms of testing or more detailed information 
about the circumstances, to judge based on LST results alone whether a person is 
exposed, infected, vaccinated or immune -- i.e., LST is a marker of different 
things. 
 The only instance when LST provided a fairly reliable marker of immunity was in 
the case of pre-vaccination LST in endemic participants in Bor3.  significant 
protection was observed among these endemically exposed participants (who also 
received BCG).  However, even in this instance the subsequent LST measurement 
in some of these participants equalled zero; unexpected in exposed individuals).  
Furthermore, LST is not able to identify all cases of endemic immunity. 
 LST induration is not directly correlated with immunity.  In Bor3, for example, 
pre-vaccination LST protection was associated with more prevalent but on 
average smaller-sized LST reactions compared to Zav3 where less prevalent but 
larger LST responses were not associated with significant protection. 
 
Whether LST can be considered a marker of immunity depends on the type of 
immunogenic stimulation and the immune response behind it.  LST measurement 
without the knowledge of what gave rise to it does not necessarily correlate with 
protection since it could just as easily correlate with unfolding CL.  As indicated 
earlier, compared to BCG alone, the ALM+BCG vaccine leads to much more frequent 
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and persistent DTH response, as measured by LST.  Ultimately, however, as far as 
these trials suggest, the superior immunogenicity by the vaccine and the subsequent 
rise in LST do not directly translate into better protection compared to BCG.  The 
protective outcomes of immunization with BCG or ALM+BCG are indistinguishable 
despite the higher LST associated with the latter.    
 
 
6.3  Summary:  LST, as a measurement of DTH, is believed to have the potential for 
assessing the strength of immune response and immunity in exposed and vaccinated 
individuals and be used as a marker of exposure and immunity. 
 
Individuals living in endemic areas are continuously exposed to the antigen.  This 
leads to a form of immunity detectable by LST.  Generally, it is believed that endemic 
exposure leads to immunity in a certain percentage of residents.  The analysis of two 
trials Bor3 and Zav3 confirms this notion and sheds more light on the LST and 
endemic immunity: 
 
 There are differences in the LST manifestation of immune response and its 
associated immunity between inhabitants of a long-term endemic focus and 
residents of a new endemic area.  LST in the former is more prevalent but also 
more moderate in its average induration.  
 Observations in Bor3 suggest that natural endemic exposure (LST≥5) in a long-
term endemic focus leads to significant immunity once boosted by BCG.   
 In a new endemic area, where residents have experienced exposure for only a few 
years immunity associated with LST≥5 due to natural exposure is not significant 
but is close.  This is probably because too few individuals are exposed with 
LST≥5. Therefore, LST positivity alone (regardless of how and where it was 
developed) can not be considered a sufficient correlate of immunity. 
 Endemic immunity in a long-term endemic focus is clearly age related.  This 
relationship is dictated by the accumulated risk of exposure in older individuals.  
This age relationship is seen even in children under 14.   
 
Several trials have reported protection in the immunologically responsive (LST>5) 
subset of participants; Brazil studies indicated such protection only in the vaccine arm.  
Meta-analysis of all trials comparing the incidence in immunologically responsive 
subset against all other participants did not lead to the same conclusion.    
 
The role of LST was assessed as a tool for evaluating vaccine effectiveness in various 
immunologically responsive groups.  The important finding was that since LST could 
indicate immune response not only to vaccination but also to developing infection (at 
least in CL), it can not be freely used to classify trial participants for efficacy 
assessment in various LST groups.  Classifying based on inappropriate LST 
measurement could lead to spurious conclusions of efficacy.  For example, LST 
measurement one year after vaccination should not be used to evaluate vaccine 
efficacy in LST+ vs LST- groups, since the denominator in the LST+ group is inflated 
by all those with vaccine induced LST+  but the numerator consists only of LST+ due 
to exposure, leading to a smaller calculated incidence in the LST+ group.  A different 
but related situation exists for classifying based on day 80 LST.  By definition, the 
high LST group is where most infected individuals are placed.  As a result, the 
moderate LST response would have relatively few infected cases, not because of 
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vaccine efficacy, but because of the LST classification rule.  It should be pointed out 
that the LST-based incidence comparison in the way that has been done by Antunes, 
Mayrink, Momeni and Khalil (Antunes et al., 1986;Khalil et al., 2000a;Momeni et al., 
1999), is valid. 
 
Continuous exposure has been stated as a requirement for developing immunity.  This 
has been presented as an argument in favour of live vaccines.  In the current study, 
participants with day 80 LST response of 0<LST<5 mm to vaccine or BCG who also 
had a positive LST response to either treatment one year after vaccination were found 
to have half the risk of those who were LST+ one year after injection but had not 
responded on day 80 LST evaluation.  They were more likely than those whose one-
year LST was negative; but this is to be expected since the one year LST directly 
correlates with the disease incidence during the first year of follow up.   In addition, in 
Bor3 and Esf1, trials in L. major foci, protection was observed in first year incidence 
independently of treatment (BCG or vaccine) in those whose day 80 LST had 
converted to LST>5.   The important implications of this analysis are: 
 
 BCG and vaccine are indistinguishable in the protection they may afford.  It could 
be concluded that in fact most of the protection from the vaccine is due to the 
BCG adjuvant.   
 LST is significantly more strongly stimulated by the ALM in the vaccine 
compared to BCG alone.  However, this increased LST is irrelevant to protection. 
 BCG or vaccine injection (if followed by LST>0 response) provides the priming 
that when coupled with natural exposure in endemic foci, could reduce the risk of 
disease by about 50%.  This could be viewed as a practical approach in many 
endemic foci. 
 
Additional support for the role of BCG in protection comes from yet another 
observation: protection against the most immediate infection, regardless of the LST 
value or vaccination status.  Bam1 and Bam2 trials were conducted in ACL foci with 
significantly longer course of infection development compared to ZCL.  Bor3, Esf1 
and Zav3 were conducted in ZCL foci where the infection is manifested and healed 
faster.  In both Bam trials, particularly Bam3 (with 3 study injections) second year 
incidence was significantly lower than the first year.  In ZCL trials (with the exception 
of Esf1 where only one study injection was administered) incidence in the first year 
was lower than the second year.  These observations are consistent with the natural 
development of the local disease.  Furthermore, these findings suggest possibly better 
protection associated with multiple injections. 
 
Overall, the protective effect of BCG in clinical trials has not been the target of 
analysis. Furthermore, as stated by other investigators (Modabber and Reed, 2004) 
both the vaccine and BCG stimulate DTH and it would be difficult to measure the 
effect of one in presence of the other as the two treatments in the same trial.   
  
Another general conclusion is that since LST correlates not only with protection but 
with disease, BCG or antigen exposure, etc, it should be viewed as a marker of 
protection only under circumstances when the nature of the immune stimulus is well 
defined.  As an example, increased LST in response to ALM+BCG does not correlate 
with increased protection.  However, LST>0 on day 80 continued over the course of 
 130
the follow up does correlates with protection.  Similarly, LST≥5 due to endemic 
exposure boosted by BCG leads to protection.   
 
Additionally, as observed in these trials, LST measurement is subject to substantial 
variation over time due to immunological reasons or measurement error and should be 
used with this variability in mind.  Although variation due to measurement error is 
immunologically meaningless, it nonetheless could cause significant variation with 
consequences in the interpretation of the results and their immunological implication. 
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CHAPTER 7 
 
DISCUSSION 
 
 
Leishmaniasis constitutes a major public health problem in many countries in the 
world and is among the most neglected diseases, mainly afflicting the poor.  Diversity 
of causative parasite species, epidemiology, immunology and clinical manifestations 
make leishmaniasis a serious public health challenge in endemic countries.  
Urbanization, deforestation and other changes to the environment, ecological changes 
due to global warming, displacement of human populations as in mass migrations due 
to war and famine could all give rise to leishmaniasis epidemics and the expansion of 
endemic foci.  Large scale control measures are difficult to plan, implement and 
sustain and case identification and therapy are difficult and costly.  First line therapy 
in almost all endemic countries consists of antimonials; relatively old, toxic 
compounds that are now facing resistance by the parasite in many areas.  Prevention 
by an efficacious vaccine would be a desirable control method.  Randomized, 
controlled clinical trials in search of an efficacious prophylactic leishmaniasis vaccine 
have been conducted since the 1970's.   
 
The results of these studies vary from trial to trial, owing to the design and conduct of 
individual trials, causative parasite species, local disease epidemiology and 
immunology, the vaccine candidate, etc.  Problems such as lower-than-expected 
incidence, misclassification of exposed/protected trial volunteers as unexposed and 
occasional problems with the conduct of a trial could all have a negative impact on a 
given trial's statistical power and the ability to detect the difference between trial arms.  
Other problems such as the length of the required follow-up period could also affect 
the final sample size and power.  Combining and comparing the results of various 
clinical trials and simultaneously analysing them could help bypass problems with 
individual trials.   
 
The present study used meta-analysis and other techniques to test the data from 9 
efficacy clinical trials of first generation leishmaniasis candidate vaccines to re-assess 
the vaccine role in protection, immune response (measured by LST) to the vaccine 
and to natural exposure, and the merits of LST as a marker of protection in various 
demographic groups.   
 
The data used in this study represent trials that are different with respect to: 
 
1. Parasite species used in the vaccine (L. amazonensis in South American vaccines, 
L. major in Iran and Sudan trials),  
2. Parasite geographical origin; e.g., local parasites used in Equador vaccine 
3. Antigen preparation (merthiolate vs autoclaved), 
4. Same antigen but different vaccine dose; e.g., single, double or triple injection of 
ALM+BCG in various trials,  
5. Disease causing parasite and its epidemiology; e.g., L. tropica in Bam, L. 
donovani in Sudan, etc.   
6. Study population; e.g., age and gender make up of the sample, endemic/non-
endemic origin of participants. 
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Vaccine efficacy 
 
With the exception of the trial of a locally produced tri-valent vaccine in Ecuador 
(Armijos et al., 1998), leishmaniasis vaccine trials have demonstrated no prophylactic 
efficacy when comparing the vaccine and the control arms as originally randomized.  
However, significantly lower infection rates in the immunologically responsive (LST 
conversion 40-80 days post vaccination) subset of the randomized sample has been 
demonstrated in trials by Mayrink, Momeni and Khalil.  Additionally, Sharifi, et al 
showed a significant difference in protection between vaccine and BCG in boys, 
compared to girls in a trial using a single vaccine dose but not in a trial using triple 
doses of the vaccine. On the therapeutic side, several trials have demonstrated the 
efficacy of killed parasite vaccines.  Based on these observations, it was hypothesized 
that combining the data from various trials could better assess the role of vaccination 
with first generation vaccines on protection due to vaccination. 
 
At the first step, meta-analysis was used to examine the efficacy all trials 
simultaneously, without explicitly considering their differences and heterogeneities.  
Results suggested no overall efficacy.  Meta-analysis was subsequently used to also 
examine the effect of vaccination in more homogeneous subsets of trials.  Grouping 
trials by factors such as the causative parasite (e.g., L. tropica or L. major) or use of 
BCG as adjuvant did not lead to significant efficacy results.  Similarly, combining 
trials with the same antigenic content (L. major or L. amazonensis) did not suggest 
significant protection for either vaccine.   
 
The exception was in the analysis of  L. amazonensis trials including trials done in 
Brazil, Colombia and Ecuador.  In this analysis, exclusion of the Colombia study (the 
largest in South America) led to significant efficacy for the Brazil and Ecuador results 
combined.  This approach can be disputed since it could be viewed as an arbitrary 
exclusion of a trial.  Additionally, excluding the Colombia trial would ignore the 
information from the largest trial in South America.  On the other hand, it could be 
argued that the Colombia trial has an overly dominant effect when combined with 
other, much smaller L. amazonensis vaccine trials in South America, imposing its 
possible trial-specific conditions/limitations on the overall results.  One such trial-
specific condition in Colombia was the possibility of ineffectiveness L. amazonensis 
in creating cross immunity with L. panamensis, a dominant causative species in 
Colombia.  There is some evidence epidemiologically that those infected with L. 
amazonensis are still susceptible to infection by L. panamensis (R. Killick-Kendric, 
personal communication).  Another trial specific factor in Colombia could be the 
inclusion of a number of participants with pre-vaccination LST between 0 and 3.  If 
any protection could arise as a result of the pre-vaccination LST>0, then this would 
have had an undetermined adverse effect on the study power and efficacy assessment.  
The efficacious results of Brazil+Ecuador-Colombia suggests a potential prophylactic 
advantage for the L. amazonensis vaccines and the merits of further investigation of 
vaccines based on this parasite in South America.   
 
Vaccine efficacy was further studied in demographic groups identified by age, gender 
and the origin of trial participants (i.e., originally from endemic or non-endemic areas).  
Isolated indications of efficacy in some demographic groups (such as vaccine efficacy 
in boys in Bam1 or in older than 9 year olds in Bam3) could not be verified in other 
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trials. Furthermore, meta-analysis of homogeneous demographic groups did not reveal 
significant and consistent efficacy in any of the groups.     
 
Despite the observation in some of the individual trials (Brazil, Iran and Sudan) that 
protection associated with vaccination could be observed in the immunologically 
responsive participants (LST>5 in 40-80 days after vaccination), no such protection 
was observed in the current study (based on the meta-analysis of 4 trials in Iran: Bam1, 
Bam2, Bor3, Esf1).  Comparisons were made between the LST≥5 group in the 
vaccine arm and all others combined. 
 
These results are consistent with the fact that the candidate vaccines in these clinical 
trials have been relatively weak immune stimulants.  Moreover, they did not provide 
on-going stimulation, which is believed to be necessary for long term protection.  It 
should be noted that when continued LST reactivity was observed (in individuals 
whose LST was reactive both 80 days after vaccination (LST>0) and one year after 
vaccination (LST≥5)), significant protection was observed.  This protection was 
however not different between the vaccine and the BCG arms.  This strongly points to 
the fact that BCG was not a true placebo or a negative comparator for all the trials 
using BCG as a control, since it seems to induce a cross reactive immune response. 
 
 
Role of demographic characteristics in exposure and incidence  
 
- Background: 
 
It is generally believed that in the context of leishmanial infection, immunity is 
correlated with previous/repeated exposure to the parasite and the resulting clinical or 
sub-clinical infection; a usual event in endemic foci.  This is also seen in other 
diseases such as malaria; where in endemic areas, a form of acquired immunity 
develops with continuous/repeated exposure.  Endemic immunity is a consequence of 
exposure and is promoted by behaviour and characteristics that increase exposure risk. 
Demographic characteristics, primarily age, gender and residence in endemic foci are 
correlated with the chance of exposure and its consequences of infection and/or 
immunity in the following ways: 
 
 In an endemic focus, age is directly correlated with the length of time of 
exposure. Over time, inhabitants of endemic foci have a continuous and 
cumulative chance of exposure, infection and the resulting immunity.  
Therefore, it is expected that immunity be higher and incidence lower in older 
individuals in endemic foci. 
 By contrast, non-endemic, Leishmania-naive populations moving into an 
endemic focus (or if a previously non-endemic area changes its characteristics), 
would be exposed to the parasite for the first time with no age-related 
background immunity.  In this case, age affects incidence only to the extent 
that certain age groups engage in risk behaviour more than others; as an 
example, 8-10 year old children (boys more than girls in some communities) 
may generally play outdoors and be exposed more frequently than adolescents.  
This exposure is not due to age (=length of exposure time from birth) but 
rather due to the risk behaviour associated with the particular age bracket.  
Therefore, an age-related continuous trend in incidence and immunity is not 
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necessarily expected (although after a number of years of exposure to endemic 
conditions, age-related immunity may settle in).  
 Endemic and non-endemic populations may be genetically different in their 
response to the antigen.    
 Gender, similarly to age, if associated with behaviour that would augment the 
risk of exposure and/or infection, could affect immunity and incidence. 
Playing and working outdoors, sleeping habits, coverage of the body and so on, 
are all age/gender related behaviour and can affect risk in an endemic area.   
 Genetic differences between males and females may potentially influence their 
response to the leishmanial antigen.   
 
Consequently, it is important to investigate exposure, incidence and the effect of 
intervention (vaccine or BCG) in relation to demographics.  Clinical trials in Iran 
(Bam1, Bam3, Bor3, Esf1, Zav3) provide participant level data and a good mix of age, 
gender and endemic origin for the demographic analysis of efficacy and incidence.  
Additionally, they all evaluated the same vaccine (ALM+BCG) compared to BCG as 
the control treatment.  Moreover, two trials (Bor3 and Zav3) included participants 
with LST>0 at screening, providing the opportunity to investigate the effect of 
previous natural exposure on incidence.  Despite consistencies, Iran trials are different 
with respect to the following important factors.  These differences were addressed and 
accounted for in the analysis and helped identify the role of some of these factors on 
infection and immunity: 
 
 Causative parasite and its related epidemiology/pathology/immunology (L. tropica 
in Bam trials vs L. major in others).   
 Participants age limitation (6-13 or 15 in Bam1, Bam3 and Bor3, 5-59 or 72 in 
Esf1 and Zav3). 
 Endemic origin of participants (Endemic in Bam1, Bam3 and Bor3, non-endemic 
in Esf1 and Zav3). 
 Additionally, unspecified/unmeasured variation in incidence in trials in the same 
region with similar disease epidemiology or in different years of follow-up in the 
same trial could potentially confound the effect of study treatment (effect of 
multiple injection vs single injection in different trials, for example), endemic 
origin, etc. 
 
 
- Incidence and demographics in Iran trials: 
 
Despite isolated findings in some of the trials (such as age related incidence in Esf1), 
separate and grouped analyses (meta-analysis) of Iran trials did not reveal consistent 
and significant differences in incidence (combined or separately in control and 
vaccine arms) in different age or gender groups.  However, they did indicate 
substantial differences in incidence (regardless of study treatment) between trials in 
endemic vs non-endemic populations who had moved to an endemic focus, or 
residents in new epidemics.   
 
A positive, consistent and statistically significant age-based trend in incidence was not 
observed in all trials.  This is contrary to the general belief that age affects immunity 
and, therefore, incidence.  However, this absence should not be interpreted as no 
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relationship between incidence and age.  Two enrolment criteria in these trials worked 
against detecting the effect of age on incidence: 
 
 Exclusion of LST>0 at screening:  previous exposure and resulting endemic 
immunity is correlated with demographics (age and gender) and is manifested by 
LST>0 at screening.  Eliminating LST>0 volunteers would eliminate many 
instances of endemic immunity and would minimize/remove from the trial sample 
the effect of age and gender on exposure, endemic immunity and consequently 
incidence (in participants of endemic background).   By design, LST>0 volunteers 
were not enrolled in Bam1, Bam3 and Esf1 but they were enrolled in Bor3 and 
Zav3, once confidence was gained of the safety of vaccine in LST+ individuals.   
 Exclusion of age>15 at screening: In parallel to the LST>0 exclusion criterion 
discussed above, age limitation of 13 or 15 (Bam1, Bam3, Bor3) could take away 
from the effect of age on incidence since older individuals (excluded at screening) 
would be the ones with longer exposure and higher chance of endemic immunity.  
Although infection and immunity in endemic foci starts early in life, it is likely 
that the prevalence of immunity (and paucity of infection) increases with age. 
 
In trials with participants from endemic origin (Bam1, Bam3, Bor3), volunteers were 
recruited according to one or both of the above screening criteria which could 
minimize or remove the effect of age from the data.  Consequently, the absence of a 
strong age/incidence relationship in these data does not rule out the existence of such 
a relationship.   
 
 
Similarly, gender was not observed to be correlated with incidence. 
  
In contrast to age and gender, participants’ endemic origin is a significant determinant 
of observed incidence in each trial.  The average annual incidence during study 
follow-up was 1.55%, 2.15% and 4.05% in Bam1, Bam3 and Bor3, trials with 
endemic participants, while it was 9.1% and 6.4% in Esf1 and Zav3, the trials 
consisting mainly of Leishmania-naive participants of non-endemic background.  The 
lower rate in Bam trials was partially explained by the epidemiology of the local ACL 
(annual incidence of about 2%).  However Bor3, Esf1 and Zav3 trials were conducted 
in ZCL foci in the Esfahan province.  The significantly lower incidence in Bor3 
compared to Esf1 and Zav3 is attributable to endemic exposure/immunity in the 
former.  This is discussed later in more detail.  Although a random surge in incidence 
during the follow-up in the Esf1 and Zav3 trial sites could not be ruled out as a cause 
of the higher incidence in these trials, it seems to be unlikely in both trial sites.   
Another important distinction between endemic and non-endemic populations when 
LST=0 is selected, is the selection of genetically “non-responsive” individuals in the 
endemic population who may have been exposed but did not respond to LST at 
screening or later.   
 
Effect of natural exposure and vaccine on DTH (measured by LST) 
 
A reactive leishmanin skin test (LST>0) indicates cellular response due to exposure to 
the leishmanial antigen naturally or via immunization. It could also indicate exposure 
to other immune stimulators with cross reactive antigens, such as BCG.   
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1) LST due to natural exposure:  
 
Naturally developed immune response (pre-vaccination LST>0) was measured only in 
Bor3 and Zav3 and was found to be less prevalent but with larger average induration 
in the latter.  This may be linked to the non-endemic origin of the participants in Zav3.  
By contrast, in Bor3 naturally induced LST was observed more frequently and with 
more moderate induration which may demonstrate the pattern of LST response under 
endemic circumstances.  
 
LST due to natural exposure was found to be, as expected, age dependent, both in its 
prevalence and size of induration.  This relationship was clearly observed in Bor3 
despite participants' age limitation of 13 years.  In Zav3, where the non-endemic 
participants as old as 59 years were enrolled, the prevalence and size of pre-
vaccination LST>0 showed age dependence but not to the same degree as in Bor3.  
These findings indicate a possible correlation between age, LST pattern and endemic 
immunity in Bor3.  
 
Pre-vaccination LST is more frequent with more moderate induration in females in 
Bor3; a pattern that also differentiates Bor3 from Zav3.   In contrast to above, 
however, there is no difference in protection associated with pre-vaccination LST 
between males and females. 
 
2) LST due to vaccination: 
 
Post-vaccination LST was measured in most trials in 80 days and then one year after 
vaccination.  As expected, ALM+BCG vaccine is a significantly stronger immune 
response stimulator than BCG alone, as demonstrated by day 80 and then one-year 
LST evaluation.  Day 80 and one-year LST results do not differ significantly in 
endemic participants, while an increase from day 80 to one-year LST, possibly 
induced by natural exposure, is observed in non-endemic, leishmania-naive 
participants.   
 
The fact that the proportion of LST>0 among endemic participants stayed relatively 
constant from day 80 to one year after vaccination may indicate a point of equilibrium 
(or maximum) for LST conversion in an endemic focus that is reached after 
vaccination and does not reach 100% even after further natural exposure during the 
follow up.  On average, the maximum prevalence of LST>0 observed as a result of 
vaccination+natural exposure is between 70% to 80%.  The difference between this 
value and 100% is primarily explained by those who are non-responsive to 
leishmanial antigen.  
 
 
LST and Protection 
 
1) Pre-vaccination LST and endemic immunity: 
 
It is generally believed that previous clinical or sub-clinical infection, common in 
endemic foci, if associated with positive LST (LST≥5) could lead to some immunity 
(endemic immunity).  In other words, LST≥5, when not indicative of a developing 
infection, could be associated with protection. Exclusion of LST reactive volunteers 
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from leishmaniasis vaccine clinical trials has the desirable consequence, among others, 
of allowing the assessment of the vaccine effect in Leishmania-naive individuals 
without confounding by the potentially protective effect of previous exposure.  
However, this limitation disallows estimating the vaccine effectiveness in those with 
previous exposure (who constitute a large part of the populations in endemic areas).   
 
Bor3 and Zav3 trials allowed enrolment of volunteers regardless of their LST values; 
thus allowing the sample to include a more representative cross section of residents 
with respect to exposure.  This enabled assessing disease prevalence associated with 
different values of screening LST.   
 
In Bor3, as expected, significant protection was seen among those with LST≥5 in both 
study arms; i.e., ALM+BCG and BCG alone.  BCG, the agent common to both study 
arms, was possibly also a factor in this protection.  The conclusion from this 
observation is that naturally acquired LST≥5 (boosted by BCG) could produce 
sizeable protection.  This finding may have practical ramifications for immunization 
in endemic foci where LST>0 is prevalent and BCG vaccination against TB a 
common practice.   
 
In Zav3, the reduction in incidence in pre-vaccination LST≥5 participants was not 
statistically significant (borderline) possibly because the prevalence of LST≥5 was 
low.  The low prevalence of LST≥5 and the average size of pre-vaccination LST in 
Zav3 was different from Bor3 probably because Zav3 is a newly endemic area.  
Nevertheless, lack of significant protection in LST positive individuals in Zav3 is 
contrary to the dogma that maintains LST≥5 is associated with protection.  Comparing 
these results suggests that natural exposure and subsequent LST reactivity could lead 
to protection after boosting with BCG with somewhat more likelihood if it occurs 
under endemic conditions, over a long time and probably after repeated exposure.   
 
In addition to the differences in the prevalence of immunity due to natural exposure, 
there are differences in the LST response between individuals in a long-term endemic 
focus and residents of a new endemic area, as discussed earlier.  LST in the former is 
more prevalent but less severe with more moderate induration. The reverse is true of 
new endemic area residents.  Contrary to expectation and the dogma, it is the more 
moderate LST reactivity in endemic participants which is associated with significant 
immunity once boosted by BCG. 
 
Endemic immunity in a long-term endemic focus is age related.  This relationship is 
dictated by the accumulated risk of exposure in older individuals.  This age 
relationship is seen in Bor3 where LST positivity and incidence seem to correlate 
negatively in all age groups. 
 
In summary, protective exposure seems to be facilitated by endemic conditions and 
time and it is associated with a certain age and LST profile distinct from that seen in 
newly exposed non-endemic populations. 
 
 
 
 
2) Post vaccination LST and protection: 
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LST measurement after vaccination has been used in vaccine clinical trials as an 
indicator of immunological response and potentially a correlate of immunity. 
 
Several trials have reported protection in the immunologically responsive (i.e., LST 
converted) subset of participants in the vaccine arm.  However, meta-analysis of all 
trials (restricted to LST=0 at screening) comparing the incidence in immunoligcally 
responsive subset against all other participants did not lead to the same conclusion.     
 
In the present study, to better investigate the possible correlation between LST 
measurement and protection due to vaccination, the association of post-vaccination 
LST response with subsequent protection was assessed: for example comparing 
protection in vaccine and control arms in those with one-year LST≥5 or comparing 
incidence between LST+ and LST- in vaccine arm.  Observations in the current study 
suggest that since LST could indicate immune response not only to vaccination but 
also to developing infection (at least in case of CL), one-year LST can not be freely 
used for this sort of comparison.  This sort of classification and comparison could lead 
to spurious conclusion of efficacy.  For example, comparing vaccine and control arms 
on protection observed in those with one year LST≥5, since in the vaccine arm the 
denominator in the LST≥5 group is inflated due to vaccination (but mainly due to 
vaccination and not necessarily due to exposure), leading to a smaller calculated 
incidence in the LST+ group.  A different but related situation arises when classifying 
based on day 80 LST.  The high LST group is where most infected participants are 
placed.  As a result, the moderate LST response group would have relatively few 
infected cases, not because of vaccine efficacy, but because of the LST classification 
rule.  It should be pointed out that the LST-based incidence comparison in the way 
that has been done by Antunes, Mayrink, Momeni and Khalil, is valid but could not 
be observed in the combined data of all 10 trials used in the analysis. 
 
Continuous exposure has been stated as a requirement for developing immunity.  This 
has been presented as an argument in favour of live vaccines.  In the current study, 
participants with moderate day 80 LST response to vaccine or BCG who also had a 
positive LST measurement one year after vaccination were found to have half the risk 
of those who were LST+ one year after injection but had not responded on day 80 
LST evaluation.  They had a higher risk of infection compared to those whose one-
year LST was negative; but this is to be expected since the one year LST directly 
correlates with the disease incidence during the first year of follow up.    
 
The important implications of this analysis are: 
 
 LST is significantly more strongly stimulated by the ALM in the vaccine 
compared to BCG alone.  However, this increased LST is irrelevant to protection. 
 BCG and vaccine are associated with similar reduction in infection prevalence in 
endemic participants who were naturally exposed prior to the study. In this case 
BCG seems to provide an effective booster after natural priming.  
 On the other hand, injection of BCG or vaccine (if inducing LST>0 response) 
provides the priming that when coupled with natural exposure in endemic foci, 
could reduce the risk of disease by about 50%.  This could be viewed as a 
practical approach in many endemic foci. 
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LST as a marker of immunity: 
 
LST is an inexact indicator of immune response.  Although it can provide information 
about immune stimulation, it has shortcomings as a reliable marker of immunity or 
exposure: 
 
 LST magnitude is subject to great variation that is not always explainable.  For 
that reason, it is generally accepted that LST is not an accurate quantitative test.  
For example, LST>0 mm in about 38% of exposed endemic individuals at trial 
screening in Bor3 was found to equal zero just a few weeks later (at day 80 
measurement).  Such a change from non-zero to zero is important since it points at 
a fundamental difference in immune response and could be a source of 
misclassification of exposed and unexposed individuals (for example allowing 
exposed, possibly immune individuals into trials with LST=0 screening criteria 
thus leading to bias in effect estimation). Whether this sort of change reflects 
measurement error or actual immunological variability may not be so important 
since the final result is similar: confusion about the immunological status of the 
person under evaluation.   
 In addition, LST reflects immune system stimulation without providing any 
information about the stimulus.  Any of a number of stimuli could cause LST 
reaction including injection with inactivated leishmanial antigen, Th1 immune 
response stimulants such as BCG and previous or current infection.    
 As indicated earlier, compared to BCG alone, the ALM+BCG vaccine leads to 
much more frequent and persistent DTH response, as measured by LST.  
Ultimately, however, as far as the results of the current study suggest, the superior 
immunogenicity (LST response) of the vaccine does not translate into superior 
protection compared to BCG in the converted population.  The protective 
outcomes of immunization with BCG or ALM+BCG are indistinguishable.   
 
Although an inexact indicator, LST can still provide the basic information about 
immune system stimulation in most individuals.   However, LST measurement 
without the knowledge of the stimuli and conditions that gave rise to it is insufficient 
information and can not be viewed as a reliable marker of immunity.  For example, 
LST reading of individuals in an endemic focus who have received a dose of BCG 
may be considered a partial correlate of immunity.  Conversely, LST reaction in 
Leishmania-naive individuals who received a dose of inactivated antigen would not be 
a correlate of immunity  In summary, LST could be used as a marker of immunity if it 
measures the relevant immune response after appropriate stimulation.  As such it is a 
better marker for inhabitants of endemic foci.  
 
 
Protection due to BCG: 
 
In the clinical trials used in this study, BCG was used as the control treatment to 
enable blinding and presumably also to provide an estimate of how much 
immunogenicity and protection in the ALM+BCG arm was attributable to the BCG 
adjuvant.  However, as mentioned above, BCG and ALM+BCG were equally 
observed to be associated with significantly reduced incidence in conjunction with 
previous exposure (positive LST) in a manner similar to prime boost vaccination 
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(priming with natural exposure and boosting with BCG).  This highlights the 
significant contribution of BCG (the agent common to both treatments), either alone 
or as adjuvant added to ALM, in conferring protection.  This is despite the fact that 
BCG alone led to generally much more moderate LST reaction compared to 
ALM+BCG in all trials.  
 
Protection was also observed in individuals with LST>0 on day 80 and LST≥5 one 
year after vaccination.   This protection was observed equally in the BCG and the 
vaccine arm.  This is another indication of the role of BCG in protection since BCG 
was the common agent in both study treatments.  
 
Also in Esf1 and Bor3 trials, protection associated with positive day 80 LST was 
observed in both BCG and ALM+BCG arms.  
 
Additional support for the significant role of BCG in protection comes from another 
observation: protection against the most immediate risk of infection (after study 
injection), in both study arms combined.  Due to the clinical development of the 
disease, in both Bam trials conducted in a focus of L. tropica, first year exposure 
should predominantly lead to clinical manifestation in the second year. Contrary to 
this expectation, in these trials, particularly Bam3 (with 3 study injections) second 
year incidence was significantly lower than the first year.  By contrast, in L. major 
trials, first year exposure should normally show clinical signs in the same year.  Again, 
contrary to expectation, in L. major trials incidence in the first year was lower than the 
second year (with the exception of Esf1 where only one study injection was 
administered).  These observations suggest that exposures in the same year as 
vaccination lead to fewer clinical infections compared to exposures in the year after or 
before vaccination.  As stated, these results are the same for the vaccine and the BCG 
arms and, therefore, point at BCG as the possible explanation for incidence reduction.    
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CHAPTER 8 
 
CONCLUSIONS AND RECOMMENDATION FOR FURTHER RESEARCH 
 
 
8.1 Conclusions: 
 
With respect to the stated objectives of this research the following conclusions can be 
made: 
 
Objective 1. Efficacy of first generation vaccines and/or BCG: 
 
 Clinical trials are subject to possible shortcomings and problems that could 
occasionally limit their ability to show effects that are in fact present. Analysing 
the available body of efficacy clinical trial data for all first generation 
leishmaniasis vaccines combined was hypothesized to bypass trial-specific 
limitations and bring about the advantages of a larger sample size in testing the 
efficacy of these vaccines as well as searching for clues to identify important 
factors in developing  new vaccines.  In the present study, the data from almost all 
leishmaniasis vaccine efficacy trials conducted in various countries were analysed 
via meta-analysis.  Results did not support the hypothesis of efficacy when all 
vaccine trials were considered together without explicitly accounting for their 
differences (differences based on antigenic composition, use of adjuvant, 
causative parasite).   
 Similarly, even after accounting for such differences by combining groups of 
more homogeneous vaccines together, efficacy could not be concluded.  For 
example, combining the data from clinical trials of vaccines made with the same 
antigen (e.g., L. major), same adjuvant (i.e., BCG), or same causative parasite in 
the trial site did not suggest efficacy for any of these groups.   
 The exception was in the analysis of L. amazonensis vaccines conducted in Brazil, 
Colombia and Ecuador.  Although combining all these trials did not demonstrate 
efficacy, further analysis indicated a large heterogeneity between the trial 
conducted in Colombia and others.  Excluding Colombia data from this group 
suggested overall efficacy for all other L. amazonensis vaccines combined.   This 
could reflect the ineffectiveness of vaccination with L. amazonensis against L. 
panamensis infection dominant in Colombia. Since the Colombia trial had several 
times the sample size of any of the other trials, when combining all data this trial 
could have the effect of drawing all results in its own direction, not allowing the 
results of other trials to significantly contribute to the overall results.  It may be 
warranted, therefore, to further investigate the effect of vaccines based on L. 
amazonensis against L. braziliensis or L. amazonensis but perhaps not L. 
panamensis.  
 When considering the results of L. major vaccine (ALM+BCG) trials in different 
demographic groups formed based on age, gender and endemic origin of 
participants, again, no efficacy was observed for the vaccine.  
 Furthermore, the observation in some clinical trials that the immunologically 
responsive subset of the vaccine arm participants (identified by post vaccination 
LST measurement ≥ 5) experience significantly reduced incidence compared to 
other trial participants could not be confirmed when combining results of Iran 
trials (for which individual level data were available).   
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 It was, however, observed that immunological reactivity (LST>0) 80 days after 
vaccination was associated with reduced incidence if LST measurement one year 
after study injection were LST≥5.  This observation, was independent of the study 
treatment (i.e., no difference observed between the ALM+BCG and BCG alone 
arms). 
 In addition, a level of protection associated with study participation (again, 
regardless of treatment) was observed in ALM+BCG trials in all participants of 
endemic origin with previous natural exposure (screening LST≥5).   
 The two findings above indicate no difference between BCG and ALM+BCG in 
their association with reduced incidence.  Since BCG was used in both trial arms, 
these findings may highlight the role of BCG, either alone or as adjuvant added to 
ALM, in conferring protection under endemic conditions.  
 
Objective 2. Immunological response to natural exposure or immunization, measured 
by LST:   
 
 By design, two of the trials used in this analysis enrolled volunteers with LST>0 
at screening.  Age dependence of exposure was seen in these trials although its 
significance was borderline.  No significant gender dependence, however, was 
observed.   
 Another characteristic affecting exposure is the endemicity of participants' 
geographical area of origin.  Autochthonous inhabitants of an endemic focus were 
observed to have a different LST profile (more frequent with smaller induration) 
from residents of a newly endemic focus.  
 Endemically exposed participants develop immunity against the disease following 
vaccination (either BCG alone or ALM-BCG), thus during the follow up, they 
develop clinical infection with lower frequency.  As a result, studies done with 
participants from non-endemic origin should theoretically have higher overall 
incidence than those with participants from endemic area.  This was verified in the 
present analysis. Comparison of infection rates in studies with endemic and 
non/endemic participants suggested that under endemic conditions, trials 
conducted with non-endemic participants show higher rates of infection than those 
with endemic participants.  
 
Objective 3:  LST as a marker of immunity 
 
 LST has a number of shortcomings as a reliable marker of immunity including:  
 
 In general, LST readings are consistent with theoretical expectation.  For 
example, compared to BCG recipients, vaccine recipients in all trials have 
significantly larger LST induration after vaccination; even after one year.   
 Ultimately, however, as far as the results of the current study suggest, this 
superior immunogenicity does not correlate with better protection than BCG 
alone 
 LST is subject to not only significant variability from measurement to 
measurement, but also deviation from theoretical expectation.  For example, in 
Borkhar, 38% of participants with LST>0 at screening, had LST=0 eighty 
days after vaccination.  This could constitute a source of misclassification of 
previous exposure.   
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 In addition, LST reflects immune system stimulation without providing any 
information about the stimulus (which could be inactivated leishmanial 
antigen, Th1 immune response stimulants such as BCG and previous or 
current infection).    
 Compared to BCG alone, the ALM+BCG vaccine leads to significantly more 
frequent and persistent DTH response, as measured by LST.  .   
 
 Despite its variability, LST can still be considered a correlate of immunity if the 
stimuli and conditions that gave rise to it are known.  For example, positive LST 
response (LST≥5) in a currently healthy individual from an endemic focus could 
indicate potential immunity, particularly if augmented with BCG injection.  On 
the contrary, high LST readings due to vaccine are not strongly correlated with 
reduced infection rates.  Therefore, if LST is supplemented with adequate 
information, it can be viewed as a correlate of immunity or infection. 
 This study did not reveal a difference in the ability of LST as a marker of 
immunity for different age and gender groups.  
 
 
8.2  Recommendations for further research: 
 
Based on the conclusions of this study, further investigation in the following areas are 
recommended: 
. 
1. In light of the significant protection observed after BCG or ALM+BCG? 
injection in LST positive individuals in Borkhar, Iran, long term effect of BCG 
vaccination of LST positives (LST≥5) vs unexposed individuals or those with 
LST<5 in endemic foci should be investigated further in a randomized 
controlled clinical trial setting.  This information could help to reliably 
evaluate the effect of BCG in immunization in endemic foci.  
2. Similarly, since a level of protection regardless of study treatment was 
observed among individuals with LST reactivity 80 days and one year after 
study injection, this phenomenon should be further investigated in clinical trial 
setting to better understand the effect of continued LST reactivity and the role 
of natural exposure and BCG injection as a booster or primer.  
3. Further investigation is required for better understanding the reasons for the 
differences between endemic and non-endemic residents in their LST response 
patterns to natural exposure. These patterns should also be more closely 
investigated for better understanding of the immunological mechanisms that 
drive LST response and immunity.   
4. Studying genetic factors in non-response to leishmanial antigens could shed 
further light on endemic immunity. 
5. Evaluation of sensitivity and specificity of LST in detecting natural exposure 
and immunity in endemic areas should be further studied.  
6. In light of the protection observed in some South American studies, further 
evaluation of L. amazonensis is recommended.  
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Abstract 
 
First generation candidate vaccines against leishmaniasis, prepared using inactivated 
whole parasites as their main ingredient, were considered as promising because of 
their relative ease of production and low cost.  These vaccines have been the subject 
of many investigations over several decades and are the only leishmaniasis vaccine 
candidates which have undergone phase 3 clinical trial evaluation. Although the 
studies demonstrated the safety of the vaccines and several studies showed reasonable 
immunogenicity and some indication of protection, an efficacious prophylactic 
vaccine is yet to be identified. Despite this overall failure, these trials contributed 
significantly to increasing knowledge on human leishmaniasis immunology.  To 
provide a collective view, this review discusses the methods and findings of field 
efficacy trials of first generation leishmaniasis vaccine clinical trials conducted in the 
Old and New Worlds.   
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1  Introduction 
 
Leishmaniasis is a vector-borne disease caused by several species of protozoan 
parasites of the genus Leishmania.  Leishmanial infections have diverse clinical 
manifestations, including cutaneous (CL), mucocutaneous (MCL), diffuse cutaneous 
(DCL), visceral (VL or kala-azar), post kala-azar dermal leishmaniasis (PKDL) and 
recidivans (LR)  [1]. Leishmaniasis is a public health problem in at least 88 countries, 
including some of the poorest in the world [2, 3].  The estimated global prevalence of 
all forms of the disease is 12 million, with 1.5 to 2 million added cases annually of CL 
(with average duration of few months to one year) and 500,000 of VL (with average 
duration of several months to more than one year) [3, 4, 4]. The geographical 
distributions of the diseases are concentrated geographically. 90% of visceral 
leishmaniasis cases occur in Bangladesh, Brazil, India, Nepal and Sudan; 90% of 
mucocutaneous leishmaniasis cases occurs in Bolivia, Brazil and Peru; and 90% of 
cutaneous leishmaniasis cases occur in Afghanistan, Brazil, Iran, Peru, Saudi Arabia 
and Syria [3].  
 
Existing methods of vector or reservoir control cannot be used effectively by poor 
countries due to their high cost and problems with implementation and sustainability 
[5-7]. In addition, toxicity of pentavalent antimonials, the current treatments of choice 
in developing countries, and increasing parasite resistance [8-13] underline the need 
for an effective preventive vaccine [5, 14, 15] that not only would protect against 
leishmaniasis but could also interrupt the transmission cycle.  
 
At the present time the only known and effective immunizing intervention for 
preventing cutaneous leishmaniasis (caused by L. major) in humans is 
Leishmanization (LZ). It is well known that the first natural infection with cutaneous 
leishmaniasis due to L .major is highly protective against subsequent infections. LZ is 
the practice of inducing the first infection by injecting live virulent parasites in an 
aesthetically acceptable site of the body in healthy individuals.  It has been used in 
high incidence endemic foci to protect individuals against natural infection in an 
exposed body site (the face for example) and to establish infection at a scheduled time 
[16].  Leishmanization has been practiced in several countries, including Uzbekistan, 
the only country where the measure is in current use [17].  The first LZ campaign in 
Uzbekistan began in 1967 and was modelled after a similar campaign in 
Turkmenistan. The standard preparation, used in Uzbekistan for prophylaxis, consists 
of a mixture of live and killed promastigotes on the basis that such a mixture will be 
less virulent [6].  
 
LZ was used in Iran (1980's) and Israel (1970's) as a prophylaxis against leishmaniasis, 
but is not currently practiced in either country [17, 18]. In Israel, the LZ program was 
discontinued because of loss of infectivity of the parasites used for LZ due to repeated 
sub-culturing, as well as immunosuppression that resulted in reduced responsiveness 
to diphtheria, pertussis and tetanus vaccine in children following LZ [17, 18].  In Iran, 
in the preliminary experiment with LZ, 80% protection was achieved [19, 20].  After 
this initial trial, nearly 2 million individuals, mainly army personnel, were 
leishmanized who were at risk of leishmaniasis after moving into endemic areas in the 
war zone as a result of the Iran-Iraq war.  Despite its effectiveness, the LZ campaign 
in Iran was stopped in 1986 due to a small percentage of cases with complications 
such as protracted and non-healing lesions [20].   
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The refinement of  methods of leishmanization using live, attenuated and/or drug-
sensitive parasites (through culture, chemical, radiation or genetic manipulation) 
could lead to a significant improvement in LZ and enable its standardization, either as 
a vaccine, if sufficiently attenuated, or as a challenge system to evaluate other 
leishmaniasis vaccines in clinical trials.  However, there may be concerns about the 
potential for attenuated parasites to revert to their original pathogenic state, and about 
the secondary transmission of parasites from leishmanized individuals, particularly in 
areas where the strains used for leishmanizing are not endemic [21]. Delivery of live 
Leishmania to the field in many endemic foci is a challenge, since Leishmania 
undergo metacyclogenic transformation in culture and must be conserved in a deep-
frozen state. 
 
First generation candidate vaccines against leishmaniasis consist of vaccines made 
with whole killed parasites.  These vaccines are conceptually simple and could be 
relatively easy to produce in developing countries at low cost.   This was one of the 
advantages that made them attractive candidates for vaccine development. However, 
the difficulty of standardization of vaccines derived from cultured parasites is a 
potential obstacle in the way of their registration.  In recent years most clinical trials 
of first generation vaccines in humans have evaluated the effect of three types of 
vaccines: a L. amazonensis-based vaccine derived from an earlier 5-valent vaccine 
(BIOBRAS, Brazil), a L. mexicana-based product (Instituto Biomedicina, Venezuela) 
and a L. major-based preparation (Razi Vaccine and Serum Institute, Iran)[22, 23].  In 
addition, a trivalent preparation consisting of L. brazilensis, L. guyanensis and L. 
amazonensis antigens was evaluated in Ecuador [24].  Bacille Calmette-Guérin (BCG) 
was used as the adjuvant in some versions of the Venezuelan, Ecuadorian and Iranian 
candidate vaccines in an attempt to improve the vaccine's ability to induce cell 
mediated response. 
 
We have reviewed data on all published Old World and New World field efficacy 
clinical trials of first generation leishmaniasis vaccines conducted between 1981 and 
2007. In addition we have included data from three unpublished studies in Iran. 
 
 
2  Efficacy trials of first generation vaccines 
 
2.1  New World 
 
First generation vaccines have been the subject of experiments in Latin America since 
the early part of the 20th century.  The two main vaccines evaluated in the New World 
were the pentavalent preparation by Mayrink and colleagues in Brazil, known as 
Leishvacin®, and the simplified monovalent L. amazonensis vaccine; neither of 
which included adjuvant.  Originally, merthiolate was used for parasite inactivation 
and preservation, but the autoclaved preparation of the same vaccine was shown to 
produce similar immunogenicity results [22, 25].  An autoclaved L. mexicana vaccine 
with BCG adjuvant was produced in Venezuela and used for immunotherapy of 
patients with cutaneous leishmaniasis.  Prophylactic studies of this vaccine were 
inconclusive because of less-than-expected incidence of leishmaniasis in the trial 
areas [22].  Additionally, a trivalent preparation consisting of L. brazilensis, L. 
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guyanensis and L. amazonensis antigens was evaluated in Ecuador [24].  A brief 
description of these trials follows: 
 
Brazil 
 
Brazilian investigators conducted trials of different preparations of killed parasites as 
early as 1939 by Sales-Gomes followed by Pessoa and colleagues in 1940's evaluated 
3 doses of a polyvalent vaccine of 18 strains of Leishmania in a trial involving 1127 
healthy individuals (527 vaccine and 600 control) and observed 80% efficacy [26-29].. 
 
These efforts were followed in the 1970's by Mayrink and colleagues who developed 
a pentavalent vaccine which, after two intramuscular injections (one week apart), was 
able to convert the leishmanin skin test (LST , also known as Montenegro skin test) 
results in 78.4% of vaccinated volunteers within three months, with no major side 
effects. Unfortunately, the efficacy of the vaccine could not be assessed in this trial 
since no cases occurred in the study area after vaccination, in either the vaccine or 
placebo group [26, 30, 31].  
 
Suggestion of protection against leishmaniasis associated with vaccination was given 
by another trial of two injections of the same vaccine [32] involving 216 volunteers in 
the vaccine arm and 266 in the control arm.  In the period two years after vaccination 
statistically significant differences in leishmaniasis incidence  were observed between 
the vaccine and control arms (1.7% vs 8.9%, respectively, P < 0.01).  However, the 
study was not a randomised double blind controlled trial, which makes the results 
difficult to interpret [26].    
  
In 1981 and 1983 two randomized, double-blind, controlled trials of the pentavalent 
vaccine, using different doses, were conducted by Mayrink and colleagues in 
Brazilian army personnel. As in previous trials, two intramuscular injections, one 
week apart were administered [33].  In the 1981 trial, over 1300 volunteers were 
randomized to the vaccine and placebo arms. LST conversion among those vaccinated 
was 35%, considerably lower than in previous trials.  The authors noted this might 
have been due to the immunosuppression effect of the routine army yellow fever 
vaccination which had been given about 60 days prior to the study injection.  The trial 
results did not show a significant difference between the vaccine and the placebo arms.  
In the 1983 trial, over 1200 army recruits were randomly assigned to the vaccine and 
placebo arms.  The LST conversion rate among those vaccinated was 68% (more than 
that in the1981 trial, possibly because the study started 120 days after routine yellow 
fever vaccination). Again, there was not a significant difference in the incidence of 
leishmaniasis among those in the two arms of the trial. Of interest in the 1981 trial 
was the finding that one group of vaccinees (who spent a longer time in the jungle and 
experienced greater incidence of the disease) whose LST converted after vaccination 
had a lower disease incidence compared to non-LST converted vaccinees or those 
who received placebo.  
 
Despite promising results, due to the problems in its production and standardization, 
the 5-strain Leishvacin® presented difficulties in preparation and registration.  
Additionally, subsequent studies demonstrated the immunogenicity of a single-strain 
L. amazonensis vaccine.  To address the development of a vaccine against CL, two 
Vaccine Advisory Groups, with the participation of representatives of national and 
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international organizations interested in developing an anti-leishmaniasis vaccine, 
were organized by World Health Organization (WHO)/ Special Programme 
for Research and Training in Tropical Diseases (TDR)  in Washington DC, USA and 
Belo Horizonte, MG, Brazil in February and September 1991. The groups advised that 
studies with the vaccine should continue, using only one strain, the L. amazonensis 
(strain IFLA/BR/67/PH8). This strain was chosen because its antigens induced high 
stimulation indexes for lymphocytes from vaccinated volunteers, it was easier to grow 
in non-cellular media, it was internationally known and it was taxonomically well 
defined [26, 34]. 
 
It was later observed that 2 doses of L. amazonensis promastigotes killed by 
merthiolate and sonication (each dose containing 100mg of Leishmania protein 
vaccine plus 250mg of Corynebacterium parvum) have similar immunogenicity in 
mice as the 5-strain Leishvacin [34].  Immunogenicity of 2 and 3 doses of various 
concentrations of the monovalent vaccine in human volunteers was confirmed in a 
separate study [35].  
 
Colombia 
 
The immunogenicity and safety of three doses of the monovalent L. amazonensis 
vaccine was confirmed in Colombia in randomized, double-blind clinical trials. A 
phase 2 trial of vaccination in 296 army volunteers was conducted  with intradermal 
vaccination and BCG as adjuvant and also intramuscularly without BCG.  Three doses 
of vaccine with BCG were planned for each vaccinated participant but it was only 
administered twice due to BCG-induced lesions that were unacceptable to volunteers.  
Intramuscular administration proved to be safe and immunogenic and as a result a 
phase 3 trial was conducted with two injections of the vaccine without BCG [36]. The 
trial was conducted in army volunteers whose skin-test response to LST was <3 mm. 
Most infections in the trial area were due to L. panamensis.   Participants in the 
vaccine arm (n = 1295) and the placebo arm (n = 1302) were followed up for 12 
months. The vaccine was found to be safe and immunogenic but did not provide 
protection [37].  Participants in this study were not LST tested until the end of the trial 
and it is thus not possible to compare incidence rates in those who did or did not skin 
test convert  to LST after vaccination.  
 
Ecuador 
 
The only leishmaniasis vaccine clinical trial in which efficacy was observed in the 
entire vaccinees' cohort (regardless of LST conversion after vaccination) was 
conducted in Ecuador [24].  In this study, safety, immunogenicity and efficacy of two 
intradermal doses of a locally prepared trivalent vaccine were assessed against two 
doses of BCG alone (n = 438 vaccine arm vs n = 406 controls).  The vaccine consisted 
of L. braziliensis, L. guyanensis and L. amazonensis promastigotes originally 
collected from the lesions of patients living in the study area, mixed with BCG.  After 
12 months of follow up, the vaccine was shown to be safe, with 2.1% incidence of CL 
in the vaccine arm vs 7.6% in the control arm, corresponding to an efficacy 73%, [24].   
 
The differentiating aspects of this trial from other leishmaniasis vaccine trials are 1) 
the origin of the vaccine being from locally obtained parasites, and 2) the young 
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average age of subjects, being around 5.5 years (5.4±3.9 vaccines and 5.7±3.9 
controls).  These aspects may partially explain the favourable results. 
 
After the original 12 months of follow up, these subjects were followed up, in a 
separate study, for another 4 years.  Results indicated that although the protective 
efficacy was still significant between the 13th and the 18th months, it was not so after 
the 19th month of follow-up [38].  The incidence in each 6-month period and the total 
incidence from the 19th to the 60th month were not significantly different between the 
vaccine and the control arm subjects who were followed-up.  
 
However, the data in Armijos, et al, suggest that the loss of statistical significance in 
the difference between arms after the 19th month was not due to an increase in the 
number of cases in the vaccine arm, but rather a reduction in the number of new cases 
in the control group.  In addition, the gradual reduction in the number of subjects 
followed up seems to be another factor contributing to differences that are not 
significant (number of subjects were calculated for each 6-month follow-up period 
based on incidence values reported in the article).  It could, therefore, be argued that 
this study is inconclusive with respect to the erosion of the vaccine-derived protection 
after 18 months of vaccination (trend test of efficacy over the 5 years is not significant, 
P=0.406).     
 
A problem with the first trial conducted by Armijos and colleagues was the 
unstandardised nature of the vaccine product tested.  A subsequent trial compared two 
doses of vaccine (n = 750) against placebo (n = 756).  The vaccine consisted of 
autoclaved L. amazonensis mixed with BCG.  Although the vaccine was safe and 
immunogenic (significantly more LST conversion in the vaccine arm), the incidence 
of CL was similar in the two arms of the trial and the incidence of disease among 
vacinees who skin test converted was similar to that among those who did not convert 
[39].  The participants in this trial were older (average age 11± 10 years).  The authors 
mention the possibility of the parasite killing method (heat), and the geographic origin 
of the parasite and the parasite species used in the vaccine as possible factors 
contributing to its ineffectiveness.   
 
2.2  Old World 
 
Following the cessation of the LZ program in Iran in the 1980's, the Iranian 
government created a national vaccine development program to develop a killed 
Leishmania vaccine at the Razi Vaccine and Serum Institute, Hessarak, Iran, using the 
same organism as used in the LZ program [17, 22].  Phase 1 and 2 studies of the 
safety and immunogenicity of different doses of inactivated L. major promastigotes 
with or without BCG as adjuvant were conducted in non-endemic areas in Iran.  
Initially full dose of BCG (as used in vaccination against tuberculosis) was used but 
subsequently it was reduced to 1/10 of the standard concentration.  The results of 
these studies demonstrated that a low dose of BCG enhanced the immune response to 
the antigen [40, 41].  Vaccines produced by two methods of parasite inactivation 
(thimerosal treatment vs autoclaving) showed similar safety and immunogenicity 
results and because of its simplicity and lower cost, autoclaving was recommended as 
the preferred method of vaccine preparation for future trials [40].  The autoclaved L. 
major (ALM) preparation mixed with BCG adjuvant (10% the dose normally used in 
vaccination against TB) was used in several field trials in Iran and Sudan.  The results 
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of some of these studies in the late 1990's (multiple injections in Bam, Iran, multiple 
injections in Zavareh, Iran and multiple injections in Borkhar, Iran) have not yet been 
published.  This preparation was later replaced by a formulation involving 
precipitation of the ALM in aluminium hydroxide (alum), known as alum-ALM.  
Alum-ALM mixed with BCG showed significantly higher ability to convert the LST, 
but so far, Alum-ALM+BCG has only been studied in phase 1 and 2 (safety and 
immunogenicity) clinical trials and an LZ challenge study (see below). 
 
Iran 
 
In a randomized, double-blind, controlled field efficacy trial of ALM+BCG against 
zoonotic CL due to L. major, one injection of the vaccine (n = 1188) was compared 
with one injection of BCG alone (n =1122).  Volunteers, whose age ranged from 5 to 
72 years, were from healthy, LST-negative (LST=0), residents of an airbase in a part 
of Esfahan, Iran endemic for leishmaniasis.  Participants had moved into the airbase 
from throughout Iran, including from areas not-endemic for leishmaniasis [42].  Post-
vaccination LST was conducted on day 80 and after one year. The LST conversion 
rates following vaccination were higher compared to some other studies conducted in 
non-endemic or low endemic areas in Iran, but high rates were also observed in the 
control arm.  The authors attributed this latter finding to natural exposure to 
leishmanial or cross-reacting antigens.  Although after two years of follow-up there 
was no significant difference in the leishmaniasis incidence rates in the two arms, 
infection rates among LST converted individuals (both in the vaccine and the control 
arms) were lower than in those whose LST had not converted (7.3% vs 11.3 in the 
vaccine arm and 3.4% vs 10% in the control arm).  This is consistent with findings in 
Brazil [33]. The difference is that in Brazil, the significant difference was between 
LST converted vaccinees and all others, while in Esfahan the difference was between 
participants whose LST converted and those who did not, regardless of BCG or 
vaccine treatment.  This may reflect the fact that in Brazil the control treatment was 
not BCG. Another outcome of this study was the lower disease severity in vaccinated 
children less than 14 years old.  A subsequent study of the immunogenicity data from 
this trial did not find a significant correlation between proliferation response to 
Leishmania antigens (IFN-γ production) and the magnitude of LST response [43].  
The authors compared several different subgroups of the study but did not compare 
the vaccinated volunteers whose LST had converted with other groups.  The authors 
raised the possibility that BCG may not be an ideal control since it could induce a 
similar immune response to that observed in those who received ALM+BCG.    
 
Another randomized, double-blind, BCG controlled clinical trial in Bam, Kerman, 
assessed the efficacy of ALM+BCG in protecting against anthroponotic CL (ACL) 
caused by L. tropica in LST-negative (LST = 0) school children aged 5 to16 years 
[44].  One injection of the vaccine (n = 1839) was compared with one injection of 
BCG alone (n = 1798).  Post vaccination LST was conducted on day 80 and again 
after one year.  After two years of follow-up infection rates were similar in the 
vaccine and the control arms (2.8% and 3.3%, respectively).  The LST conversion on 
day 80 after vaccination was significantly greater in the vaccine arm (16.5% vs 3.6%), 
but overall, less than that observed in Esfahan.  The disease rates in the LST 
converted subgroups were not reported.  Protection was observed in vaccinated boys, 
but not girls, though the difference in protection between the genders was not 
statistically significant. Also, it was noticed that through the 6th month of follow up 
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more cases were identified in the vaccine arm, while fewer were identified thereafter.  
This observation may point at the longer incubation time for the L. tropica infection. 
 
Other studies were conducted in Iran with multiple injections of ALM+BCG.  These 
studies were carried out in Bam, province of Kerman against anthroponotic 
lesihmaniasis caused by L. tropica and in Borkhar and Zavareh in the province of 
Esfahan against the zoonotic disease due to L. major.  Results have not yet been 
published from these trials.  Sharifi, et al (personal communication) conducted a study 
in LST = 0 school age children with 3 injections, one month apart, of ALM+BCG.  
BCG was used in the control arm.  Two post vaccination LST measurements (day 80 
and 1 year) were taken.  Khamesipour et al (personal communication) conducted a 
three-dose trial in school age children in Borkhar, Esfahan province.  The two main 
distinguishing aspects of this trial was 1) inclusion criteria allowed any initial LST 
values accepted into the trial and 2) although the first two injections of the vaccine 
were two month apart, the third injection was one year after the first. Several LST 
measurements were taken throughout the trial. Khamesipour et al (personal 
communication) also conducted a three-dose trial in Zavareh, in the province of 
Esfahan.  Participants ages ranged from 5 to 59 years. In this study only the pre-
vaccination LST was measured and, similar to the trial in Borkhar, participants with 
any value of LST were enrolled.  Vaccine injections were one month apart.  . In none 
of these trials was any evidence found of a protective effect of the vaccine against 
leishmaniasis. 
 
Additionally, a clinical trial assessing the safety, immunogenicity and efficacy of 
alum-ALM (alum-precipitated ALM, an improved formulation of ALM) mixed with 
BCG followed by LZ challenge was conducted in a hyper-endemic area of Esfahan.   
This study (unpublished) did show the safety of alum-ALM+BCG but was 
inconclusive about the vaccine efficacy against challenge due to problems with the LZ 
reagent.  A similar trial with an improved study design is currently underway in Iran. 
(Khamesipour, personal communication) 
 
Sudan 
 
The safety and immunogenicity of ALM+BCG was assessed in endemic and non-
endemic areas of Sudan [45, 46].  Subsequently, a double-blind randomized field 
efficacy trial of two doses of ALM+BCG (n = 1155) vs BCG alone (n = 1151) was 
conducted in Sudan in an area endemic for VL due to L. donovani [47].  LST-negative 
(LST = 0) volunteers between the ages of 1 and 65 years were admitted to the study.  
Post vaccination LST conversion was significantly higher in the vaccine arm (30% vs 
7% 42 days after vaccination).  However, after two years of follow up, the rates of 
infection in the two study arms were not significantly different (11.5% in the vaccine 
arm and 12.3% in the control arm). Although the overall vaccine efficacy was not 
significant, individuals whose LST converted after vaccination (in each study arm 
separately or combined in both arms) had a significantly lower incidence of VL than 
non-responders (Vaccine arm: 8% vs 12.6%, P = 0.03; BCG arm: 3% vs 12.7%, P = 
0.015; both arms combined: 7.2% vs 12.7%, P= 0.003).  Reduced incidence in LST 
converted participants in Sudan is consistent with findings in Brazil and Esfahan 
studies, discussed earlier (with the difference that in Brazil the control treatment was 
not BCG and in Esfahan significantly reduced incidence was not observed separately 
in each study arms). 
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In addition to the studies of ALM+BCG, the safety and immunogenicity of different 
doses (10, 100, 200 and 400 µg of leishmanial protein) of alum-ALM+BCG was 
assessed in a small study in Khartoum [48].  LST conversion 42 days after vaccination 
was observed in all volunteers in the 10 µg, 100 µg and 400 µg doses but only in one 
of five volunteers in the 200 µg group.  All doses were safe with minimal, local side 
effects [48].  Additionally, an extended phase 2 study [49] confirmed the safety and 
immunogenicty of alum-ALM+BCG compared to vaccine diluent as the control 
treatment in 544 leishmanin non-reactive children younger than 15 years old.  Of 
interest is that the four cases of leishmaniasis observed in this study were all in the 
control arm.  Alum-ALM+BCG was also evaluated in a hospital-based clinical trial 
for its immunotherapeutic effect in chronic PKDL patients in Sudan and demonstrated 
promising results [50]. 
 
Table 1 summarizes the background, trial design, vaccine profile and findings of 
prophylactic field efficacy trials of first generation leishmaniasis vaccine discussed 
above. 
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Table 1 - Leishmaniasis first generation vaccine efficacy trials 
Author
Sharifi           Momeni         Sharifi            
Khamesi-
pour            
Khamesi-
pour              Khalil             
Antunes, 
Mayrink          
Antunes, 
Mayrink         Velez             Armijos      Armijos         
Year Published 1998 1998 N/P N/P N/P 2000 1986 1986 2005 1998 2004
Study designation Bam1 Esf1 Bam3 Bor3 Zav3 Sudan2 Brazil 1981-2 Brazil 1983-2 Colombia3 Ecuador2 N/A
Background
Country,                                                           
Area
Iran,           
Bam
Iran,     
Esfahan
Iran,           
Bam
Iran,    
Borkhar
Iran,    
Zavareh
Sudan, 
Gedaref
Brazil, 
Amazonas
Brazil, 
Amazonas Colombia Ecuador Ecuador
Year(s) study conducted 1994-1997 1994-1997 1997-2000 1997-2000 1997-2000 1997-1999 1981 1983 2001-2003 1995-6? 2002?
Targetted parasite causing local disease
L. tropica L. major L. tropica L. major L. major L. donovani
L. pnamensis,     
L. braziliensis
L. panamensis, 
L. basiliensis, 
L.amazonensis
L. panamensis, 
L. basiliensis, 
L.amazonensis
Expected annual  incidence in controls 2% 5% 2% 6% 6% ? 9% 10%-25% 10%-25% 5% 7.5% 3%
Number of volunteers screened 12156 4712 6524 5869 a 2053 5093 ? ? 3018 ? 4164
Trial Design
Number of volunteers accepted and 
randomized 3637 2453 4217 2191 2008 2306 1312 1274 2597 b 1042 1995
N in vaccine arm (original, received 
complete vaccination schedule ---if known) 1839 1256, 1118 2149, 2082 1107, 964 945 1155 667 658 1302, 1252 552, 438 1009, 750
N in control arm (original, final) 1798 1197, 1122 2068, 2008 1084, 956 1063 1151 645 616 1295, 1251 487, 406 986, 756
originally planned (nominal) power 80% 80% 90% 90% 90% 90% 90% 90% 80% 90% 90%
Hypothesized vaccine effectiveness 
(expected %reduction in annual incidence)
50% 50% 50% 50% 50% 50% 50% 50% 50% 50% 50%
LST requirement for inclusion (LST=0 mm, 
LST<5 mm , etc) LST=0 mm LST=0 mm LST=0 mm LST> 0 mm LST> 0 mm LST=0 mm LST negative LST negative LST<3 mm LST< 5 mm LST< 5 mm
Length of time post vaccination for LST 
testing 80 days, 1 yr 80 days, 1 yr 80 days, 1 yr
80 days, 1yr, 
1yr+80 days Not done 42 days, 1 yr 40-45 days 40-45 days Not done 1 month 2 months
Number of vaccine injections 1 1 3 3 3 2 2 2 3 2 2
Time between vaccine injections single dose single dose 30 days 75 days, 1 yr 30 dqys 28 days 7 days 7 days 20 days 30 days 56 days
Dose of Leishmania  antigen injected (each 
injection) 1 mg ALM 1 mg ALM 1 mg ALM 1 mg ALM 1 mg ALM 1 mg ALM
240 ug 
Nitrogen
240 ug 
Nitrogen
11.11 mg 
protein/mL 72 mill promast. 240 ug Nitrogen
Injection method ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) ID (0.1 mL) IM (1 mL) IM 1(mL) IM (1 mL) ID (0.1 mL) ID (0.1 mL)
Control treatment
BCG BCG BCG BCG BCG BCG
PBS + 
merthiolate
PBS+ 
mrthiolate Saline (ph=7.4) BCG BCG
Duration of follow up (months) 12+12 12+12 36 24 24 12 12 12 12+48 12+14
Type of case detection during follow up 
(A=active, I=inactive) A/I A/I A/I A/I A/I A/I A A A A A  
a 2671 of 5869 were qualified for randomization but 492 participated in phase I/II trial. 
b Recruitment was done in 3 groups:  Sept-Nov/01 (989), Jan-March/)2 (1131), Jul-Aug/02 (477)  
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Table 1 (continued) - Leishmaniasis first generation vaccine efficacy trials 
Author
Sharifi           Momeni         Sharifi            
Khamesi-
pour            
Khamesi-
pour              Khalil             
Antunes, 
Mayrink          
Antunes, 
Mayrink         Velez             Armijos      Armijos         
Year Published 1998 1998 N/P N/P N/P 2000 1986 1986 2005 1998 2004
Product Profile
Parasite species in vaccine L. major L. major L. major L. major L. major L. major L. guyanensis L. 
guyanensis
L. amazonensis L. braziliensis,  
L. guyanensis,  
L. amazonensis
L.amazonensis
Parasite killing method Heat Heat Heat Heat Heat Heat Merthiolate Merthiolate Merthiolate Phenol Heat
Antigen origin Iran Iran Iran Iran Iran Iran Brazil Brazil Brazil Ecuador Brazil
Adjuvant BCG BCG BCG BCG BCG BCG None None None BCG BCG
Vaccine Antigen manufacturer Razi, Iran Razi, Iran Razi, Iran Razi, Iran Razi, Iran Razi, Iran Local Local Biobras Local Biobras
Adjuvant (BCG) manufacturer Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran N/A N/A N/A Tokyo
BCG concentration/injection
1/10 normal 
dose
1/10 normal 
dose
1/10 normal 
dose
1/10 normal 
dose
1/10 normal 
dose
1/10 normal 
dose N/A N/A N/A
1/2 normal dose 
(500,000 
organisms) 80000 bacilli
Leishmanin manufacturer
Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran Pasteur, Iran ? ?
Colombian Nat'l  
Inst. of Health Local Biobras
Leishmanin composition
L. major L. major L. major L. major L. major L. major ? ?
L. amazonensis, 
L. panamensis
same as 
vaccine ?
Findings
Yr 1: Observed incidence in controls
2.17% c N/A d 3.77% 1.75% 1.70% N/A f
11.07% (gr 1), 
1.40% (gr 2) 1.30% 6.80% 7.60% 0.13%
Yr 1: Observed incidence in vaccine arm
2.01% c N/A d 3.16% 1.36% 1.40% N/A f
8.70% (gr 1), 
1.16% (gr 2) 0.61% 7.76% 2.10% 0.54%
Yr 1: Efficacy (= 1-(% case vaccine 
arm/%case control arm) 7.4% N/A 16.2% 22.3% 17.6% N/A
21.4% (gr 1),   
17.1% (gr 2) 53.1% -14.1% 72.4% -315.4%
Yr 2: Observed incidence in controls 1.2% c N/A d 1.76% 4.04% e 10.70% N/A f N/A N/A N/A 9.19% g 1.21%
Yr 2: Observed incidence in vaccine arm 0.83% c N/A d 1.68% 4.67% e 11.40% N/A f N/A N/A N/A 4.41% g 1.22%
Yr 2: Efficacy 30.8% N/A 4.5% -15.6% -6.5% N/A N/A N/A 52.0% -0.8%
Volunteers endemic origin
Low endemic
Mixed (army 
base) Low endemic Endemic New endemic
different 
villages
Mixed (army 
concripts)
Mixed (army 
conscripts) Mixed (army) Endemic Endemic
Age (range, mean) 6-15, 9.1 5-72, 18.2 6-12, 7.41 6-13, 8.45 5-59, 19.12 1-65, 6.9 18.6 18.6 >18, 19.8 5.6 10.7
Sex (% male) 50.60% 47.40% 50.80% 50.70% 46.80% 45.70% 100% 100% 100% 44.16% 44.90%
Protection observed in the overall sample No No No No No No No No No Yes No
Protection  in those with converted  LST 
after vaccination No Yes No No Not done Yes Yes No Not done N/A No
LST conversion rate (per protocol) 40-80 
days post vaccination (vaccine arm, 
Controle arm) 16.5%, 3.2% 36.2%, 7.9% 18.2%, 2.0% 
29.9%, 6.1% 
(Received 2 
doses year 1) Not done 30%, 7% 33% 70% Not done 85.1%, 20.1% 74.4%, 14.7%  
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Footnotes for "Table 1 (continued)" 
 
Bor3, Zav3, Bam3 findings are ITT. Other trials from published information.
c Cumulative 2-year incidence: Vacc=2.8%, BCG=3.3%, overall efficacy=15%
d Annual rate not reported. Cumulative 2-year incidence: vacc=18.0%, BCG=18.5%, overall efficacy=3%
e Third year incidence in Bor3: 6.64% (Control), 6.44% (Vaccine)
f Annual rate not reported. Cumulative 2-year incidence: vacc=11.5%, BCG=12.3%. Overall efficacy=6%
g Reported by Armijos 2003  
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3 Discussion 
 
Overall, reproducible evidence of protective efficacy has not emerged from clinical 
trials of first generation leishmaniasis vaccines. In most of the randomized controlled 
trials reviewed (except Armijos 1998),  no efficacy was demonstrated and this is 
consistent with the killed whole parasite preparations being inadequate to produce 
long lasting, relevant immune responses required for protection.  In trials where post 
vaccination LST was measured, responses were notably larger in the vaccine group, 
but this evidence of immunogenicity induced by the vaccine was not carried over to a 
protective effect.  This casts doubt on the merit of the vaccine induced LST response 
as a correlate of immunity.  Nevertheless, conversion from negative LST reaction to 
LST>5 after vaccination has been observed to be associated with significantly lower 
infection incidence in Brazil, Iran and Sudan. In Brazil, where a true placebo (rather 
than BCG) was used in the control arm, significantly reduced incidence was observed 
only in the LST converted individuals in the vaccine arm (compared to all other 
participants in the vaccine or placebo arms). In Sudan (with BCG as control 
treatment)significantly reduced incidence was observed in the LST converted 
individuals in each study arm separately and also in the two arms combined, while in 
Iran, this was observed in both the vaccine and the BCG arms.  This suggests that 
LST conversion may be associated with an immune response that can provide some 
protection.  It certainly distinguishes a subpopulation of “responders” to leishmanial 
antigens or BCG after vaccination. On the other hand, there is a strong correlation 
between LST positivity and protection after recovery from the disease caused by 
several species [51] (although exceptions to this general statement exist); hence the 
immunological implication of the LST response depends on the factors and conditions 
that gave rise to it.  
 
It is important to consider the possible role of BCG as not only was this used as an 
adjuvant but also served as the control vaccine in many of the trials.  In the New 
World, the vaccines tested in Brazil and Colombia did not contain adjuvant.  In 
Ecuador, Armijos used BCG (about 1/2 the dose normally used for vaccination 
against tuberculosis) in both his trials; with the locally produced trivalent vaccine and 
with the Brazilian Leishvacin.  In immunotherapy, variable doses of BCG were used 
depending on the PPD results of each volunteer in Convit's initial protocol [52]. In the 
Old World different doses of BCG were tested in phase one trials [41] and 
subsequently 1/10 of the normal dose (used in vaccination against tuberculosis) was 
used in all leishmaniasis vaccine trials [40, 42, 44, 45, 47, 53].  
 
An important aspect of all prophylactic clinical trials of killed parasites +BCG 
adjuvant was the use of BCG alone as the control, usually to preserve blinding in the 
trials, as BCG leaves a distinctive scar. Injection of BCG mixed with killed parasites 
significantly increases cell mediated immune responses to the vaccine measured by 
LST (but not interferon-γ production).  Additionally, it has been observed that LST 
conversion due to vaccination is associated with reduced incidence of infection  [33, 
42, 47].  These observations point at the value of BCG as a vaccine adjuvant. 
However, in a clinical trial setting, the use of BCG in the control arm does not 
constitute a true placebo, since BCG induces LST conversion in some individuals in 
the control arm – albeit, to a lesser extent than in the experimental arm.  Reduced 
incidence has been observed in participants whose LST converted post-vaccination, in 
both study arms (ALM+BCG or BCG alone)[42, 47]. This suggests a potential 
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association between BCG and reduced infection rates in the control arm.  Therefore, 
on the one hand, BCG inclusion as an adjuvant increases the immunogenicity of the 
vaccine and its use is justified in the experimental arm.  On the other hand, the use of 
BCG in the control arm can induce LST conversion and possibly modulates 
susceptibility to infection.  Therefore, from the standpoint of assessing the efficacy of 
the vaccine, BCG may not be an appropriate candidate for use in the control arm of 
efficacy trials since it may detract from the ability of the trial to demonstrate the full 
effect of the vaccine [24, 53].   
 
Surprisingly, in view of the prophylactic findings discussed above, therapeutic trials 
of first generation leishmaniasis vaccine have shown very encouraging results.  From 
Convit's trials for treatment of patients in Venezuela and Machado Pinto’s results in 
Brazil to Musa et.al’s results on therapy of PKDL in Sudan, immunochemotherapy 
seems a promising mode of treatment [50, 54-56].  This justifies further investigation 
of first generation leishmaniasis vaccines for therapeutic purposes.   
 
It should be mentioned that to date, only one second generation vaccine has been 
evaluated in phase 1-2 clinical trials [57].  Although previous trials with first 
generation vaccines did not result in identification of an efficacious vaccine, they did 
demonstrate the safety profile of these vaccine candidates.  Moreover, these trials 
made a significant contribution to improving the overall quality of vaccine 
investigation in the endemic countries where they were conducted, training personnel 
and identifying particular issues related to vaccine development in general and 
vaccines against leishmaniasis in particular.   
 
It is estimated that the total cost to conduct first generation vaccine trials through 
TDR over a period of 10 to 12 years in Iran, Sudan, Colombia and Ecuador (in 
addition to a follow up safety study of Myrink's vaccine in Brazil) was between 2 and 
3 million dollars (Farrokh Modabber, personal communication). This also covered 
production of leishmanin for use outside of vaccine trials, training and some 
components of capacity building.   
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Abstract 
 
Despite decades of investigation in countries on three continents, an efficacious 
vaccine against Leishmania infections has not been developed. Although some 
indication of protection was observed in some of the controlled trials conducted with 
"first-generation" whole, inactivated Leishmania parasite vaccines, convincing 
evidence of protection was lacking. After reviewing all previously published or 
unpublished randomized, controlled field efficacy clinical trials of prophylactic 
candidate vaccines, a meta-analysis of qualified trials was conducted to evaluate 
whether there was some evidence of protection revealed by considering the results of 
all trials together. The findings indicate that the whole parasite vaccine candidates 
tested do not confer significant protection against human leishmaniasis. 
 
 
Key words: Leishmaniasis vaccine, meta-analysis, clinical trial 
 
 
Abbreviated title: Meta-analysis of efficacy trials of leishmaniasis vaccines 
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1   Introduction 
 
Leishmaniasis is endemic in at least 88 countries, some of which are among the 
poorest in the world[1, 2]. The estimated global prevalence of all forms of the disease 
is 12 million, with 1.5 to 2 million cases of cutaneous leishmaniasis (CL) added 
annually (with duration of lesions typically from few months to a year) and 500,000 
cases of visceral form of the disease (with duration of disease from several months to 
more than a year) [2, 3]. Current control measures, including environmental sanitation 
and drug treatment of cases, are expensive and cannot be sustained effectively by poor 
countries due to the problems of financing and implementation [4-6]. Moreover, 
toxicity associated with some of the most widely available drug treatments, including 
injections of pentavalent antimony compounds, and the resistance developed by the 
parasite [7-12], underline the need for development of effective methods of 
prevention, especially vaccines [4, 13, 14].  
 
1.1   Historical perspective 
 
To date, the only effective way of inducing immunity against leishmaniasis in humans 
is provided by leishmanization (LZ), the practice of injecting live virulent parasites in 
healthy individuals [15].  LZ has been practiced historically in high incidence 
endemic foci as a means of controlling the timing and site of the initial lesion, but it is 
no longer widely used because of rare complications and difficulties in 
standardization of the injected parasites [15-18]. 
 
During the first half of the 20th century researchers in Latin America investigated 
different antigens as potential vaccines [19, 20].  Beginning in the 1970s and 1980s, 
Mayrink and colleagues in Brazil and Convit and colleagues in Venezuela 
experimented with the use of whole, killed parasites, both for prophylaxis and therapy.  
Later studies were conducted with inactivated whole parasite vaccines in Ecuador 
(trivalent vaccine composed of three strains of locally obtained parasites), Colombia 
(Biobras single strain L. amazonensis vaccine), Iran and Sudan (autoclaved L. major 
with BCG included as an adjuvant: ALM+BCG) [21-28].  With the exception of the 
trial by Armijos in Ecuador in which a locally-prepared vaccine was used [21], none 
of the other trials demonstrated significant protection associated with vaccination [26].   
 
Some investigators observed a lower incidence of leishmaniasis in the subset of those 
in the vaccinated group whose Leishmanin Skin Test (LST) had converted (from an 
induration of  <5mm to >5 mm) after vaccination [24, 25, 29].  Also, researchers in 
Iran observed significant protection in school age boys but not in girls [27].  Evidence 
of potential clinical value of such vaccines for treatment, rather than the prevention, of 
disease was demonstrated in trials among leishmaniasis patients in the New World [30, 
31].  
 
We have re-examined the combined data from all except one published, and 
unpublished, randomized, controlled clinical trials (RCT) of prophylactic first 
generation leishmaniasis vaccine conducted to date to evaluate whether, overall, there 
is evidence of efficacy, or there is efficacy in some sub-groups of the trial populations.  
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2   Data selected for analysis 
 
Definition of Studies:  
All published and unpublished field efficacy trials of prophylactic candidate vaccines 
against leishmaniasis conducted to date were considered for inclusion.  As a result, 
publication bias is not a concern in this meta-analysis. 
 
Information sources:  
Trial protocols and progress reports for studies in Iran, Sudan and Colombia were 
reviewed. For each clinical trial identified, the principal investigator was requested to 
provide the original trial database. Thus, individual-level data for trials conducted in 
Iran and Sudan as well as aggregated data for the trial in Colombia were obtained.  
These data were used to estimate or verify the effect statistics (relative risk) as well as 
age and gender composition in Iran studies. For other studies values reported in the 
published articles were used (see Included Studies, below). 
 
Selection criteria: 
1) Trial objective: efficacy of a first generation vaccine for prevention of 
leishmaniasis in healthy individuals in an endemic area. 
2) Study design: randomized, double blind, controlled clinical trial designed to 
estimate vaccine efficacy. 
3) Candidate vaccine: Killed, whole Leishmania promastigotes. 
4) Normal field conditions during follow up: Sample size and power calculations are 
generally based on previously observed disease rates in the trial area. Unforeseen, 
major changes in environmental and climatic factors could lead to a significant 
change in disease incidence, affecting the study power and conclusions. Selected 
clinical trials were conducted under the usual field conditions that gave rise to the 
previously observed incidence rates. 
 
Excluded Studies:  
On the basis of the above criteria, one study [32] was excluded due to the unusual 
climatic changes that were attributed by authors to the El Nino phenomenon during 
the study follow up [32].  These changes led to significantly lower disease incidence 
rate than expected 
 
Included Studies:  
Data and reports from the randomized, blinded, controlled efficacy trials listed in 
table 1 were used.  Trial details are presented in tables 1-3. Further details are 
available in Noazin et al., 2008[26]. 
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Table 1 - Design characteristics of selected trials 
Study Label
Number of 
injections
Vaccine         
parasite 
Inactivation 
method Adjuvant
Control 
treatment
Causative 
parasite Area, Country
Study 
population 
origin
Investigators, year 
published
A  Zav3 3 L. major Autoclaved BCG BCG L. major Zavareh, Iran Endemic Khamesipour, et al., 
not published
B  Bor3 3 L. major Autoclaved BCG BCG L. major Borkhar, Iran Endemic Khamesipour, et al., 
not published
C  Bam3 3 L. major Autoclaved BCG BCG L. tropica Bam, Iran Endemic Sharifi et al.,             
not published
D  Bam1 1 L. major Autoclaved BCG BCG L. tropica Bam, Iran Endemic Sharifi et al., 1998
E  Esf1 1 L. major Autoclaved BCG BCG L. major Esfahan, Iran Endemic and 
non-endemic
Momeni et al., 1999
F  Sudan 2 2 L. major Autoclaved BCG BCG L. donovani Gedarif, Sudan Endemic Khalil et al., 2000
G  Brazil 1981 
and 1983
2 5-strain vaccine 
(species of 
brasiliensis and 
mexicana 
complexes, including 
L. guyanensis and   
L. amazonensis ) 
Merthiolate None Phosphate 
buffer + 
Merthiolate
? Amazonas, Brazil  - 
Exposure during 
military missions
Endemic and 
non-endemic- 
army recruits
Antunes et al., 1986
H  Colombia 3 3 L. amazonensis Merthiolate None Saline L. Panamensis Colombia - Exposure 
during military 
missions
Endemic and 
non-endemic, 
army recruits
Velez et al., 2005
I  Ecuador2 2 3-strain vaccine        
(L. guyanensis,          
L. brasiliensis,          
L. amazonensis )
Merthiolate BCG BCG L. guyanensis, 
L. brasiliensis, 
L. amazonensis
Rural rainforest, 
Ecuador
Endemic Armijos et al., 1998
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Individual level data were used for trials A-E, and published information was used for 
trials F-I (table 1). 
 
Although most trials excluded individuals with LST>0mm, in the Borkhar (Bor3) and 
Zavareh (Zav3) trials (A and B in table 1) volunteers with any LST value at screening 
were enrolled.  Since an LST>0 could indicate previous exposure to leishmaniasis and 
be associated with immunity, for these 2 trials we analysed data only on participants 
with a pre-vaccination LST of zero.  This excluded 12% of trial participants in 
Zavareh and 40% in Borkhar. 
 
The study conducted in Brazil in 1981 was conducted in two separate cohorts[29].  
These cohorts were different in several respects, including the risk of disease, duration 
of exposure and previous vaccination history, and we have treated them as two 
separate studies (identified as Brazil 1981A and Brazil 1981B).  
 
3   Statistical analysis 
 
We used a meta-analysis approach based on relative risk (RR = incidence in the 
vaccine arm / incidence in the control arm) calculated for each study separately and 
then pooled across studies.  Briefly, in calculating the pooled effect, an average of the 
trial-specific relative risks was calculated by weighting individual study effects 
according to their trial size (i.e., weighting by the relative quantity of information 
provided by the trial).  These weights can be calculated using a variety of methods, 
including the inverse variance (I-V) and Mantel Haenszel (M-H) methods.  If the 
relative risks in different studies are not widely different (i.e., studies are 
homogeneous), a fixed effect model would be appropriate. If the variation is more 
than would be expected by chance then a random effects model is more appropriate, 
for which a common method for calculation of the pooled effect is that of 
DerSimonian-Laird (D-L) [33].  To assess heterogeneity, we used a chi-square test of 
the Q statistic (Q = sum of squared deviations of weighted RR's from their overall 
mean); with degrees of freedom = k-1, where k is the number of studies. In addition, 
due to limitations of Q [34], I -squared was also used to assess heterogeneity.  I-
squared measures the percent of variation due to between-studies variability.  A value 
of zero for I-squared indicates that all variability in relative risks is due to sampling 
error [34]. 
 
EpiInfo 2002, Stata 9 and MS Excel were used in the analyses.  The "metan" program 
in Stata 9 was used to calculate relative risk (RR) estimates and corresponding 95% 
confidence intervals.  The inverse variance (I-V) and the Mantel-Haenszel (M-H) 
methods were used separately to fit the fixed effect model and the DerSimonian-Laird 
(D+L) method to fit the random effect model.   
 
4   Results 
 
Age and gender breakdown of participants in vaccine trials included in this analysis 
are provided in table 2. Some trials were confined to children, whereas other included 
all ages and the trials among the military in Brazil and Colombia were confined to 
adult males.  In two of the trials there was a significant excess of males in the 
vaccinated group and in two the vaccinees were significantly younger, on average.
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Table 2 - Age and gender distribution of participants in trials selected for meta-analysis 
 
 
Study
Trial arm V * C * V C V C V C V C V C V C V C V C V C
N 1838 1795 1190 1124 2149 2068 1107 1084 941 1055 1155 1151 667 644 658 616 1302 1295 438 406
Age (yrs)
Minimum 6 6 5 5 6 6 6 6 5 5 <3 <3
Maximun 15 15 67 72 12 12 13 13 59 59
Mean 9.1 9.1 18.0 18.8 7.4 7.4 8.2 8.7 19.0 19.2 6.5 7.2 18.6 18.6 18.6 18.6 19.8 19.8 5.4 5.7
P value  
(Kruskal-
Wallis H)
SEX
% Female 47.1 51.8 52.7 52.6 48.8 49.6 46.3 52.4 50.2 48.9 53.3 55.3 0.0 0.0 0.0 0.0 0.0 0.0 57.5 54.3
P value 
(Fisher 
Exact)
Bam1 Esf1 Bam3 Bor3 Colombia3 Ecuador2Zav3 Sudan2 Brazil1981 - 2 Brazil 1983 - 2
0.666 0.010 --
--
0.822 0.118 0.132 0.000
0.323 0.599 N/A N/A0.003 0.496 0.302 0.002 N/A 0.349
-- 0.271
 
* V=vaccine; C=Control 
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Participants included in the analysis of vaccine immunogenicity were restricted to 
those with negative pre-vaccination LST.  LST measurements 42 to 80 days post-
vaccination (depending on the trial) are displayed in Table 3. LST ≥ 5 is generally 
accepted as an indication of a significant skin test response in volunteers after 
vaccination.   In all trials where immunogenicity was assessed in both vaccinated and 
unvaccinated participants there was a significantly higher level of skin test conversion 
among vaccinated individuals. However, the level of skin test conversion varied 
substantially among trials, ranging from only 16% among those vaccinated in the 
Bam1 trial to 68% in the Brazil 1983-2 trial. In table 3 and thereafter, and in our 
analysis, we have treated the Brazil 1981-2 study as 2 distinct trials: Brazil 1981A-2 
and Brazil 1981B-2.  This approach was adopted due to the differences between the 
two cohorts of volunteers in this study in their duration and timing of exposure as well 
as the length of time after yellow fever vaccination that the vaccines were given 
(which could affect their immunological response) [29]. 
 
Table 3 - LST conversion 42-80 days post vaccination (among participants with 
LST=0 prior to vaccination). 
 
Trial Trial arm N
% LST  
≥5 mm
V * 1807 16.5
C * 1761 3.3
V 1168 36.2
C 1104 7.9
V 1980 18.2
C 1935 2
V 608 29.9
C 538 6.1
V 772 --
C 901 --
V 1919 30
C 1005 7
V 311 33
C -- --
V 338 37
C -- --
V 611 68
C -- --
V -- --
C -- --
V -- --
C -- --
Bam3
Bor3
Ecuador2
Zav3
Sudan2
Brazil1981A-2
Brazil1981B-2
Colombia3
Brazil 1983-2
Bam1
Esf1
 
*   V = vaccine arm, C = control arm 
 -- = Not measured 
 
 
The incidence rates of leishmaniasis in vaccine and control arms in the different trials 
are summarised in table 4 (participants in Zav3 and Bor3 with pre-vaccination LST≥0 
mm were excluded from this analysis). Vaccine efficacy (VE) is calculated as 
(100*(1-RR)). The percent of the trial populations who developed disease varied from 
around 1% to 18%. In only one of the trials (Ecuador2) was the difference in 
incidences between the vaccinated and unvaccinated group statistically significant. 
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Table 4 - Incidence of leishmaniasis among vaccinated and unvaccinated individuals 
and estimated vaccine efficacy.    
 
Study 
Follow-up 
(months)
Vaccine 
Total N
Vaccine 
Cases 
Control 
Total N
Control 
Cases
% Case 
(vaccine)
% Case 
(control)
Vaccine 
efficacy
Bam1 24 1838 52 1795 60 2.83 3.34 15%
Esf1 24 1190 214 1124 208 17.98 18.51 3%
Bam3 24 2082 81 2008 93 3.89 4.63 16%
Bor3 36* 604 64 561 63 10.60 11.23 6%
Zav3 24 742 102 868 109 13.75 12.56 -9%
Sudan2 24 1155 133 1151 141 11.52 12.25 6%
Brazil 1981A-2 12 322 28 289 32 8.70 11.07 21%
Brazil 1981B-2 12 345 4 356 5 1.16 1.40 17%
Brazil 1983-2 12 658 4 616 8 0.61 1.30 53%
Colombia3 12 1302 101 1295 88 7.76 6.80 -14%
Ecuador2 12 333 7 316 24 2.10 7.60 72%  
* Although there were 3 years follow up in Bor3, only cases from years 2 and 3 are included 
in this analysis because vaccination was completed (3rd dose) at the end of year 1. 
 
 
Table 5 shows the confidence intervals on the relative risk (RR) estimates from the 
trials and the relative weights derived for each study according to the method of 
pooling the results.  
 
The weights assigned to the Ecuador trial vary substantially between the three 
estimation methods. This reflects the tendency of the fixed effect models (I-V and M-
H) to give less weight to smaller trials.  
 
Table 5 - Relative risks (incidence in vaccinated/incidence in unvaccinated), 95% 
confidence intervals and relative weights for each study according to the method used 
for meta-analysis. 
Study N RR I-V M-H D+L
Bam1 3633 0.846 0.587 1.22 6.32 7.26 8.33
Esf1 2314 0.972 0.818 1.155 28.37 25.59 19.66
Bam3 4090 0.84 0.628 1.124 9.94 11.32 11.41
Bor3 1165 0.944 0.679 1.31 7.84 7.81 9.72
Zav3 1610 1.095 0.851 1.408 13.34 12.02 13.66
Sudan2 2306 0.94 0.753 1.174 17.08 16.89 15.63
Brazil 1981A-2 611 0.785 0.485 1.271 3.64 4.03 5.39
Brazil 1981B-2 701 0.826 0.224 3.049 0.49 0.59 0.86
Brazil 1983-2 1274 0.468 0.142 1.547 0.59 0.99 1.02
Colombia3 2597 1.142 0.867 1.503 11.15 10.55 12.27
Ecuador2 649 0.277 0.121 0.633 1.23 2.95 2.05
100 100 100
95% Conf. Int
Weight (%)
 
 
 
We sought evidence of heterogeneity in the results from the different trials. The 
heterogeneity statistics estimated by the three methods are very similar, as indicated 
in table 6 and in no case was there evidence of significant heterogeneity, providing 
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justification for using fixed effect models. A comparison of the RR's from the Old 
World and the New World trials indicated such heterogeneity as there is may be 
attributed to the latter group.  
 
Pooled RR estimates and the 95% confidence interval (CI) estimated by the 3 
methods (table 6) are very similar, regardless of the model used, providing little 
evidence to reject the hypothesis of no vaccine effect on leishmaniasis incidence. 
 
Table 6 - Heterogeneity and effect statistics in the 3 methods of meta-analysis 
Method
 Chi 
square d.f. p I-squared
Pooled 
RR z value P
I-V 14.59 10 0.148 31.5% 0.947 0.864 1.038 1.16 0.246
M-H 14.62 10 0.146 31.6% 0.939 0.857 1.029 1.34 0.179
D+L 14.62 10 0.146 31.6% 0.928 0.821 1.049 1.2 0.231
Test of RR=1 
95% Conf. Int
Heterogeneity statistics Effect statistics 
 
 
Figure 1 shows the “forest plot” of the findings in the trials. The area of the gray 
square boxes represent the relative size of each trial with the centre dot and the line in 
the centre of each square representing the RR and its 95% CI. The overall RR is 
depicted by two blank diamond boxes, representing the M-H and the D+L estimates.   
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Figure 1 - Forest plot of vaccine efficacy measures in different leishmaniasis vaccine trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M-H Overall  (I-squared = 31.6%, p = 0.146)
Esfahan 1-inj
D+L Overall
Brazil 1981B 1-inj
Sudan 2-inj
Brazil 1983 1-inj
Brazil 1981A 1-inj
Zavareh 3-inj
Borkhar 2+1-inj
Study ID
Colombia 3-inj
Ecuador 2-inj
Bam 1-inj
Bam 3-inj
0.94 (0.86, 1.03)
0.97 (0.82, 1.15)
0.93 (0.82, 1.05)
0.83 (0.22, 3.05)
0.94 (0.75, 1.17)
0.47 (0.14, 1.55)
0.79 (0.49, 1.27)
1.09 (0.85, 1.41)
0.94 (0.68, 1.31)
RR (95% CI)
1.14 (0.87, 1.50)
0.28 (0.12, 0.63)
0.85 (0.59, 1.22)
0.84 (0.63, 1.12)
100.00
%
Weight
25.59
0.59
16.89
0.99
4.03
12.02
7.81
(M-H)
10.55
2.95
7.26
11.32
  
1.121 8.27
Relative Risk
Bam1
sf1
r3
il 1983 -2
lombia3
cuador2
Zav3
Sudan2
r zil 1981A-2
r zil 1981B-2
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While Old World trials are clustered around the vertical line of RR=1 (i.e., 
homogeneous but with minimal efficacy), the results from the trials conducted in 
Latin American tend to be scattered on the left of that line, suggesting more 
heterogeneity but also more efficacious results.  The Ecuador trial, the only trial with 
significant results, is located in the far left of the forest plot.  Despite their lower 
individual RR values, these trials have limited impact on the pooled RR due to their 
smaller sample sizes (and wide confidence intervals).  
 
A graphical display of the influence of individual trials on the pooled RR is presented 
in Figure 2.  This graph shows the values of the pooled RR, when studies are omitted 
one at a time. The reference line is the overall, pooled RR.   Thus, the pooled RR is 
lower when Esf1, Zav3 or Colombia3 trials are omitted and the reverse is the case 
when any one of the  Bam trials, Brazil 1981A-2 and the Ecuador2 are omitted 
 
Figure 2 - Influence of individual trials on pooled RR The circles indicate the pooled 
relative risk estimate when each individual trial is omitted. 95% confidence intervals 
are also shown 
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5   Discussion 
 
In some trials, vaccinated participants who skin test converted following vaccination 
were reported to have a lower incidence of leishmaniasis than other trial participants 
[24, 25, 29].  However, our meta-analysis clearly demonstrates the overall inability of 
first generation leishmaniasis vaccines evaluated to date in phase 3 clinical trials to 
protect vaccinated individuals against infection by the Leishmania parasite.  
 
The apparent absence of efficacy of these vaccines may be due to a number of 
potential factors. First, the immune stimulation provided by a single dose, or even 
multiple doses, of inactivated parasite antigen, even when mixed with BCG as an 
adjuvant, may be inadequate.  Secondly, BCG was used in the control arm in several 
of the studies and was also used as a vaccine adjuvant. BCG stimulates Th1 response  
and contributes to the immunogenicity of the vaccine [35].  However, when used as 
the clinical trial control vaccine (for blinding), and as a vaccine adjuvant, it induces 
Th1 response in both arms, thus making it potentially more difficult for any potential 
vaccine effect to be detected. To the extent that BCG alone might protect against 
leishmaniasis, the difference in incidence between the two study arms would be 
reduced and the statistical power of the study would be compromised.  Thirdly, LST 
is an imprecise and highly variable indicator of previous exposure to leishmaniasis.  
This could lead to misclassification of some individuals with previous exposure and 
immunity as unexposed and allow their inclusion in both arms of the clinical trial.  If 
such persons are still at some risk of leishmaniasis, but the vaccine confers no 
additional protection in such partially immune individuals, then the protective 
efficacy of the vaccine in “unexposed” individuals may be underestimated. Fourthly, 
it is possible that some genetically non-responsive volunteers in endemic areas would 
show no LST reaction while they could have been exposed and possibly immune.  To 
the extent that this occurs, the resulting misclassification would contribute to a 
reduced difference between the two arms and contribute to misleading efficacy 
estimation.  
 
Our use of the meta analytic approach is subject to the some limitations. The different 
vaccine candidates used in the trials were similar in their dependence on killed 
parasites, but the composition of the vaccines varied between trials, BCG was used as 
an adjuvant in some cases and the ecological setting of the different trials varied 
substantially.  Thus it may be argued that combining the results from the trials should 
be done with great caution.  We would not disagree with this view but have combined 
the findings to seek evidence that might encourage further work on first-generation 
vaccines.  In this respect, our finding are depressing and suggest that other approaches 
to leishmaniasis vaccine development should be vigorously pursued.  
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